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Summary 
 
Who are vulnerable people? Why are they vulnerable in clinical trials? How are they protected 
by European law? These initial questions rapidly evolve into the formulation of an old dilemma that is 
constantly renewed by medical progress and increasing levels of human rights protection. Protection 
of individual participants’ rights may conflict with the promotion of public health. Specifically, the 
challenge is to justify and organise the participation of people who are unable to defend their own 
interests in clinical trials and are essential not only to public health but also to the health of the group 
they represent. 
The case of vulnerable people will serve both as the subject of interest and as a heuristic tool. 
Why are older adults not a category of vulnerable participants? Why assimilate pregnant women to 
people unable to defend their interests? Why can patients suffering from orphan diseases be 
classified as a vulnerable category in clinical trials? How should participants from developing 
countries be classified? Hence, by first clarifying the concept of vulnerability will it be possible to get a 
preliminary answer to this ethical dilemma. Then, by examining the different types of risks to which a 
person can be vulnerable will it be possible to distinguish between two emerging types of 
vulnerability in the field of clinical trials: vulnerability to risks of violation of autonomy in the decision 
making process of a (potential) trial participant, and vulnerability to risks of violation of health and 
safety when ingesting a potentially dangerous experimental medicine. The former case concerns 
decisional vulnerability, i.e. the inability to defend one’s own interests and the resulting exposure to 
abuse and exploitation. The latter case, rarely apprehended through the notion of vulnerability, 
concerns the health vulnerability of the future patient, his medical condition, and the need for 
representation in clinical trials in order to avoid a medical weakness to be exacerbated via 
marginalisation from clinical trials, leading to the lack of research and reliable medical data. 
Although very different, those two types of vulnerability are often conflated or assimilated with 
one another because they are frequently present in a single person, the best example being children, 
both legally incapacitated and physiologically different than adults. And yet the distinction is crucial 
in order to modulate the protection of vulnerable people depending on their different needs. In fact 
this distinction then allows to select vulnerability factors that are particularly relevant in the specific 
field of clinical trials. Only then is it possible to examine the factors of vulnerability for which 
protection is possible and for which a normative response can be ethically justifiable, legally feasible, 
and economically viable. 
Without claiming to bring an ideal solution to these complex dilemmas, this thesis advances an 
ethical and critical perspective on European law. It stresses the considerable progress made in 
protecting vulnerable people, highlights the means and instruments that are most efficacious, and 
stimulates reflection on how to further ameliorate the protection of vulnerable people in clinical 
trials. 
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Foreword 
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of the University of Basel. 
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Introduction 
1 ORIGIN OF RESEARCH 
1. The origin of this research was initially the question of clinical trials on elderly 
people as it raises two main problems. The first one is related to the difficulties in obtaining 
consent since older adults tend to suffer from cognitive limitations. The second problem 
revolves around the lack of clinical research with older persons, irrespective of whether it is 
within geriatric disease context or medicine in general. When examined jointly they reveal the 
challenge of finding a good balance between promoting health and quality medicines for older 
adults and protecting them from abusive recruitment practices in clinical trials.  
2. However, it became obvious that these problems were not specific to older adults in 
clinical trials: it is also the case for children, pregnant women or in emergency situations. Hence 
it is as well the case for other people who are allocated a status of “vulnerable group” in 
European law relative to clinical trials. Although older adults are not a “vulnerable group” as 
such, they pose similar problems.  
3. This dilemma raised the rather theoretical question of how to define vulnerability in 
general and in clinical trials, as well as the practical question of how vulnerable groups are 
protected in European law. Hence the research was expanded to the broader topic of vulnerable 
people in clinical trials in order to compare protections to those within this group and critically 
analyse them, but also to understand why older adults are not a “vulnerable group” under 
European law related to clinical trials. 
4. Moreover, two supplementary reasons make the broadening of this topic 
particularly relevant in the context of European law. First, the explicit term “vulnerable” has 
recently penetrated European law on clinical trials with the 2014 reform in the European Union 
as we will see later on. Second, this same reform also permitted to bring closer the provisions on 
vulnerable populations in the two legal instruments in European law related to clinical trials1. 
                                                                    
1 Regulation (UE) n° 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal 
products for human use and repealing Directive 2001/20/EC (Hereafter “Regulation 536/2014”) ; Additional Protocol to the 
Convention on Human Rights and Biomedicine, concerning Biomedical Research, CETS N°195, Strasbourg, 25 January 2005 
(Hereafter “Additional Protocol”). 
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2 OBJECT OF RESEARCH 
2.1 VULNERABLE PEOPLE AND CONCEPT OF VULNERABILITY 
5. Lists of vulnerable people in European law may differ according to the field of 
interest. Regarding clinical trials, there are two lists depending on the chosen source: 2005 
Additional Protocol to the Oviedo Convention on biomedical research from the Council of 
Europe or Regulation 536/2014 on clinical trials from the European Union. According to the 
Additional Protocol on biomedical research, several groups deserve specific attention, namely: 
people who are not able to give consent (minors and incapacitated adults), pregnant and breast-
feeding women, people in emergency situations and persons deprived of liberty (articles 15, 18, 
19 and 20). Similarly, Regulation 536/2014 considers minors, incapacitated adults, pregnant and 
breast-feeding women and persons in emergency situations as vulnerable (article 10). 
Interestingly, a generic group has been added in comparison to the Council of Europe: “specific 
groups or subgroups” which we will develop further on. However, persons deprived of liberty 
are not among the list of Regulation 536/2014, but they are quickly mentioned in article 34 in 
order to allow Member States to consider them as vulnerable along with other groups: “persons 
performing mandatory military service, persons deprived of liberty, persons who, due to a 
judicial decision, cannot take part in clinical trials, or persons in residential care institutions”. 
6. This work will challenge the relevance and accuracy of both these lists. This 
questioning is possible because it is inherent to the concept of vulnerability which can be 
paradoxical, ambiguous and malleable2. In fact, vulnerability is both universal and particular, it 
can concern anyone depending on the situation, it can change over time, some authors name it 
“existential vulnerability”3. Thus it is an inherently human characteristic, which is the very reason 
of elaborating human rights protection4. Lists of vulnerable groups can be very broad, can be 
different according to the topic, and sometimes they are not even explicit termed as such5. This 
                                                                    
2 “the difficulties in navigating between insufficient comprehensiveness and excessive broadness, if all are to be considered 
vulnerable, have fuelled a critique of using the concept of vulnerability at all”. Hurst S., “Vulnerability in research and health 
care ; describing the elephant in the room ?”, Bioethics, Vol. 22, n°4, 2008, p. 195 ; See also Levine C. et al., “The limitations 
of ‘vulnerability’ as a protection for human research participants”, American Journal of Bioethics, Vol. 4, n°3, 2004, p. 4 ; 
Fiechter-Boulvard F., “La notion de vulnérabilité et sa consécration par le droit”, in Cohey-Cordet F. (ed.), Vulnérabilité et 
droit. Le développement de la vulnérabilité et ses enjeux en droit, Presses Universitaires de Grenoble, Grenoble, 2000, pp. 
13-32; Fineman M. A., "The vulnerable subject : Anchoring equality in the human condition", Yale Journal of Law and 
Feminism, Vol. 20, n°1, 2008, pp. 1-23. 
3 Bielby P., Competence and vulnerability in biomedical research, International Library of Ethics, Law and the New Medicine, 
Springer, 2008, p. 53. 
4 Grear A., “Challenging corporate ‘humanity’ : legal disembodiment, embodiment and human rights”, Human Rights Law 
Review, Vol. 7, n°3, 2007, p. 532 ; Morawa A. H. E., “Vulnerability as a concept of international human rights law”, Journal of 
International Relations and Development, Vol. 6, n°2, 2003, pp. 139-155 ; Turner, S. T., Vulnerability and human rights, 
Essays on human rights, Pennsylvania State University Press, University Park, 2006, p. 25. 
5 Cour de cassation, Rapport annuel 2009. Les personnes vulnérables dans la jurisprudence de la Cour de cassation, La 
Documentation Française, Paris, 2009, p. 56. 
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malleability is thus both the strength and the weakness of the concept of vulnerability. It allows 
to unite, within one highly emblematic notion, all the different interpretations6. 
7. In this work, vulnerability refers to a “heightened state of vulnerability”, when it 
exceeds a certain acceptable level or benchmark. This descriptive approach of vulnerability 
showing inequities between people gives the concept of vulnerability its practical and normative 
relevance7. Thus from an anthropological or descriptive concept, vulnerability can become a 
normative concept, be it ethical, moral or legal. In law especially, vulnerability corresponds to an 
abnormal inability to enjoy one’s rights and freedoms8. Vulnerability is the sign of ineffectiveness 
of human rights protection9, and the sign of the need for a more subtle protection guaranteeing 
to vulnerable people the means for their own resilience, taking inspiration from theories like 
ethics of care or capabilities10. In spite of all different interpretations of vulnerability, the societal 
responsibility of protecting vulnerable people seems to be outright11.  
2.2 CLINICAL TRIALS AND BIOMEDICAL RESEARCH 
8. 2005 Additional Protocol to the Oviedo Convention from the Council of Europe 
examines “biomedical research” and not “clinical trials” like European Union 536/2014 
Regulation. Biomedical research is a lot broader than clinical trials as it can include any type of 
research such as observational work, simple questionnaires or interviews without any clinical 
intervention12. 536/2014 Regulation only relates to clinical trials on medicinal products for 
human use, i.e. tests in human participants or experimental medicines in order to study their 
safety and efficacy in providing health treatment (article 2.2.1). It thus excludes observational 
studies in normal clinical practice, animal testing, as well as in silico trials13. As both legal 
                                                                    
6 Faberon F., "Vulnérabilité et besoin dans le droit de l’aide et de l’action sociale", in Paillet É. & Richard P. (eds.), Effectivité 
des droits et vulnérabilité de la personne, Bruylant, Bruxelles, 2014, p. 52. 
7 “Most strands of literature agree that vulnerability is a useful (and measurable) concept only if it is defined as vulnerability 
to a measurable loss (the metric) below a minimum level (the benchmark). Without use of a benchmark, the term 
‘vulnerability’ becomes too imprecise for practical use ». Alwang J., Siegel P. B. et Jørgensen S. L., « Vulnerability : a view 
from different disciplines”, Social Protection Discussion Paper Series, n°0115, 2001, p. 29. 
8 Cour de cassation, Les personnes vulnérables dans la jurisprudence de la Cour de cassation, op. cit. 
9 Paillet É. & Richard P. (eds.), Effectivité des droits et vulnérabilité de la personne, Bruylant, Bruxelles, 2014, p. 4 ; Cour de 
cassation, Les personnes vulnérables dans la jurisprudence de la Cour de cassation, op. cit.; Rendtorff J. D., “Basic ethical 
principles in European bioethics and biolaw: Autonomy, dignity, integrity and vulnerability – towards a foundation of 
bioethics and biolaw”, Medicine, Health Care and Philosophy, Vol. 5, n°3, 2002, p. 238. 
10 Nussbaum M. C., “Capabilities and human rights”, Fordham Law Review, Vol. 66, n°2, 1997, p. 275 ; Maillard N., La 
vulnérabilité. Une nouvelle catégorie morale ?, Le champ éthique n°56, Labor et Fides, Geneva, 2011, p. 158. 
11 Goodin R., Protection the vulnerable : a re-analysis of our social responsibilities, London & Chicago, The University of 
Chicago Press, 1985, p. 39. 
12 Explanatory report to the Convention for the Protection of Human Rights and Dignity of the Human Being with regard to 
the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, ETS N° 164, Oviedo, 4 April 1997, 
(Hereafter “Oviedo Convention”), § 17. 
13 Viceconti M., Henney A. et Morley-Fletcher E., "In silico clinical trials : how computer simulation will transform the 
biomedical industry", International Journal of Clinical Trials, Vol. 3, n°2, 2016, pp. 37-46 ; Gal J. et al., "Optimisation du 
processus de développement d’un nouveau médicament par modélisation et simulation : état des lieux et enjeux", Revue 
d’Épidémiologie et de Santé Publique, Vol. 64S, 2016, pp. S117-S136. 
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frameworks will constantly be compared throughout this research, this study is limited to the 
more restrictive field of clinical trials. 
9. Clinical trials take place in three main phases, and sometimes in a fourth one. Phase 
I concerns first-in-human trials, testing the safety of (the maximum dose of) the experimental 
medicine on a small number of healthy volunteers. Phase II tests the efficacy (and minimum 
dose for efficacy) of the drug on a bigger group of volunteers suffering from the condition which 
the experimental drug is supposed to diagnose, prevent or cure. Phase III, also called pivotal 
trials, consists in testing the drug on a large number of patients in order to precisely know the 
posology for instance in different age groups, and most of all in order to compare the safety and 
efficacy of the drug to the currently available treatment or to a placebo if necessary, and to 
prove the relevance and utility of its marketing. 
10. If the new medicinal product is granted a marketing authorisation and is 
commercialised, pharmacovigilance begins: information is collected from patients and 
practitioners about the effects of the drug. Even with this surveillance, 197 000 deaths per year 
in the European Union would be related to adverse effects of medicinal products according to 
the European Medicines Agency 14. In fact, many effects of a drug cannot be observed during 
phases I-III because they only appear rarely and thus only when used in a large number of 
people; because they only appear with long-term use; or because they only appear in certain 
groups of people who were not studied in clinical trials, which is the case for most vulnerable 
people15 . Hence, there can be a phase IV clinical trial, which is different from simple 
pharmacovigilance.  
11. Finally, there are three essential issues at stake with clinical trials. First, the goal is to 
promote public health through improvement of quality and security of a new drug, as well as 
their efficacy16. Second, clinical trials serve the purpose of benefiting the health of future 
patients, but not necessarily the health of its participants. This explains the consecutive 
international reactions, pleading for informed consent and further ethics principles which came 
after the barbaric Nazi experiments and many more abusive research conducted in Japan or in 
America17. Even with restrictions and safeguards, tragic events still happen, like the recent death 
of a healthy volunteer in France in January 2016 solely a few days after the start of a phase I 
                                                                    
14 EMA, Strengthening pharmacovigilance to reduce adverse effects of medicines, MEMO/08/782, London, 2008, p. 1. 
15 Directive 2010/84/EU of the European Parliament and of the Council of 15 december 2010, amending, as regards 
pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use, Recital 2. 
16 Simon P., Le médicament sous toutes ses coutures, Éditions de Santé Coll. Polémiques, Paris, 2003, p. 73 ; For historical 
examples : Mattei J.-F. (ed.), Questions d'éthique biomédicale, Flammarion, Nouvelle Bibliothèque Scientifique, Paris, 2008, 
p. 321 ; Bouvenot G., "Problèmes éthiques posés par l’expérimentation humaine des médicaments", in Bouvenot G. et Vray 
M., Essais cliniques : théorie, pratique et critique, Flammarion médecine-sciences Coll. Statistique en biologie et en 
médecine, Paris, 2006, p. 162 ; European Parliament Resolution of 2 March 2017 on EU options for improving access to 
medicines, (2016/2057(INI)), P8_TA(2017)0061, Observation 11.  
17 Nuernberg Military Tribunals, “Trials of War Criminals before the Nuremberg Military Tribunals under Control Council 
Law No. 10”, US Government Printing Office, Washington DC, 1949, Vol. 2, pp. 181-182 ; Delfosse M.-L. & Bert C., 
Bioéthique, droits de l’homme et biodroit. Recueil de textes annotés internationaux, régionaux, belges et français, Larcier, 
Brussels, 2005, p. 301. 
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trial18. Restrictions however can also be counterproductive and expose future patients to great 
dangers if drugs are not properly tested. This explains the slow transition towards an approach 
to participants’ recruitment that is more considerate with equitably sharing benefits of research 
through patients’ proper representation in clinical trials19. The third issue at stake in clinical trials 
lies in economic competitiveness of the pharmaceuticals’ market. In fact, 61% of trials in the 
European Union are conducted by pharmaceutical companies trying to market new drugs to 
compensate the humongous costs of clinical trials as well as to make profits20. Market dynamics 
can have a beneficial impact on health protection21, unfortunately as this work will show, this is 
rarely the case for vulnerable people. 
3 SCOPE OF RESEARCH 
3.1 EUROPEAN LEGAL FRAMEWORK(S) 
12. Clinical trials and biomedical research are regulated at national levels, however 
adopting a European perspective is fundamental for this research work. First, recruiting enough 
participants for a clinical trial almost systematically obliges to cross a border: any trial of more 
than 40 participants conducted in Europe involves more than one Member State22, and 67% of 
participants recruited in the European Union are part of a multinational trial23, which is probably 
even more exacerbated regarding vulnerable participants who are more difficult to recruit, for 
instance in the case of rare diseases. Second, due to the European Union market and freedoms 
to circulate, the pharmaceutical market is highly dependent on European competitiveness24 and 
is no exception to ethics tourism25, then again confirming the importance of harmonised 
protection provisions. Third, the European perspective is relevant as both the Council of Europe 
                                                                    
18 Benkimoun P., "Essai clinique mortel de Rennes : la toxicité de la molécule en cause", Le Monde, 3 Novembre 2016, 
https://www.lemonde.fr/sante/article/2016/11/03/essai-clinique-mortel-de-rennes-la-toxicite-de-la-molecule-en-
cause_5024450_1651302.html [24 January 2018]. 
19 Delfosse M.-L. & Bert C., Bioéthique, droits de l’homme et biodroit, op. cit.. 
20 EMA Website, http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000489.js 
p&mid=WC0b01ac058060676f [10 May 2018]. 
21 Bailleux A., "Les alliances entre libre circulation et droits fondamentaux. Le flou au cœur de la jurisprudence 
communautaire", Journal de Droit Européen, n° 160, 2009, p. 11 ; Brosset E. (ed.), Droit européen et protection de la santé. 
Bilan et perspectives, Bruylant, Brussels, 2015, p. 21. 
22 European Commission, Impact assessment report on the revision of the "Clinical Trials Directive" 2001/20/EC, VOLUME I, 
Document de travail des services de la Commission, SWD(2012) 200 final, Brussels, 17 July 2012, § 25. 
23 Ibid., § 24. 
24 Dubouis L., Blumann C., Droit matériel de l’Union européenne, 6th edition, Domat Droit public, Montchrétien, Paris, 2009, 
p. 184. 
25 For instance : Waligora M., “Failures in clinical trials in the European Union: Lessons from the Polish experience”, Science 
and Engineering Ethics, Vol. 19, 2013, pp. 1087-1098. 
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and the European Union have provided for a legal framework on the topic which is important to 
compare26 as well as to confront with research ethics instruments. 
13. Instruments from the Council of Europe, the Convention for the Protection of 
Human Rights and Dignity of the Human Being with regard to the Application of Biology and 
Medicine (Convention on Human Rights and Biomedicine or Oviedo Convention) as well as its 
Additional Protocol on biomedical research, adopt a human rights approach which is inherent to 
the international organisation. In addition to these two instruments specific to bioethics and 
research ethics, the Convention for the Protection of Human Rights and Fundamental Freedoms 
(European Convention on Human Rights or ECHR) does protect rights that are relevant to 
biomedical research, like article 2 on the right to life, article 3 on the ban of inhuman treatments 
or article 8 on the respect for private life, as well as many others. The advantage of using this 
more general instrument is sometimes to circumvent the fact that only 29 Member States have 
ratified the Oviedo Convention and 11 the Additional Protocol on biomedical research, and 
benefit from the protection of the Court. 
14. The European Union on the contrary is rather focused on market considerations 
than on participants’ protection, emphasising the fact that the latter falls within national 
competencies27. The issue of a clear receptivity of the European Commission to the lobbying of 
pharmaceutical companies is repeatedly raised28. Market considerations were the main scope 
for the initial Directive 2001/20/EC on clinical trials29, and they were also the main reason for the 
reform and elaboration of Regulation 536/2014. As administrative and insurance costs were 
increasing unreasonably (administrative costs were at least multiplied by two, insurance costs by 
eight)30, deadlines for evaluation of applications were expanding endlessly, and Member States 
had different interpretations of the directive… All these elements lead to 25% decrease in the 
number of clinical trials between 2007 and 201131, triggering the active elaboration of the new 
regulation. The main general change, outside the topic of vulnerable populations, lies in the 
creation of a unique European Union portal and database gathering all information and serving 
as platform for communication between clinical trials sponsors, Member States, the European 
                                                                    
26 Andorno R., “Regulatory discrepancies between the Council of Europe and the EU regarding biomedical research”, in 
Andorno R. (ed.), Principles of international biolaw. Seeking common ground at the intersection of bioethics and human 
rights, Coll. Droit, bioéthique et santé, Bruylant, 2013, pp. 175-194. 
27 Regulation 536/2014, Recital 6. 
28 “it is difficult to shake the feeling that the voices of industry received more than due attention”. Lidell K. et al., “Medical 
research involving incapacitated adults: implications of the EU Clinical Trials Directive 2001/20/EC", Medical Law Review, 
2006, Vol. 14, n°3, p. 374. 
29 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in 
the conduct of clinical trials on medicinal products for human use, O. J., 1.5.2001, L 121, pp. 34-44. 
30 European Commission, Impact assessment report on the revision of the "Clinical Trials Directive" 2001/20/EC, op. cit., 
VOLUME II, p. 5; Delawi D. et al., “Conducting a European multi-center trial: First experiences with the new EU clinical trials 
directive from an academic perspective", European Spine Journal, Vol. 17, 2008, pp. 1113-1115. 
31 Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for 
human use, and repealing Directive 2001/20/EC, COM(2012) 369 final, 2012/0192 (COD), Explanatory memorandum, p. 3.  
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Medicines Agency and the European Commission, but also as a transparency platform for the 
public. Regulation 536/2014 will be applicable once this Union portal will function, by the end of 
201932. Even if market related issues have led to this reform, it also brought considerable 
improvements in participants’ protection that are clearly – even if not explicitly admitted33 – 
inspired from the Council of Europe. 
3.2 EUROPEAN RESEARCH ETHICS 
15. Ethics is an ambiguous notion, especially when used in a legal setting. Historically, 
the first normative framework related to clinical trials is related to biomedical ethics and human 
rights34. The ambiguity between ethics and fundamental rights has remained since then as most 
legal literature demonstrating an ethical approach in law tend to do so by emphasising the value 
given to human rights35. But ethics is not exactly law. Rather, ethics is the balancing of 
competing values, the response to a dilemma for which no solution is satisfactory36. Thus, ethics 
provides a critical view on the pertinence and justice of the rules enacted by the law. Finally, 
ethics and soft law are often mistakenly conflated. However ethics refers to substantial, material 
rules whereas soft law refers to formal considerations, it refers to the type of legal instrument 
and its nonbinding nature. Often indeed, soft law is used to convey ethical content37: 
recommendations, good practices, opinions, notably from ethics committees (national ethics 
committees advising governments on general issues, clinical ethics committees advising 
physicians on actual cases or research ethics committees evaluating research protocols)38. As it is 
very difficult or even impossible in our pluralist societies to reach a consensus, ethics sometimes 
                                                                    
32  EMA Website, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp 
[14 May 2018]. 
33 Interestingly, this is not just a simple omission as parliamentary amendments had suggested to insert a reference. 
Willmott G., Committee on the Environment, Public Health and Food Safety (ENVI), Report on the proposal for a regulation 
of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing 
Directive 2001/20/EC (COM(2012)0369 – C7 0194/2012 – 2012/0192(COD)), A7-0208/2013, Strasbourg, 7 June 2013, 
Amendment 32. 
34 "It is interesting to note that the first issue with which both new disciplines – modern medical ethics and human rights 
law – were confronted was precisely medical research on human beings”. Andorno R., “Regulatory discrepancies between 
the Council of Europe and the EU regarding biomedical research”, op. cit., p. 178 ; Duprat J.-P., "La portée des normes dans 
le domaine de la biomédecine", Revue française des affaires sociales, Vol. 3, n°3, 2002, p. 32. 
35 For instance : primacy of human beings, integrity and informed consent "constituent la base d’un droit éthique européen 
qui est fondé sur la Charte des droits fondamentaux de l’Union". Rage-Andrieu V., "L’apport du règlement 2017/745 à 
l’évaluation clinique des dispositifs médicaux", RDSS, Vol. 1, 2018, p. 50 ; Chassang G. et al., "Les fondements de l'éthique 
de la recherche en droit communautaire", International Journal of Bioethics, Vol. 22, n°1-2, 2011, pp. 185-203 ; Sutour S. & 
Lorrain J.-L., Sénat, Rapport d'information sur la prise en compte des questions éthiques à l'échelon européen, n°67, 
Commission des affaires européennes, Ordinary session 2013-2014, 2013 ; "In this paper, I reflect on the parallel 
development and accidental divorce of bioethics and human rights to urge their reconciliation". Baker R., "Bioethics and 
human rights: A historical perspective", Cambridge Quarterly of Healthcare Ethics, Vol.  n°10, 2001, p. 241. 
36 Vöneky S., Recht, Moral und Ethik. Grundlagen und Grenzen demokratischer Legitimation für Ethikgremien, Jus publicum. 
Beiträge zum Öffentlichen Recht, Mohr Siebeck, Tübingen, 2010, p. 24-26 ; Sutour S. & Lorrain J.-L., Rapport d'information 
sur la prise en compte des questions éthiques à l'échelon européen, op. cit., p. 19. 
37 Conseil d'État, Étude annuelle 2013. Le droit souple, La Documentation Française, Paris, 2013, p. 61. 
38 Monnier S., Les comités d’éthique et le droit. Éléments d’analyse sur le système normatif de la bioéthique, L'Harmattan 
Coll. Logiques Juridiques, Paris, 2005, p. 418 
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rather becomes procedural ethics39. That is a decision becomes “ethical” only if it has been 
discussed according to specific procedural rules like the presence of scientific experts as well as 
representatives from patients or from different religions40. 
16. Dealing with ethics in European law is in itself paradoxical as it conveys values that 
are intrinsic to national competencies41. However both the Council of Europe and the European 
Union have developed abundant legislations42. Most of all, each have created their own ethics 
committees. The Council of Europe set up in 1985 what has now become the Bioethics 
Committee or DH-BIO, composed of representatives of Member States who elaborated the 
Oviedo Convention - first internationally binding instrument in bioethics - and who are in charge 
of implementing it as well as developing it further. In the European Union, the European Group 
on Ethics in science and new technologies has been created in 1991. It is an independent, 
pluralistic and multidisciplinary ethics committee 43  in charge of advising the European 
Commission, often with concrete impact on European Union law44. 
17. In Europe, research ethics principles stem from two sources: European law itself and 
international research ethics guidelines, notably as they are conveyed in the European legal 
framework. The involvement of the DH-BIO of the Council of Europe is undoubtedly present as 
the Oviedo Convention and its Additional Protocol on biomedical research are inherently 
relevant to research ethics. The involvement of the European Union in research ethics is less 
obvious and rather perceptible through nonbinding and scattered reports or recommendations. 
For instance, the European Group on Ethics, the European Parliament and the European 
Medicines Agency have each drafted separate documents on research ethics in developing 
countries45. The European Commission has mandated an ad hoc committee to draft ethical 
                                                                    
39 Habermas J., De l'éthique de la discussion, Cerf, Champ Essais, 1992, 204 p ; Lanfranchi M.-P., "Le rôle des comités 
d’éthique dans l’élaboration et le suivi du droit international relatif au vivant humain", in Brosset E. (ed.), Le droit 
international et européen du vivant. Quel rôle pour les acteurs privés ?, La Documentation Française Coll. Monde européen 
et international, Paris, 2009, p. 55 ; Martinez É., "Comités d'éthique et démocratie (quelques réflexions sur l'exemple 
français)", International Journal of Bioethics, Vol. 18, n°1-2, 2007, p. 117. 
40 "Le mouvement consultatif exprime l’émergence d’un droit négocié consacrant le passage d’un droit autoritaire à un 
droit autorisé, qui utilise les opinions éclairées comme armes de persuasion". Martinez É., "Les enjeux de la ‘recomposition’ 
du droit de la bioéthique", International Journal of Bioethics, Vol. 15, n°2-3, 2004, p. 56. 
41 Hennette-Vauchez S. et Roman D., Droits de l’Homme et libertés fondamentales, 1st edition, Dalloz, 2013, p. 142.  
42 Council of Europe : Directorate General I – Human Rights Directorate, Bioethics Unit, Legal instruments of the Council of 
Europe in the field of bioethics, Strasbourg, 2014, Volume I, p. 2 & Volume II, p. 2 ; European Union : Chassang G. et al., "Les 
fondements de l'éthique de la recherche en droit communautaire", op. cit., p. 195 ; Both : Sutour S. & Lorrain J.-L., Rapport 
d'information sur la prise en compte des questions éthiques à l'échelon européen, op. cit., p. 34. 
43 Sutour S. & Lorrain J.-L., Rapport d'information sur la prise en compte des questions éthiques à l'échelon européen, op. 
cit., p. 24. 
44 Dubos O., "Droit communautaire et bioéthique: Étude des internormativités à travers les avis du Groupe européen 
d'éthique", International Journal of Bioethics, Vol. 15, n°2-3, 2004, pp. 101-127. 
45 European Group on Ethics in Science and Technologies (EGE), Opinion N° 17 on ethical aspects of clinical research in 
developing countries, 2003 ; Schipper I., Directorate-General for external policies of the Union (DG-EXPO), European 
Parliament, Clinical trials in developing countries: How to protect people against unethical practices ?, 
EXPO/B/DEVE/2008/45 PE 406.974, Brussels, 2009 ; EMA, Reflection paper on ethical and GCP aspects of clinical trials of 
medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications 
to the EU regulatory authorities, EMA/121340/2011, London, 2012. 
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recommendations for clinical trials in children46, as well as academic experts to elaborate a 
textbook on research ethics47. Moreover, the legal framework itself conveys ethical issues and 
values, for instance when Directive 2001/20/EC obliged each Member States to put in place 
research ethics committees48 or when provisions on informed consent became very precise in 
Regulation 536/201449 as was also highlighted by the European Parliament50. 
18. Finally, it is interesting to analyse the impact of international guidelines on research 
ethics in European law and bioethics, notably the World Medical Association’s Declaration of 
Helsinki51, the good practices from the International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH)52 and the guidelines from 
the Council for International Organizations of Medical Sciences (CIOMS)53.  
19. 1964 Declaration of Helsinki stated ethics principles applicable to medical research 
involving human subjects, has become the main reference for research on a global level54. It has 
often been criticised as well for two reasons: first it is deemed to be very general and unprecise, 
leading to many interpretations, and second, as it is often updated, regulators are reluctant to 
give it binding force55. The instruments from the Council of Europe do not mention the 
Declaration of Helsinki, however the judges of the European Court of Human Rights have used it 
as supplementary argument grounding their reflexions in a few research ethics cases56. As for 
the European Union, Regulation 536/2014 does mention the Declaration of Helsinki but only in 
cases where the regulation would not be self-sufficient (Recitals 43 and 80). 
                                                                    
46 These recommendations were drafted in 2008 but updated in 2017. Ethical considerations for clinical trials on medicinal 
products conducted with the paediatric population. Recommendations of the ad hoc group for the development of 
implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on 
medicinal products for human use, Final 2008 ; Updated version: Ethical considerations for clinical trials on medicinal 
products conducted with minors, Recommendations of the expert group on clinical trials for the implementation of 
Regulation (EU) N° 536/2014 on clinical trials on medicinal products for human use, 18 September 2017, revision 1. 
47 European Commission, European textbook on ethics in research, EUR 24452 EN, Brussels, 2010. 
48 European Commission, Summary of the responses to the public consultation paper, Assessment of the functioning of the 
"Clinical Trials Directive" 2001/20/EC, SANCO/C/8/SF/dn D(2010) 380240, Brussels, 30 March 2010, p. 2. 
49 Regulation 536/2014, Article 29. 
50 “Justification: Compliance with the core elements of informed consent as set out in Chapter V should be assessed by the 
reporting Member State in Part I. While individual Member States are best placed to decide on certain cultural aspects, the 
core elements set out in Chapter V should also be considered in Part I”. Willmott G. (ENVI), Report on the proposal for a 
regulation, op. cit., Amendment 96. 
51 WMA (World Medical Association), Declaration of Helsinki - Ethics principles applicable to medical involving human 
subjects, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 64th WMA 
General Assembly, Fortaleza, Brazil, October 2013. 
52 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), Guideline for Good Clinical Practices, E6(R1), Geneva, 1996. 
53 These guidelines have first been drafted and published in 2002, and recently updated in 2016. CIOMS (Council for 
International Organizations of Medical Sciences), International Ethical Guidelines for Health-related Research Involving 
Humans, in collaboration with the World Health Organization (WHO), Geneva, 2016 (Hereafter CIOMS Guidelines). 
54 Human D. & Fluss S. S., “The World Medical Association’s Declaration of Helsinki : Historical and contemporary 
perspectives”, 24 July 2001, http://www.wma.net/fr/20activities/10ethics/10helsinki/draft_historical_contemporary_ 
perspectives.pdf [23 August 2015]. 
55 Schipper I. (DG-EXPO), Clinical trials in developing countries: How to protect people against unethical practices ?, op. cit., 
p. 5 & p. 17. 
56 ECtHR, Grand Chamber, Case of Gillberg v. Sweden, Application n° 41723/06, 3 Avril 2012, §89 ; ECtHR, First Section, Case 
of Bataliny v. Russia, Application n°10060/07, 23 July 2015, §90. 
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20. The ICH guidelines are a set of scientific guidelines developed between Europe, 
Japan and the United States of America since 199057. Although they are quite widespread and 
used in practice for instance in developing countries, their lack of concerns for ethical issues has 
often been deplored. Trying to compensate for this lack, they often refer to the Declaration of 
Helsinki, which unfortunate as the United States have explicitly rejected it in 200858. The Council 
of Europe does not refer to ICH guidelines, but the European Union very often does, be it in 
article 47 of Regulation 536/2014 as well as in numerous work documents from the European 
Medicines Agency59. 
21. Last but not least, the CIOMS, created in 1949 by the UNESCO and World Health 
Organisation, elaborated first in 2002 and then updated in 2016, is a guideline for health related 
research involving human. This is probably the most detailed and thorough set of research ethics 
principles. Unfortunately, it is not mentioned at all in European law in spite of one attempt by 
European Union parliamentary members60.  
4 RESEARCH AIMS AND METHODOLOGY 
22. The aim of this research is to highlight the main issues at stakes when referring to 
vulnerable people in clinical trials. The concept of vulnerability is too often restricted to 
problems related with autonomy and decision making, which would limit this work to examining 
the decisional vulnerability of clinical trials participants. However, it was chosen not to restrict 
the great potential of the concept of vulnerability and go further in the analysis in order to 
demonstrate that vulnerability is also related to the health of future patients (as opposed to 
participants), and that this vulnerability has to be protected and prevented starting from the 
design of clinical trials. 
23. The methodology of this research is theoretical in nature as it consisted of gathering 
and critically analysing European law documents, from binding instruments to any relevant work 
from European institutions and its organs. This analysis was carried in the light of relevant 
international ethical guidelines in the field and applicable in Europe, as well as in the light of 
legal, medical and ethical literature that has been published on the related topic. 
24. The following chapters will delve into these numerous issues. Chapter 1 will deal 
with the concept of vulnerability and how it should not be limited to decisional vulnerability as it 
leads to very different and even contradictory ways to protect vulnerable people. Chapter 2 will 
                                                                    
57  ICH, Website, http://www.ich.org/fileadmin/Public_Web_Site/ABOUT_ICH/Vision/Overview_of_ICH_Website_9Jul2015 
.pdf [24 August 2015]. 
58 Schipper I. (DG-EXPO), Clinical trials in developing countries: How to protect people against unethical practices ?, op. cit., 
p. 17. 
59  EMA Website, http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_cont 
ent_000227.jsp&mid=WC0b01ac05801df740 [20 May 2018]. 
60 Willmott G. (ENVI), Report on the proposal for a regulation, op. cit., Amendment 149. 
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analyse more precisely the situation of two particularly complex groups of vulnerable persons: 
children and frail older adults because their “double” vulnerability often triggers the confusion 
between health vulnerability and decisional vulnerability. Thus, this chapter will analyse in detail 
the evolving ethical challenges related to paediatric research. Chapter 3 will build on chapter 2 
by examining the possibility of integrating research advance directives in European law, which 
would be of particular interest for frail older adults as those do not constitute a “vulnerable 
group” per se in clinical trials. Interestingly, they are on the contrary one of the most vulnerable 
groups, both regarding medical needs and decision-making capacity (Chapter 4). In light of these 
different chapters, we will critically analyse in a thorough discussion section the status and 
protection in European law of vulnerable people in clinical trials.  
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Chapter 1: Does the new EU Regulation on clinical 
trials adequately protect vulnerable research 
participants? 
ORIGINAL PUBLICATION 
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ABSTRACT 
Vulnerable research participants deserve special protection because of their increased risks of 
being wronged. Yet, paradoxically, the conduct of trials involving vulnerable groups is sometimes 
inescapable to develop safe and efficient therapies suitable to these groups. The key question is 
therefore how to protect vulnerable research participants from harm and exploitation without 
excluding the populations they belong to from the benefits of research. The European Union 
faced this challenge in April 2014 when adopting the new Regulation on clinical trials, which will 
replace the currently applicable 2001 Clinical Trials Directive in 2016. In order to assess the 
protection of vulnerable persons in the new Regulation, this paper makes four suggestions: first, 
the need to adopt a risk-based approach to vulnerability in biomedical research; second, to 
better distinguish between decisional vulnerabilities and health-related vulnerabilities; third, to 
emphasise the need to preserve the freedom of consent of subjects with decisional vulnerability, 
who are more susceptible to undue influence; and finally to assert the need of actively 
promoting specific clinical trials involving people with physical or psychological vulnerabilities. In 
conclusion, this paper claims that the protection of vulnerable subjects still needs to be 
improved in the new EU Regulation. 
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1 Introduction 
25. All major international61 and European62 standards relating to biomedical research 
expressly stipulate that vulnerable research participants deserve special protection because they 
“may have an increased likelihood of being wronged or of incurring additional harm”63. 
Vulnerability is often described as the inability to protect one’s own interest, but it is usually not 
defined more precisely, leaving the possibility of different understandings of this concept. 
Typically, the category of “vulnerable persons” in biomedical research includes, among others, 
children, people with mental disabilities, older frail persons, pregnant women, persons deprived 
of their liberty, and socially or economically disadvantaged people. It is not justified to conduct 
research with vulnerable groups if a research of comparable effectiveness can be obtained with 
non-vulnerable groups 64 . However, paradoxically, the conduct of clinical trials involving 
vulnerable participants is sometimes inescapable because of the need to develop safe and 
efficient therapies suitable for these specific groups. This paradox reflects the complexities that 
regulations about research including vulnerable groups have to address when defining the 
concept of vulnerability and the appropriate protections for vulnerable participants.   
26. The various parliamentary committees of the European Union (EU) that were 
involved between 2012 and 2014 in the discussions for the elaboration of a new Regulation on 
clinical trials struggled to find appropriate regulatory responses to these difficulties. After almost 
two years of discussions, the EU Parliament and the Council adopted in April 2014 the new 
Regulation No 536/201465, which will replace in 2016 the currently applicable 2001 Clinical Trials 
Directive (CTD)66. The latter did not measure up to the hopes that had been placed in it and is 
deemed partly responsible for the significant increase in costs and delays for the conduct of 
clinical trials, and for the recent 25% decline of the number of clinical trials in the EU67. These 
                                                                    
61 CIOMS (Council for International Organizations of Medical Sciences), International Ethical Guidelines for Health-related 
Research Involving Humans, in collaboration with the World Health Organization (WHO), Geneva, 2002 (Hereafter “CIOMS 
Guidelines”), Guideline 13 ; International Conference on Harmonisation of Technical Requirements for Registration of 
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problems were particularly exacerbated for multinational clinical trials – which concern almost 
any trials involving more than 40 research participants – because of the discrepancies between 
Member States in the transposition of the CTD into national law. Therefore, the objective of the 
new Regulation is to streamline the rules governing clinical trials and to provide a unique legal 
framework to be directly applicable and binding for all EU Member States by the end of 2016.  
27. As the key objective of the adoption of a new regulation was to facilitate the 
conduct of clinical trials in Europe, several scholars were critical of the insufficient attention that 
the Draft Regulation paid to research participants’ protection68. This particular issue is notably 
one of the most amended topics when comparing the 2012 Draft Regulation with the version 
that was finally adopted in 2014. Even if the new Regulation has been definitively passed, the 
implementation guidelines and recommendations are still being updated in order to fit the 
changes brought by the new regulatory framework69. 
28. With this important EU policy change as a background, this paper aims, first, to 
suggest the need to adopt a risk-based approach to vulnerability in biomedical research; second, 
to argue for the importance of distinguishing between two kinds of risks for vulnerable research 
participants: the risk of exploitation and the risk of physical or psychological harm; third, to claim 
that the protection of vulnerable subjects still needs to be improved in the new EU Regulation, 
and finally to make four suggestions in this direction. 
 
 
 
2 A risk-based definition of vulnerable persons  
29. The notion of vulnerability is omnipresent in bioethics but its utility is often 
challenged. Some argue that other principles give a sufficient protection to vulnerable persons70, 
or that it is too difficult to conceptualize the notion of vulnerability71. This is why ethicists and 
lawmakers tend to adopt a so-called labelling approach: instead of giving an abstract definition 
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of vulnerability, they give a list of populations who are considered vulnerable72. Yet, as we will 
see below, this approach leads to both an overprotection of persons belonging to a vulnerable 
group, and an under-protection of vulnerable persons who do not belong to a typical vulnerable 
group category. 
30. All human beings are vulnerable at several points of their lives and in many different 
ways because vulnerability is inherent to human beings, which means that it belongs 
ontologically to the human condition 73 . However, this intrinsic human vulnerability is 
substantially greater when people are subject to medical interventions which do not aim to 
prevent or treat their condition, but merely –or mainly– to increase scientific knowledge. Due to 
a complex of varied circumstances, some individuals are particularly exposed to exploitation or 
harm in such a context. The complexity of factors that may increase susceptibility to harm or 
exploitation makes it very difficult to define in abstract terms who is “vulnerable”. Instead, it 
seems preferable to first identify the different types of risks to which research participants are 
exposed, and then deduce which individuals might be particularly vulnerable to those risks. In 
this way, we argue that vulnerability results from the addition of two elements: an exposure to a 
specific risk, and a particular susceptibility of the exposed person to this precise risk.  
31. For instance, cognitively impaired individuals are vulnerable when deciding to 
participate in a clinical trial because they might not fully understand or remember the 
implications and risks of trial participation. Nevertheless, these same persons will not necessarily 
be at greater risk of physical harm than healthy research participants. On the contrary, frail 
elderly persons who are free from cognition problems are not vulnerable in terms of the 
decision-making process, but only regarding their greater exposure to physical or psychological 
harm. 
32. Consequently we will determine the persons who are vulnerable depending on the 
risks involved in clinical trials. Two types of risk are distinguishable: those of exploitation and 
those of health harm. The risk of exploitation is the risk of a subjects unduly consenting to 
participation, of their weakness to be abused at the benefit of research because of cognitive 
impairment, deprivation of liberty, socio-economic condition (for instance when trials are 
conducted in developing countries), hierarchical pressure, “therapeutic misconception”, etc. The 
risk of health harm is the risk of greater negative health effects from the trial because of, for 
instance, disease, age, poly-medication, co-morbidity, pregnancy, etc.  
33. Some persons can be categorized as vulnerable in terms of both risks. For example, 
minors are unable to give a valid consent but are also physically and psychologically more fragile 
than adults. Equally, older dementia patients are exposed to increased risks of exploitation 
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because of their cognitive impairment and because they are often not legally capable of taking 
decisions anymore. But they have also, due to their age, a physical frailty, which may impair the 
absorption or effects of drugs. As these combinations are frequent, scholars and lawmakers 
normally treat these two kinds of risks as a whole, which complicates the organisation of an 
appropriate protection for vulnerable research participants. 
34. The legal and ethical literature usually does not distinguish between the risks of 
exploitation and those of health harm. However, this theoretical distinction has practical 
relevance as it justifies two contrasting legal responses. On the one hand, more persons should 
be considered at risk of exploitation and thus should be considered as vulnerable; on the other 
hand, more persons at risk of health harm should be systematically included in clinical trials, 
with the necessary safeguards, in order to facilitate the development of safe and efficient 
therapies for the specific population groups they represent. Where participants are both 
vulnerable to exploitation and to physical or psychological harm, the two different types of legal 
response have to be applied, which might necessitate some special arrangements.  
3 Legal and ethical responses to vulnerability of research 
participants 
3.1 DECISIONAL VULNERABILITIES: THE RISK OF EXPLOITATION  
35. Theoretically, requiring free and informed consent to involvement in clinical trials 
protects participants against the risk of exploitation. The tendency is to consider as vulnerable 
only the persons who do not have legal capacity (minors and incapacitated), persons who de 
facto are unable to consent (unconscious persons in emergency situations), or sometimes 
persons who are deprived of liberty (like prisoners or residents of medico-social institutions) 74. 
36. However, the understanding of decisional vulnerability in this article is wider than 
those typical examples being legally capable (or allowed) to give informed consent and being 
actually autonomous are two different things. 
37. In addition, scholars as well as ethical guidelines, for instance the CIOMS Guidelines 
for Biomedical Research (Guideline 13) and the ICH Guidelines for Good Clinical Practice (§1.61) 
draw attention to “invisible”75 vulnerable persons: those under hierarchical pressure, or socially 
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or economically or educationally disadvantaged76. In this sense, some scholars distinguish 
between “intrinsic vulnerability” and “relational vulnerability”.77 The inability to give a truly free 
informed consent does not only result from the intrinsic frailty of potential participants (e.g. 
their cognitive impairment or unconsciousness), but also from some external or relational 
factors. A current illustration for external factors is the fact that more and more trials are 
conducted in low-income countries78, sometimes abusing from the lack of money, from the lack 
of education, the lack of health care, or the lack of ethics committees. 
38. On the contrary, confusion arises when other vulnerable subjects are added to the 
list, as if they also had the same decisional vulnerability and needed the same protection. Why 
would a pregnant woman have decisional vulnerability? Why would she not be able to give free 
and informed consent to a clinical trial? Does the pregnancy affect her reason to the point where 
she cannot understand the medical information and cannot decide freely for herself? The real 
reason for her exclusion from trials is the risk of health harm, for her and for the future child, but 
not any risk of exploitation of her mental inability to give consent. 
3.2 HEALTH-RELATED VULNERABILITY: THE RISK OF PHYSICAL OR 
PSYCHOLOGICAL HARM  
39. Physically or psychologically vulnerable persons, like frail elderly people or those 
with chronic conditions like depression, are not formally categorized as “vulnerable participants” 
as long as they are legally able to consent to research participation. Yet they often do not match 
with the inclusion criteria to participate in clinical trials for several reasons indirectly related to 
the safety and reliability requirements. Investigators often choose to exclude them because their 
physical or psychological vulnerability can make it too difficult to protect their safety. 
Furthermore, in order to get reliable results, the groups of participants have to be homogeneous 
and it might also be difficult to gather a sufficient number of participants with the same 
vulnerability. The obstacles to conduct research with vulnerable subjects can lead investigators 
to recruit “healthy” participants. As a consequence, they may be collecting research results that 
could be inapplicable to physically and psychologically vulnerable patients. The general 
“marginalization of vulnerable populations”79, which has been denounced, consists in an under-
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representation in clinical trials, for instance of pregnant women80, very elderly81  or palliative 
care populations82. It was also the case for children, but since 2006 the problem of their under-
representation has been recognized and partly solved by the EU Regulation on medicinal 
products for paediatric use (Paediatric Regulation), which aims to facilitate the development and 
availability of medicines for children83.  
40. Excluding physically or psychologically vulnerable research subjects from clinical 
trials has a negative impact on the safety of future patients having the same vulnerability, 
because the risks of the trial are only postponed to the pharmacovigilance phase, where medical 
surveillance is at its lowest in comparison to clinical trials. The principle of justice should play a 
role when conceptualizing the notion of “vulnerability”84. This principle obliges researchers to 
promote research benefitting persons who are particularly in need of suitable therapies because 
of their physical or psychological vulnerability 85 . Their inclusion in clinical trials should 
incorporate supplementary ethical requirements and additional medical surveillance.  
4 The protection of trial participants in the new EU 
regulation on clinical trials  
41. As mentioned above, the new Regulation on Clinical Trials was adopted in April 2014 
by the European Parliament and the Council to replace the 2001 Clinical Trials Directive (CTD). 
According to Article 99 of the Regulation, it will not be applied before May 2016. The advantages 
of switching from a directive to a regulation are twofold: first, all Member States will now have 
exactly the same text, and second, this Regulation will be directly binding and applicable at the 
national level, without any need for an implementation process by domestic law. As we will see, 
the new Regulation improves the consideration of vulnerable populations in clinical trials in 
comparison to the CTD, but the protection is still lacking clarity and thoroughness. 
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4.1 AN IMPROVED BUT STILL UNCLEAR CONSIDERATION OF VULNERABLE 
POPULATIONS 
42. In its first version of July 2012, the Regulation offered a surprisingly limited 
protection of vulnerable subjects with only three categories: minors, incapacitated adults and 
unconscious patients in emergency situations. Certainly it was a step further in comparison to 
the CTD with the addition of emergency situations. However, it was still unsatisfying compared 
to the previously mentioned European standards relating to biomedical research.  
43. After almost two years of discussion and many amendments, the extent of 
vulnerable categories has been substantially increased. First, Recital 15 of the Regulation’s 
Preamble alludes to the vulnerability of “frail or older people, people suffering from multiple 
chronic conditions, and people affected by mental health disorders”, which seems to correspond 
to what we call health-related vulnerability. Recital 31, without explicitly labelling them as 
vulnerable, refers to participants belonging to an “economically or socially disadvantaged group” 
or placed “in a situation of institutional or hierarchical dependency that could inappropriately 
influence” their decision to participate. This latter Recital corresponds, in part, to our decisional 
vulnerabilities and confirms the need for differentiated legal responses, depending on the type 
of vulnerability.  
44. However, this distinction is not clear in the body of the Regulation. Article 10 
provides that specific considerations shall be given to the assessment of applications for 
authorisation of clinical trials involving vulnerable populations, on the basis of expertise in the 
relevant disease and population. It includes minors, incapacitated subjects, pregnant and 
breastfeeding women, specific groups or subgroups and patients in emergency situations. It is 
unclear whether the expression “specific groups or subgroups” refers to all groups mentioned in 
Recitals 15 and 31 or only to some of them. Furthermore, in the specific considerations 
regarding the informed consent, several categories are benefiting from a special status: 
incapacitated subjects (Article 31), minors (Article 32), pregnant and breastfeeding women 
(Article 33), and patients in emergency situations (Article 35). But most interestingly, Article 34 
gives the possibility for Member States to organize a further protection for certain subjects in a 
situation of institutional or hierarchical dependency likely to inappropriately influence their 
consent. However it does not mention economically or socially disadvantaged groups, and does 
not provide any specific protection for them. In a certain but incomplete way, their protection is 
concretized in the Regulation thanks to Article 25(5), which introduces the equivalence principle 
for the protection of trial participants outside of the EU. The latter thus also applies for the 
protection of vulnerable subjects, notably when recruited in developing countries, who are 
usually socially and economical disadvantaged in comparison to the developed countries 
conducting the clinical trials. Finally, there is no mention at all of the vulnerable groups -yet 
expressly mentioned as such in the Recital 15- of the “frail or older people, people suffering from 
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multiple chronic conditions, and people affected by mental health disorders” at any further 
provisions of the Regulation.  
45. If the situation of vulnerable populations is herewith nonetheless considered more 
comprehensively than in the CTD, the category of “vulnerable participants” remains vague. The 
new Regulation does not clearly define who is considered as vulnerable and who deserves which 
type of protection. Protection is limited to some general considerations in the Preamble, a 
restrictive provision on vulnerable subjects and a wider range of specific protective measures 
related to informed consent. This is problematic since theoretical clarity of the concept of 
vulnerability in biomedical research is crucial because it has significant consequences on the 
quality of protection86.  
4.2 A LEGAL PROTECTION OF VULNERABLE PARTICIPANTS LACKING 
THOROUGHNESS 
46. In order to evaluate the protection of vulnerable trial participants in the new EU 
Regulation, we again turn to the distinction between decisional vulnerabilities (risk of 
exploitation) and health-related vulnerabilities (risk of physical or psychological harm). 
4.2.1 Decisional vulnerabilities 
47. Many potential participants in clinical trials, because of their reduced cognitive 
capacities or freedom of choice, are at risk of being exploited for the benefit of scientific 
knowledge. First of all, subjects might be unable to give free and informed consent to research 
participation, be it de jure (minors and incapacitated adults) or de facto (unconscious patients in 
emergency situations). Second of all, other subjects might be at risk of being unduly influenced 
to accept to participate in clinical trials: socially, economically, financially and educationally 
disadvantaged groups, persons deprived of liberty or in medical institutions, persons in a 
situation of institutional, familial or hierarchical pressure etc. An excessive compensation or 
pressure could induce them to participate in clinical trials against their better judgment. In such 
cases, specific safeguards are needed to ensure that they have the ability to provide truly free 
consent to research participation.  
48. Still, while the new Regulation requires “informed consent” in Article 28, only Recital 
31 of the Preamble emphasises and explains the need for this consent to be given freely: “the 
investigator should take into account all relevant circumstances which might influence the 
decision of a potential subject to participate in a clinical trial”.  
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49. Certainly, Article 28.1.h sets as a condition for clinical trials that “no undue 
influence, including that of a financial nature, is exerted on subjects to participate in the clinical 
trial”. However there is a big discrepancy between such a short reference and the reality of the 
exploitation, notably in developing countries, but not only as it should also emphasize, 
hierarchical, institutional, religious or familial pressure that can make a subject vulnerable to 
undue influence to participate.  
50. Article 34 allows Member States to maintain additional measures regarding 
“persons performing mandatory military service, persons deprived of liberty, persons who, due 
to a judicial decision, cannot take part in clinical trials, or persons in residential care institutions”, 
but does not actually require States to provide special protection to those subjects regarding 
their free and informed consent. But even so, only allowing for additional protection is not 
protection per se.  
51. Consequently, Recital 31 does not find a concrete nor complete implementation in 
the Regulation. Persons with decisional vulnerabilities are thus not sufficiently protected from 
the risk of exploitation in clinical trials.  
4.2.2 Health-related vulnerability 
52. Some patients (children, frail or older adults, pregnant women, people with multiple 
chronic diseases, etc.) present particular physical, physiological or psychological conditions that 
may have a negative impact on the safety and efficacy of treatments and might put them at 
greater risk of harm in comparison to non-vulnerable participants. These population groups 
need therapies or drug dosages adapted to their condition, which implies the conduct of specific 
trials, which must be accompanied by additional safeguards (closer medical surveillance, 
competence of the investigator) to palliate the greater risk of harm.  
53. The new Regulation does consider physical and psychological vulnerability and calls 
for clinical trials involving those specific groups in Recital 15 of the Preamble: “medicinal 
products which are likely to be of significant clinical value should be fully and appropriately 
studied for their effects in these specific groups”. However, this is the only allusion to health-
related vulnerabilities in the Regulation.  
54. Technically, research participants with health related vulnerabilities are allowed to 
consent to research participation, even when the trial does not offer any direct benefit to them, 
but only to the population they represent. This is possible either because they are not vulnerable 
according to the Regulation and fall under Article 28.1(a); or because although they are 
vulnerable according to the Regulation, they are still legally capable, like for instance pregnant 
women (Article 33(b)I and ii); or finally because, although legally incapable like minors and 
incapacitated, they have a specific provision allowing them, in restricted cases, to participate to 
research for the benefit of the group that they represent (Articles 31.1(g)ii and article 32.1(g)ii).  
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55. It is unfortunate that the strategy applied to minors in the above mentioned 
Paediatric Regulation of 2006 has not been implemented for other physically or psychologically 
vulnerable subjects. The latter promotes high quality research involving children through 
incentives directed to pharmaceutical companies. As we have seen before, children are 
physically and psychologically vulnerable, but are also vulnerable in relation to decision-making. 
The complexity of this double vulnerability might explain why they are the only subjects 
benefiting from a specific set of rules. 
5 Four suggestions for a more accurate protection of 
vulnerable persons in the new EU Regulation on clinical 
trials 
56. Despite making strides towards the protection of vulnerable groups, the new 
Regulation is still lacking clarity and thoroughness and continues using the labelling approach, 
which we consider inadequate. In this section we make four general suggestions to improve the 
situation of vulnerable research participants in the EU. 
Suggestion 1: A risk-based definition of vulnerability  
57. The first suggestion is to adopt a risk-based definition of vulnerability. This would 
actually be in line with the ambition of the European Union to include and exclude participants 
more accurately according to the level of risk entailed in a trial (Preamble of the Regulation, 
Recital 11). This means, the more risks there are or the higher the risks are, the more demanding 
the participants’ protection has to be, and vice-versa. In this regard, it is interesting to note that 
the Regulation has adopted a risk-based approach by creating a new category of trials: the “low-
intervention clinical trials”, which pose only “very limited additional risk to the subject compared 
to normal practice (…). They should be subject to less stringent rules (…)” (Recital 11).  
58. It is important to stress that the risk-based approach of the Regulation only refers to 
the levels of the risk of harm, by classifying the medicines according to their potential 
dangerousness, e.g. between marketed medicines and investigational medicines. On the 
contrary the scope of this article is, as a first step, to identify the type of risk and not its level. 
The risk-based approach of the regulation will be applicable to health vulnerabilities (risk of 
harm), but not directly to decisional vulnerabilities (risk of exploitation). 
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Suggestion 2: A distinction between decisional and health related 
vulnerabilities 
59. The second suggestion consists of distinguishing between, on the one hand, 
decisional vulnerabilities, and, on the other hand, health-related vulnerabilities. This would help 
clarifying the concept of vulnerability in biomedical research as well as the specific health care 
needs of vulnerable groups. The provisions devoted to vulnerable subjects (Art. 10) and to 
informed consent (Arts. 31 to 35) mix those categories. However, this fundamental distinction is 
implied in the Preamble, in particular, in Recital 15, which corresponds to what we call health-
related vulnerability (increased risk of physical or psychological harm) and in Recital 31, which 
corresponds to our decisional vulnerabilities (increased risk of exploitation).  
Suggestion 3: A wider protection of consent against undue influence  
60. There are persons who have the legal capacity to consent to medical research, but 
who, mainly because of external factors are more vulnerable than others to undue influence (the 
poor, the unemployed, the dependent).  
61. As mentioned above, the new Regulation includes the absence of undue influence 
on potential participants as one of the conditions for conducting clinical trials (Article 28.1.h). 
Nevertheless, only financial incentives are explicitly mentioned, leaving aside other external 
factors which are as important like for instance hierarchical, institutional, familial or religious 
pressures, like is emphasized in the ICH guidelines (§1.61) 
62. Similarly, the Preamble explains that the investigator should take into account all 
certain circumstances which might “inappropriately influence” the decision of certain potential 
subjects (Recital 31). However, no criteria are provided to determine which influence is “undue” 
or “inappropriate”, and there is no mention of the fact that this factor should be assessed by an 
ethics committee, as is done in the CIOMS Guidelines (Guideline 7).  
Suggestion 4: An assertion of the need to organize clinical trials with 
physically or psychologically vulnerable participants  
63. As we have demonstrated before, the new Regulation does offer opportunities for 
vulnerable persons to be included in non-therapeutic research as long as it can benefit the group 
they represent (Infra 4.2.2). But as demonstrated, only offering the possibility might not be 
sufficient to protect future vulnerable patients of the same group. Incentives – as it has been 
done for children – would be welcome, provided that sufficient safeguards are guaranteed. 
64. Consequently, our fourth suggestion is to promote a more inclusive policy to 
encourage investigators to include physically or psychologically vulnerable participants in clinical 
trials, with the necessary additional safeguards. This promotion could be done, for instance, 
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through governmental incentives allocated to researchers accompanied with specific ethical 
considerations for vulnerable subjects, following the example of the Paediatric Regulation. 
 
6 Conclusion 
65. Having defined vulnerability as the result of a correlation between a susceptibility 
and a corresponding exposure to a risk, we claim that two types of vulnerabilities within clinical 
trials should be distinguished: one related to the risk of exploitation (decisional vulnerability), 
the other related to the risk of physical or psychological harm (health-related vulnerability). The 
first risk demands the protection of people who are unable to give their consent or who might 
be unduly influenced to consent to research participation. The second risk requires protecting 
people who are more likely to suffer any harm as a result of the experimental treatment. This 
protection does not entail excluding them from trials, but instead by providing these participants 
with additional safeguards like specific ethical requirement and medical monitoring. When 
participants have both kinds of vulnerabilities, the two types of protection have to be combined. 
Still, it seems important to distinguish them in order to fully assess the quality of the protection. 
66. The new EU Regulation adopts a wider understanding of vulnerable participants 
than the 2001 Clinical Trials Directive, but their protection remains unsatisfying for two reasons: 
firstly, the definition of vulnerability stays unclear and not conceptualized, secondly, this leads to 
a patchy protection of vulnerable subjects. In sum, we make four suggestions to protect the 
interests of vulnerable research participants: to adopt a risk-based definition of vulnerability, to 
clearly distinguish between, on the one hand, decisional vulnerabilities and, on the other hand, 
health-related vulnerability; to emphasise the need to ensure the freedom of consent of those 
persons who are more susceptible to undue influences (decisional vulnerability), and finally to 
assert the importance of actively promoting specific clinical trials involving people with physical 
or psychological vulnerabilities. 
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ABSTRACT 
Regulating paediatric research means searching for the balance between two valuable goals: 
protecting children while ensuring they benefit from safe and efficient medicines. Different legal 
instruments were adopted in the EU in order to regulate clinical trials, foster paediatric research 
and promote European and international ethical guidelines. However a new Regulation on 
clinical trials was adopted in 2014, and might change the current framework of paediatric 
research. How does the new Regulation 536/2014 foster research on children taking into 
account both the EU Paediatric Regulation and the EU Ethical Recommendations? Does it live up 
to the standards of the Directive 2001/20/EC and does it represent a step forward in accordance 
with international ethical guidelines? This article shows that, despite the adoption of new rules, 
many clarifications are still needed. Stakeholders involved in paediatric research have to play a 
driving role in the implementation process of the new Regulation. 
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1 Introduction 
67. Regulating paediatric research means striking the right balance between two 
valuable goals: protecting children because they are vulnerable, and making sure they benefit 
from safe and efficient medicines. After the outrageous medical experiments performed on 
humans during the Second World War, there has been a tendency to exclude any vulnerable 
participants from clinical trials. With time, this well-intentioned reaction showed its limitations. 
Due to the fact that children’s bodies could react differently to drugs as compared to adults but 
there has been a dearth of data regarding testing in children, many drugs were used off-label.  
Thus calls for safe and efficient medicines specifically for children arose. 
68. The Directive 2001/20/EC 87 , implementing ICH-GCP international guidelines, 
introduced for the first time specific provisions88 aimed at favouring the conduct of ethically 
acceptable clinical trials in children 89 . These provisions were enhanced by the ICH-E11 
specifically devoted to paediatrics90. In 2006, the Paediatric Regulation established “a system of 
both obligations and rewards and incentives”91 with the aim of fostering paediatric research92. 
One key measure of this Regulation is the institution, at the European Medicines Agency, of the 
Paediatric Committee (PDCO), in charge of giving advice and examining Paediatric Investigation 
Plans (PIP)93. Finally in 2008, EU Ethical Recommendations were developed with the aim of 
implementing non-binding ethical guidelines for Directive 2001/20/EC in the paediatric 
population.  
69. However, the European legal framework and especially the Directive 2001/20/EC 
was deemed partly responsible for a dramatic increase in bureaucracy, costs and delays for 
launching clinical trials in the EU, leading to a 25% decrease in trials94 as well as to their off-
                                                                    
87 Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, 
regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in 
the conduct of clinical trials on medicinal products for human use (Hereafter “Directive 2001/20/EC”) 
88 Directive 2001/20/EC, Article 4. 
89 “Children represent a vulnerable population with developmental, physiological and psychological differences from adults, 
which make age- and development- related research important for their benefit. Medicinal products, including vaccines, for 
children need to be tested scientifically before widespread use. This can only be achieved by ensuring that medicinal 
products which are likely to be of significant clinical value for children are fully studied”. Directive 2001/20/EC, Recital 3.  
90 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), Clinical Investigation of Medicinal Products in the Pediatric Population, E11, Geneva, 2000 (Hereafter “ICH E11)”. 
91 Regulation (EC) N° 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products 
for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation 
(EC) No 726/2004 (Hereafter “Regulation 1901/2006”), Recital 6. 
92 European Medicines Agency (EMA), Successes of the Paediatric Regulation after 5 years. August 2007-December 2012, 
EMA/250577/2013, London, 2013. 
93 Paediatric Investigation Plans are documents “upon which the development and authorisation of medicinal products for 
the paediatric population should be based”. Regulation 1901/2006, Recital 9. 
94 European Commission, Impact assessment report on the revision of the "Clinical Trials Directive" 2001/20/EC, VOLUME I, 
Working Document Commission Services, SWD(2012) 200 final, Brussels, 17 July 2012, (Annexes), p. 9. 
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shoring to emerging countries95. Those problems led to the elaboration and adoption of the new 
EU Regulation 536/201496 on clinical trials, which repeals the Directive 2001/20/EC, and will be 
directly binding and applicable for all EU-Member States by 2016. The major changes are as 
follows: first, the application procedure will be simplified, notably for multinational clinical trials, 
thanks to a unique application submitted to a single submission portal97. Second, assessment of 
the application is split in two: one part for the Reporting Member State (RMS), the other one for 
each Member State concerned by the trial98. Third, a new category of clinical low-intervention 
trials was created in order to facilitate research, notably academic trials, when the drug being 
tested is already authorized and additional procedures involve only minimal risk and burden99. 
Finally, there are several provisions that could impact paediatric research. For example, there 
are new criteria for the representativeness of subjects’ age and sex to be similar to that of future 
patients100, the possibility to conduct trials with minors in emergency situations101, and the 
status of the PDCO.  
70. How does the new Regulation foster paediatric research, taking into account the 
framework set up by the EU Paediatric Regulation? Does it implement the EU Ethical 
Recommendations; live up to the standards of the Directive 2001/20/EC; and represent a step 
forward in accordance with international relevant legal texts and guidelines? 
71. This article will deal with specific novelties that might require further attention 
regarding their implementation in paediatric research, such as the concept of minimal risk 
introduced in the new EU regulation as a requirement to authorise paediatric trials (2); the new 
category of low-intervention trials and its applicability (3); the role and expertise of Ethics 
Committees in paediatrics (4), the newly introduced possibility of secondary use of children’s 
data (5), as well as other internationally recognised ethical standards relevant to paediatrics that 
necessitate some clarification in the implementation of the new EU Regulation on clinical trials 
(6). 
                                                                    
95 The 2013 EMA report shows that, between 2005 and 2011, only 38.1% of the patients in pivotal trials submitted in 
marketing authorization applications to the EMA were from the EU. EMA, Clinical trials submitted in marketing-
authorisation applications to the European Medicines Agency ; Overview of patient recruitment and the geographical 
location of investigator sites. Containing data from 2005 to 2011, EMA/INS/GCP/676319/2012, London, 2013, p. 9.  
96 Regulation (UE) n° 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal 
products for human use and repealing Directive 2001/20/EC (Hereafter “Regulation 536/2014”) 
97 Ibid., Article 5. 
98 Ibid., Articles 6 and 7. The whole process is submitted to strict timelines sanctioned by the tacit agreement principle. 
Ibid., Preamble Recital 8. 
99 Ibid., Article 2.2(3). 
100 Ibid., Article 6.1(b)i. 
101 Ibid., Article 35.2(a). 
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2 Minimal Risk: A Key but Still Heterogeneous Concept to 
Authorize Paediatric Trials 
 
72. Whereas Directive 2001/20/EC only required risks to be minimized for children, the 
new Regulation introduces the criteria of minimal risk and minimal burden that now must be 
assessed “in comparison to the standard treatment of the minor’s condition”102. 
73. Except for the ICH-GCP103, many ethical guidelines consider “minimal risk” as a 
prerequisite for paediatric research (e.g. Declaration of Helsinki104, CIOMS guidelines105, UNESCO 
Declaration on Bioethics and Human Rights106, EU Ethical Recommendations107). This is also the 
case for legal instruments such as the Oviedo Convention of the Council of Europe108 and its 
Additional Protocol on Biomedical Research109, as well as most national laws in Europe (e.g. 
Austrian law110, Danish law111, French law112, German law113, Dutch law114, or Spanish law115) and 
abroad (the US116 and Canada117). However, most of these texts do not define what constitutes 
minimal risk. When definitions are provided, there is a lack of consistency among them. 
However, there exist two main interpretations of minimal risk: the US “absolute interpretation” 
                                                                    
102 Regulation 536/2014, Article 32. 
103 In the ICH guidelines, the requirement for conducting trials with persons who are not able to consent is that the 
foreseeable risks are low. ICH, Guideline for Good Clinical Practices, E6(R1), Geneva, 1996, § 4.8.14.b, p. 17. 
104 WMA (World Medical Association), Declaration of Helsinki - Ethics principles applicable to medical involving human 
subjects, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 64th WMA 
General Assembly, Fortaleza, Brazil, October 2013 (Hereafter “Declaration of Helsinki”), §28. 
105 “Minimal risk – that is, risk that is no more likely and not greater than that attached to routine medical or psychological 
examination”. CIOMS (Council for International Organizations of Medical Sciences), International Ethical Guidelines for 
Health-related Research Involving Humans, in collaboration with the World Health Organization (WHO), Geneva, 2002 
(Hereafter 2002 CIOMS Guidelines), Guideline 10.  
106 United Nations Educational, Scientific and Cultural Organization (UNESCO), Universal Declaration on Bioethics and 
Human Rights, 2006, Article 7.b). 
107 Ethical considerations for clinical trials performed in children. Recommendations of the Ad hoc group for the 
development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical 
trials on medicinal products for human use, final 2008, §11.1. 
108 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology 
and Medicine: Convention on Human Rights and Biomedicine, Oviedo, 4 April 1997, ETS n°164, (Hereafter “Oviedo 
Convention”), Article 17.2. 
109 Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, Strasbourg, 
25 January 2005, CETS n°195, (Hereafter “Additional Protocol”), Article 15.2. 
110 Arzneimittelgesetz (AMG), §42(2)2 ; as well as Medizinproduktegesetz (MPG), §51(2)2. 
111 Act on Research Ethics Review of Health Research Projects as updated on 9 October 2013, Section 19(3)3. 
112 Code de la Santé Publique (CSP), Article L 1121-7. 
113 AMG, §41(2)2.d). 
114 Act of 26 February 1998, containing rules on medical research involving human subjects (Medical Research Act), Section 
4.1. 
115 Law 14/2007, of 3 July 2007, on biomedical research, Article 20.2)b). Royal Decree 223/2004, of 6 February 2004, Article 
4.b). 
116 Code of Federal Regulations (CFR), Title 45, Section 46.404 Research not involving greater than minimal risk.  
117 Canadian Institute of Health Research (CIHR), Natural Sciences and Engineering Research Council of Canada (NSERCC), 
and Social Sciences and Humanities Research Council of Canada (SSHRCC), Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans, 2010, Articles 3.7.a and  6.12. 
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(2.1) and the Council of Europe “relative interpretation” (2.2). The EU Ethical Recommendations 
introduce a third, compromise approach (2.3). Questions remain as to how the Clinical Trials 
Regulation 536/2014 interprets minimal risk criteria (2.4). 
2.1 THE US ABSOLUTE INTERPRETATION OF MINIMAL RISK 
74. In the Code of Federal Regulations (CFR), minimal risk means that “the probability 
and magnitude of harm or discomfort anticipated in the research are not greater in and of 
themselves than those ordinarily encountered in daily life or during the performance of routine 
physical or psychological examinations or tests”118. 
75. This “absolute interpretation”119, or “healthy child interpretation”120, was first 
criticised because it could hinder valuable research by limiting acceptable risk to the very low 
risks that a healthy child faces in his daily life. Additionally, this interpretation, although 
restrictive in general, would not be protective enough in some cases. For example, healthy 
children might live in geographically or socially dangerous areas, which would lead to their 
inclusion in research of relatively high risk, which could still be minimal in comparison to their 
daily life121. Even if several suggestions exist as to how to interpret the absolute definition of 
minimal risk122, ambiguities remain as well as a lack of consensus on what is “small”, 
“moderate”, or “serious” risk of harm or “considerable” discomfort123. The comparator of “daily-
life” itself also has often been questioned124. 
76. This restrictive interpretation of minimal risk is balanced with possible exceptions. 
Specific conditions have been required in the CFR125, but more importantly, a crucial role is given 
to the IRB in the assessment of risk and the approval of the trial in accordance with these 
conditions126. 
                                                                    
118 CFR, Section 46.102 (i); This is almost similar to the previously mentioned definition of the CIOMS, except that the 2002 
CIOMS guidelines do not refer to the daily-life but only to medical and psychological examinations. 2002 CIOMS Guidelines, 
Guideline 10. 
119 Westra A. E. et al., “How best to define the concept of minimal risk”, Journal of Pediatrics, Vol. 159, n°3, 2011, p. 496. 
120 Binik A., “On the minimal risk threshold in children”, American Journal of Bioethics, Vol. 14, n°9, 2014, p. 3. 
121 Ibid., p. 4. 
122 For instance: to “limit the comparison of risks in nontherapeutic research to the risks posed by activities in daily-life that 
are designed to benefit others”. Wendler D., “Justice and nontherapeutic pediatric research”, American Journal of Bioethics, 
Vol. 14, n°9, 2014, pp. 13-15; or to distinguish between minimal risk of discomfort and minimal risk of harm. Westra A. E. et 
al., “How best to define the concept of minimal risk”, op. cit., p. 497. 
123 Ibid., p. 500. 
124 Ibid., p. 497. 
125 CFR, Section 46.405 Research involving greater than minimal risk but presenting the prospect of direct benefit to the 
individual subjects. CFR, Section §46.406 Research involving greater than minimal risk and no prospect of direct benefit to 
individual subjects, but likely to yield generalizable knowledge about the subject's disorder or condition. CFR, Section 
§46.407 Research not otherwise approvable which presents an opportunity to understand, prevent, or alleviate a serious 
problem affecting the health or welfare of children. 
126 In summary, “greater than minimal risk” is allowed when there is a prospect of direct benefit, if the balance risk/benefit 
is at least as favourable as that presented by available alternative approaches. But it can also be allowed without prospect 
of direct benefit to the child, if it is likely to yield generalizable knowledge about the subject's disorder or condition and if 
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2.2 THE COUNCIL OF EUROPE RELATIVE INTERPRETATION OF MINIMAL 
RISK 
77. According to the Council of Europe127, research is deemed to bear minimal risk if, 
“having regard to the nature and scale of the intervention, it is to be expected that it will result, 
at the most, in a very slight and temporary negative impact on the health of the person 
concerned”128.  
78. It is further specified that “minimal risk and minimal burden depend on the current 
state of knowledge and availability of procedures, and less invasive procedures should be 
utilised once they become available”129. Precise examples clearly show that the interpretation of 
minimal risk is relative, which means that it depends on each individual, his/her condition and 
treatment. This is the case, for instance, of taking small additional tissue samples “at the time 
when tissue samples are being taken, i.e. a surgical operation”.  
79. This interpretation is “relative”130 because it has to be assessed on a case-by-case 
basis, for instance distinguishing between the daily risks of healthy children versus sick 
children131. It depends on the specific risks that the research subject faces in his/her daily life. 
Therefore this interpretation of minimal risk is called “subject of research interpretation”132. The 
advantage and danger of this interpretation is that it permits to conduct research with higher 
risks in sick children. It might promote knowledge about their disease, but it also results in 
weaker protection of yet particularly vulnerable children. Can illness be a legitimate reason for 
treating children differently133? In any case, in both its texts, the Council of Europe excludes trials 
for children with any increase over minimal risk. The Council of Europe specifies that “any 
                                                                                                                                                                                                                   
the procedures involved in the research are “reasonably commensurate with those inherent in their actual or expected 
medical, dental, psychological, social, or educational situations” (45 CFR 46.406). In this case, the risk has to represent a 
“minor increase over minimal risk”, according to the IRB (Institutional Review Board) evaluation. Finally, it could be possible 
to carry out “research not otherwise approvable” if it presents an opportunity to understand, prevent, or alleviate a serious 
problem affecting the health or welfare of the child and if it will be conducted “in accordance with sound ethical principles” 
(45 CFR 46.407). In any case, adequate provisions have to be made for soliciting the assent of the children and permission 
of their parents or guardians. 
127 The Oviedo Convention does not exactly define the minimal risk for children, but provides a long list of examples in its 
Explanatory report. For instance: “obtaining bodily fluids without invasive intervention, e.g. taking saliva or urine samples 
or cheek swab; at the time when tissues samples are being taken, for example during a surgical operation, taking small 
additional tissue samples; taking a blood sample from a peripheral vein or taking a sample of capillary blood; minor 
extensions to non-invasive diagnostic measures using technical equipment, such as sonographic examinations, taking an 
electrocardiogram following rest, one X-ray exposure, carrying out one computer tomographic exposure or one exposure 
using magnetic resonance imaging without a contrast medium”. Explanatory report to the Additional Protocol, §100. 
128 Additional Protocol, Article 17.1. 
129 Explanatory report to the Additional Protocol, §96.  
130 Westra A. E. et al., “How best to define the concept of minimal risk”, op. cit., p. 495. 
131 “However, for certain participants, even these procedures might entail risk or burden which cannot be considered 
minimal. Assessment on an individual basis must therefore be carried out”. Explanatory report to the Additional Protocol, 
§100.  
132 Binik A., “On the minimal risk threshold in children”, op. cit., p. 4. 
133 Ibid., p. 5. 
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consideration of additional potential benefits of the research shall not be used to justify an 
increased level of risk or burden”134. 
2.3 THE EU ETHICAL RECOMMENDATIONS: A COMPROMISE APPROACH 
TOWARD MINIMAL RISK 
80. The EU Ethical Recommendations allow research with children when there is 
minimal risk and a prospect of benefit for the individual or for the group with the same 
condition. A minor increase over minimal risk is permitted when there is a benefit for the 
individual or for the group, but only if the risk/benefit ratio is at least as favourable as that of 
available alternative approaches. Finally, the Recommendations allow a greater than minor 
increase over minimal risk, but only when there is a benefit for the participant, and only if the 
risk/benefit ratio is especially favourable in relation to available alternatives approaches for the 
individual condition. 
81. The EU Ethical Recommendations for paediatric research released in 2008 tried to 
find a balance between the two existing approaches. They refer to the texts of the Council of 
Europe and use a relative interpretation of minimal risk as they compare it to the risks of the 
participant’s condition and treatment135. However, without referring to risks in daily-life, the EU 
Ethical Recommendations also seem to be aligned with the US absolute interpretation. The EU 
Ethical Recommendations consider “minimal risk” in a literal way, i.e. as a risk that would be 
minimal in every possible situation, similar to interpretation by the CFR. This explains why the 
Recommendations’ examples of minimal risk136 are in sharp contrast to those from the Oviedo 
Convention and on the contrary, why the EU Ethical Recommendations define exceptions to 
minimal risk137, similarly to the CFR.  
                                                                    
134 Additional Protocol, Article 15.2 ii. 
135 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., 12.1. 
136 “No or minimal risk: history taking, clinical examination, auxological measurments, tanner staging, behavioural testing, 
psychological testing, quality of life assessment, venepuncture, heel prick, finger prick, subcutaneous injection, urine 
collection with bag, breath condensate collection, collection of saliva or sputum, collection of hair sample, collection of 
tissue removed form body as part of medical treatment, topical analgesia, stool tests, Bio-impedancemetry, transcutaneous 
oxygen saturation monitoring (pulse oxymetry), blood pressure monitoring, electroencephalography, electrocardiography, 
vision or hearing testing, ophthalmoscopy, tympanometry, lung function tests (peak flow, exhaled NO, spirometry), oral 
glucose tolerance test, ultrasound scan, digitally amplified chest or limb X-ray, stable isotope examination)”. 
Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., Annex 4, p. 
30.  
137“Minor increase over minimal risk: Urine collection via endoluminal or suprapubic catheter, Arterial puncture, Umbilical 
catheter, pH metry, Nasogastric tube insertion and use, Transcutaneous oxygen or carbondioxide tension monitoring, 
Electrophysiological measurements (using stimulation), Exercise testing (ergometry, spiroergometry), Raised volume 
pulmonary function testing (infants), Peripheral venous lines, Polysomnography, Fasting (≥ 1 meal), Spinal CSF tap, Bone 
marrow aspiration, MRI scan, X-ray other than digitally amplified chest or limb X-ray, CT scan*, X-ray DEXA bone density 
measurement, Use of contrast media, Paracentesis, Skin punch biopsy, Airways or skin hyperreactivity challenge test”; 
“Greater than minor increase over minimal risk: Heart catheterisation, Endoscopy, Biopsy, Surgery or modification of 
standard surgical procedure carried out as part of medical treatment, Sedation, Anaesthesia, Systemic analgesia, 
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82. As a consequence, European legal texts referring to the criteria of minimal risk are 
inconsistent: on the one hand there is the Oviedo Convention and its “relative interpretation” of 
minimal risk, while on the other hand, the EU Ethical Recommendations offer a compromise 
between this interpretation and the ‘absolute interpretation’ inspired by US regulations. This 
inconsistency can lead to differences in the assessment of paediatric trials and consequent 
approval of the same research protocol138. One example demonstrates that the EU Ethical 
Recommendations are not protective enough because of this possibility to authorise a minor 
increase over minimal risk139, which is not even the highest risk that the document allows. The 
Oviedo Convention, supposedly more permissive with a relative interpretation of minimal risk, 
was on the contrary too restrictive and thus more likely to limit research. 
2.4 MINIMAL RISK IN THE NEW EU REGULATION ON CLINICAL TRIALS 
83. The new Regulation’s formulation, referring to the standard treatment of the 
minor’s condition, suggests that the interpretation of minimal risk will be relative because it 
depends on the minor’s condition and treatment. Does it mean that the level of acceptable risk 
can vary according to each child? If so, does it mean that children who are exposed to more risks 
should be exposed to even higher risks? Or does the notion of minimal risk entail only risks that 
are minimal in comparison to any treatment? Unfortunately, the Regulation does not provide 
any further indication on how to define minimal risks in practice. 
84. This seems to be quite surprising given that the notion of risk is part of a broader 
challenge: implementation of a risk-adapted approach to clinical trials140. Furthermore, the sole 
notion of risk causes implementation problems, as brought to the attention of the European 
Commission during the legislative process by the Bioethics Committee of the Council of 
Europe141 as well as by EU Parliament members in their 2013 amendments142. 
                                                                                                                                                                                                                   
Hypoglycaemia test, Unstable isotope usage, PET scanning”. Recommendations of the Ad hoc group, Ethical considerations 
for clinical trials performed in children,  op. cit., Annex 4, p. 30. 
138 Westra A. E. et al., “Drug development for children : How adequate is the current European ethical guidance ?”, Archives 
of Disease in Childhood, Vol. 95, n°1, 2010, p. 3. 
139 Ibid., p. 5. 
140 It consists in building a framework which strictness would be proportionate to the level of risk involved in the trial. Rid 
A., “How should we regulate risk in biomedical research ? An ethical analysis of recent policy proposals and initiatives”, 
Health Policy, Vol. 117, n°3, 2014, pp. 409-420. 
141 Bioethics Committee (DH-BIO), “Commentaires sur la proposition de Règlement du Parlement européen et du Conseil 
relative aux essais cliniques de médicaments à usage humain et abrogeant la directive 2001/20/CE à la lumière de la 
Convention sur les Droits de l’Homme et la biomédecine et de son Protocole additionnel relatif à la recherche biomédicale”, 
DH-BIO (2012) 24, 2012, , p. 4. 
142 Notably in order to distinguish between 1) risks for physical integrity, 2) risks for individual rights of the participants, and 
3) risks for data integrity and public health (which are quite similar to the OECD recommendations). Willmott G., Committee 
on the Environment, Public Health and Food Safety (ENVI), Report on the proposal for a regulation of the European 
Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC 
(COM(2012)0369 – C7 0194/2012 – 2012/0192(COD)), A7-0208/2013, Strasbourg, 7 June 2013, Amendment 274, p. 136. 
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85. Questions clearly remain and it is evident that the new Regulation could benefit 
from further clarifications or conceptualization on risk and minimal risk, especially if we consider 
that many other interpretations could serve as a guide for risk-adapted implementation of the 
Regulation 536/2014 such as those contained in the Canadian Tri-Council Policy Statement143 or 
the recommendations of the Organisation for Economic Co-operation and Development 
(OECD)144.  
86. In this context, there is no doubt that heterogeneous interpretations of minimal risk, 
and more generally the vagueness of the notion of risk, could raise uncertainties with respect to 
evaluating trial protocols and assessing when a trial should be considered as low-intervention.  
3 Low-Intervention Trials Notion and Applicability 
87. One main novelty in Regulation 536/2014 is the introduction of a new category of 
clinical trials, the low-intervention trial. The Regulation aims to facilitate trials145 with already 
authorised medicinal products either when used in accordance with their Marketing 
Authorization or their use is “evidence-based and supported by published scientific evidence”146. 
In any case, any additional diagnostic or monitoring procedures have to pose no more than 
“minimal additional risk or burden to the safety of the subjects compared to normal clinical 
practice”147. The low-intervention trial category could become a very useful tool in paediatric 
research in order to properly test drugs in children and report on, after marketing authorization, 
off-label uses of drugs in paediatric medicine’s daily practice. This procedure, which is more 
flexible and yet less consuming in terms of time and money, could also motivate sponsors to 
invest in research that focuses more on the needs of children, particularly academic sponsors for 
which clinical trials are far too expensive otherwise.  
88. However, the main problem with implementation of this new category is the 
interpretation of the notion of “normal clinical practice”. Usually, trials in minors must entail 
only minimal risks and burden in comparison “with the standard treatment of the minor’s 
condition” while for a low-intervention clinical trial, any additional risk or burden need to be 
                                                                    
143 The Canadian Tri-Council Policy Statement, define minimal risk as the risk in which the probability and magnitude of 
possible harms implied by participation in the research is no greater than those encountered by participants in those 
aspects of their everyday life that relate to the research. CIHR, NSERCC, SSHRCC, “Tri-Council Policy Statement: Ethical 
Conduct for Research Involving Humans”, 2010, Chapter 2, section B. 
144 The OECD suggested to compare the additional or incremental risk for the subject participating in a trial with the risk of 
non-participation, i.e., “the risk of usual care for patients (or the risk of daily life for healthy volunteers)”. Organisation for 
Economic Co-operation and Development (OECD), “OECD Recommendation on the Governance of Clinical Trials”, 2013, p. 
23. 
145 There will be more flexibility in the content of the application, traceability, and in damage compensation system, shorter 
timelines and sometimes even simplified informed consent. Regulation 536/2014, Articles 76.3 and 3.3.c. 
146 Regulation 536/2014, Article 2.2(3)b. 
147 Ibid., Article 2.2(3)c. 
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compared with “normal clinical practice”. At first sight, standard treatment of a minor’s 
condition has a greater likelihood to entail higher risks (e.g., a standard treatment in paediatric 
oncology) as compared to normal clinical practice, when we understand normal clinical practice 
as “routine examination”. Do the expressions “standard treatment” and “normal clinical 
practice” designate the same thing? If so, why do legislators use two different expressions? If 
not, what is the exact difference? Furthermore, should we consider normal clinical practice for a 
healthy or sick child? In the EU Regulation, normal clinical practice is defined as the “treatment 
regime typically followed to treat, prevent, or diagnose a disease or a disorder”. This notion is 
crucial because it determines an acceptable level of risk in low-intervention clinical trials148. 
89. It is understandable to harbour some doubts in relation to this notion, notably its 
vagueness. Does “normal” mean the statistically most frequent practice? If so, how are Ethics 
Committees going to gather empirical data on each type of practice? Or does “normal” mean the 
latest available treatment? The German Medical Association asserts that “the standard of care 
should be based on the most up-to-date scientific knowledge, not on normal clinical practice. 
The definition should be defined more precisely” 149 . In the same direction, the OECD 
recommendations distinguish between “standard of care” as the “treatment regimen or medical 
management based on state of the art participant care”150 and “usual care” (which could be 
similar to the EU normal clinical practice definition) defined as the use of a medicinal product “in 
accordance with the marketing authorisation”151. Several associations also have concerns and 
suggest to instead employ the expression “best current evidenced-based intervention”152. An 
amendment was presented in the parliamentary report in 2013, suggesting that the notion 
required concrete implementation guidelines from the Commission in order to avoid contrasting 
interpretations from each Member State153. Unfortunately, the amendment was not adopted in 
the final version, and the notion was not more clearly defined. The assessment of low-
intervention trials could be particularly complicated in paediatric research where the concept of 
normal clinical practice is even less clear, largely because of widespread “off-label” use of 
medicines in children. 
                                                                    
148 Regulation 536/2014, Article 2.2(2). 
149 German Medical Association (GMA), “Response to the European Commission on the proposal for a regulation of the 
European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 
2001/20/EC (COM/2012/369)”, 2012, p. 11. 
150 OECD, “OECD Recommendation on the Governance of Clinical Trials”, 2013, p. 44. 
151 Ibid., p. 24. 
152 The term “best current proven intervention”, defined as “the treatment regimen followed to treat, prevent, or diagnose 
a disease or a disorder according to current reliable scientific evidence” (amend Article 1(6) of the proposed Regulation), 
should replace the term “normal clinical practice” throughout the text. Association Internationale de la Mutualité (AIM) et 
al., Joint Analysis “New Proposal for a Regulation on Clinical Trials: - The protection of human subjects must be upheld - 
Citizens’ right to information must be strengthened”, 2013, p. 8. 
153 Willmott G. (ENVI), Report on the proposal for a regulation of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, op. cit., Amendment 12, p. 12. 
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4 The Role and Expertise of Ethics Committees in Paediatric 
Research 
90. Trial applications must undergo ethical review154, as conducted by an Ethics 
Committee (EC). Risk/benefit evaluation is to be carried out, within stringent and compulsory 
timelines, by the Reporting Member State (RMS) (Part I of the assessment), whereas the 
assessment of ethical and local aspects (such as the informed consent…) is to be carried out by 
all the Member States acting individually (Part II of the assessment). Risk-benefit is thus assessed 
only by the RMS and not also by the Ethics Committee at national level. It means that, despite 
the existing international guidelines and literature, the risk-benefit assessment is de facto taken 
out of the “ethical domain”.  While the RMS’s assessment and decision are valid to all other EU 
Member States155, the new Regulation could lead to sponsors giving preference to some states 
over others156. This issue reflects the EU’s general reluctance to address ethical issues in this 
regulation, such as the definition of ECs157, harmonization of different ethical review systems158, 
and practical and operational aspects of the assessment of part II159. This reluctance is just one 
of many issues that ECs face with respect to paediatric research, including the question of their 
                                                                    
154 Regulation 536/2014, Article 4. 
155 Members States can only opt-out from the trial, but without having any impact on the decision regarding the trial 
application. Regulation 536/2014, Article 8.2.c. 
156 The chosen RMS can only refuse this appointment if other Member States concerned manage to agree on one of them 
being appointed. Regulation 536/2014, Article 5. 
157Regulation 536/2014, Article 2.2(11). An Ethics Committee is defined as “an independent body established in a Member 
State in accordance with the law of that Member State and empowered to give opinions for the purpose of this Regulation, 
taking into account the views of laypersons, in particular patients or patients» organisations”. This new definition seems to 
have undergone quite a few cuts, notably on the symbolic statement of the ECs role to “protect the rights, safety and 
wellbeing of human subjects” and “to provide public assurance of that participation” foreseen in Directive 2001/20/EC. 
Directive 2001/20/EC, Article 6. 
158 The European Commission released a proposal in 2012 which had deleted any reference to ethics except for the 
provision stating that it is not part of the competence of the EU and should therefore be at the discretion of national laws 
(European Commission, “Proposal for a Regulation 2012/0192 of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, and repealing Directive 2001/20/EC, COM(2012) 369 final”, Recitals 6 and 12.); 
Many reactions from the scientific and academic community lead to the reestablishment of the ECs thanks to parliamentary 
amendments. But as underlined, this reestablishment was only done half-heartedly; For more on the topic: Bioethics 
Committee (DH-BIO), “Commentaires sur la proposition de Règlement du Parlement européen et du Conseil relative aux 
essais cliniques de médicaments à usage humain”, op. cit.; European Group on Ethics in Science and New Technologies 
(EGE), Statement on the proposal for a regulation of the European Parliament and of the Council on clinical trials on 
medicinal products for human use, and repealing Directive 2001/20/EC (COM 2012) 369 final, 2012; Nys H., “New European 
rules regarding the approval of clinical trials, the role of ethics committees and the protection of subjects”, Archivum 
Immunologiae et Therapia Experimentalis, n°60, 2012, pp. 405-414; Den Boer A. et Schipper I., “New EU regulation on 
clinical trials : The impact on ethics and safeguards for participants”, Indian Journal of Medical Ethics, Vol. X, n°2, 2013, pp. 
106-109; Heringa J. & Dute J., “The proposed EU-regulation on clinical trials on medicinal products : An unethical 
proposal ?”, European Journal of Health Law, n°20, 2013, pp. 347-362; Global Research in Paediatrics (GRiP), Children 
matter: important amendments in the draft Clinical Trials Regulation, 2013; Westra A.E. et. al, “New EU clinical trials 
regulation needs a few tweaks before implementation”, BMJ, Vol. 348, 2014, pp. 1-2. 
159 The Part II data sent through the EU portal does not appear to include approval of ethical aspects by the EC, although it 
specifically concerns ethical aspects. Petrini C., “Regulation (EU) n° 536/2014 on clinical trials on medicinal products for 
human use : An overview”, Ann Ist Super Sanita, Vol. 50, n°4, 2014, p. 320. 
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paediatric expertise (4.1), their collaboration (4.2), and interaction with Paediatric Committee 
(PDCO) PDCO (4.3). 
4.1 PAEDIATRIC EXPERTISE OF ETHICS COMMITTEES  
91. The new Regulation did not really change the requirement from Directive 
2001/20/EC that ECs have paediatric expertise or take “advice in clinical, ethical and 
psychosocial problems in the field of paediatrics” for trials on children160. These provisions, 
however, were thoroughly supplemented by the EU Ethical Recommendations, by adding 
requirements for ECs’ members to demonstrate proper documented education and experience 
in the various aspects of working in paediatrics161. This document gives precise indications of 
what constitute paediatric expertise which goes “beyond having professionally worked with 
children and could be defined on the basis of education, training and experience on the various 
aspects of child development, ethics and psychosocial aspects”162. It also recommends having a 
specialised EC in paediatrics “for the evaluation of trial protocols that are complex or in serious 
paediatric diseases”163. 
92.  The new Regulation does not yet satisfy these recommendations as it does not 
consider any of these and instead, adopts the formulation of the Directive 2001/20/EC almost 
word for word164. One amendment had been suggested, emphasising the need of paediatric 
expertise of the EC when the trial involves children165, but was not adopted in the final version. 
This is unfortunate and surprising, as a survey involving ECs in Europe demonstrates ECs’ lack of 
knowledge on both legal and ethical aspects of paediatric research, and the need of training and 
education of ECs in paediatrics166.  
                                                                    
160 Directive 2001/20/EC, Article 4.h. 
161 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §8. 
162 The rest of the recommendation gives examples of paediatric expertise: “Therefore, this would include i) physicians with 
paediatric qualification; ii) paediatric ethicists; iii) a paediatric pharmacologist, iv) qualified paediatric nurses or 
psychologists, etc”, the experts also have to demonstrate and document their experience with children in addition to 
expertise. Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., 
§8.1. 
163 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §8. 
164 Regulation 536/2014, Recital 19 and Article 10.1. 
165 “In cases of clinical trials involving minors, the ethics committee shall include at least one healthcare professional with 
paediatric expertise”. Willmott G. (ENVI), Report on the proposal for a regulation of the European Parliament and of the 
Council on clinical trials on medicinal products for human use, op. cit., Amendment 64, §2, 10a (new).  
166 Altavilla A. et al., “Impact of the new European paediatric regulatory framework on ethics committees: Overview and 
perspectives”, Acta Paediatrica, Vol. 101, n°1, 2012, p. 5. 
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4.2 COLLABORATION OF EUROPEAN RESEARCH ETHICS COMMITTEES IN 
PAEDIATRICS 
93. An EU-wide study identified networking among ECs as a fundamental tool for 
enhancing collaboration, experience and information exchange167, especially on ethical issues 
including procedures and principles of ethical assessment. The need of a network or platform 
organized at the European level was suggested at multiple times168 169 170. Two amendments, 
submitted in 2013 for an organisation at the European level of a network of ECs, argue that it is 
the role of the Commission to set up a European Platform to bring consistency in ethical reviews 
by encouraging cooperation and sharing of best practices among ECs171. This proposal is 
particularly important if we consider that ethical and legal disparities among Member States are 
still a major concern, possibly leading to so-called “ethics shopping”, as highlighted by different 
stakeholders and by the European Group of Ethics172. Unfortunately, none of those potentially 
helpful suggestions has been adopted during the legislative process of the new EU Regulation on 
clinical trials.  
94. Actually a network (EUREC) bringing together national Research Ethics Committees 
(REC) associations, networks or comparable initiatives on the European level exist. It aims at 
promoting awareness of specific working practices of RECs across Europe, enhancing the shared 
knowledge base of European RECs173. Nevertheless, as clinical trials in children shows very 
distinct particularities and challenges, there is still a need for a specific network among ECs 
involved in paediatric research. To promote and foster their cooperation and improve their 
                                                                    
167 Altavilla A. et al., “Impact of the new European paediatric regulatory framework on ethics committees: Overview and 
perspectives”, op. cit., p. 5. 
168 European Commission, Assessment of the functioning of the “Clinical Trials Directive” 2001/20/EC. Summary of the 
responses to the public consultation paper, SANCO/C/8/SF/dn D(2010) 380240, 2010, p. 6. 
169 European Commission, Revision of the “Clinical Trials Directive” 2001/20/EC. Summary of the replies to the public 
consultation on the “Concept Paper”, SANCO/D/3/PB/SF/ddg1.d.3(2011)816084, 2011, §38, p. 5. 
170 A quality and accreditation system could be established for all Ethics Committees so that all trials are reviewed by 
“competent” bodies playing a key role also in the “risk-benefit assessment”. Westra A.E.  et. al, “New EU clinical trials 
regulation needs a few tweaks before implementation”, op. cit. 
171 “Currently, the ethical review procedure varies greatly between Member States, often with various bodies at national, 
regional and local levels, and multiple procedures leading to divergent assessments. This is a source of delays and 
fragmentation. In the interests of European patients and public health, the procedures and principles of ethical review 
should be better harmonised through the sharing of best practices between ethics committees. To this end the Commission 
should facilitate the cooperation of ethics committees”. Willmott G. (ENVI), Report on the proposal for a regulation of the 
European Parliament and of the Council on clinical trials on medicinal products for human use, op. cit., Amendment 27, 
Recital 14b (new); See also: “The Commission shall facilitate cooperation of ethics committees and the sharing of best 
practices on ethical issues including the procedures and principles of ethical assessment”. Ibid., Amendment 79, Article 4a 
(new) 2.  
172 EGE, Statement on the proposal for a regulation of the European Parliament and of the Council on clinical trials on 
medicinal products for human use, op. cit. 
173 EUREC is connected with the EURECNET Project that is a consortium of twenty European research facilities which has 
been established in March 2011 and is being funded by the European Commission under Framework Program 7 (FP7). It is 
coordinated by the German Reference Centre for Ethics in the Life Sciences (DRZE). Following already existing efforts, 
especially efforts within a previous project (EUREC), one of its primary objectives is to foster a sustainable infrastructure for 
European RECs. http://www.eurecnet.org/index.html. 
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expertise, best practice models of ethical evaluation of paediatric trials should be developed. A 
quality and accreditation system could be established for these Committees so that all trials are 
reviewed by “competent” bodies playing a key role also in the “risk-benefit assessment”174 
particularly complex for children. 
4.3 INTERACTIONS WITH THE PAEDIATRIC COMMITTEE (PDCO) 
95. However, at the European institutional level, the new Regulation confirms the 
importance of the role of the Paediatric Committee (PDCO) by expressly requiring the opinions 
of the latter to be taken into account in the assessment of anticipated therapeutic and public 
health benefits175. 
96. Still there remain uncertainties about the roles of ECs and their interactions with the 
RMS authorities and PDCO. Coordination between competent authorities and ECs will need to be 
carefully established, particularly when Part I and II are presented together and the two 
assessments are processed in parallel within the same national timetable176. What happens 
when the PDCO gives the approval to the Paediatric Investigation Plan but the RMS and/or the 
EC does not approve the protocol of the same trial? The decision of the EC will entail more than 
balancing risk/benefit because it takes into account the whole protocol. On the contrary, the 
protocol was not yet designed at the time of the PDCO’s decision, which only concern the PIP. 
Nevertheless as you would expect, the PDCO has a paediatric expertise that the EC and the 
national authorities in charge of the protocols evaluation does not necessarily have. Whose 
decision should prevail over the other? Further clarification would be helpful regarding 
interaction with authorities involved in the protocol review, ethical review conducted at a 
national level, evaluation of PIPs by the paediatric experts of PDCO, as well as detailed criteria 
and ethical guidelines for systematic use in the assessment of protocols and PIPs177. 
5 Secondary Use of Data in Children 
97. One novelty of the Regulation 536/2014 is the introduction of secondary use of data 
collected in children: “Without prejudice to Directive 95/46/EC, the sponsor may ask the subject 
or, where the subject is not able to give informed consent, his or her legally designated 
representative at the time when the subject or the legally designated representative gives his or 
                                                                    
174 Westra A.E.  et. al, “New EU clinical trials regulation needs a few tweaks before implementation”, op. cit. 
175 Regulation 536/2014, Article 6.1.b.i. 
176 Petrini C., “Regulation (EU) n° 536/2014 on clinical trials on medicinal products for human use : An overview”, op. cit. 
177 Enpr-EMA has set up a Working Group to gather examples of “good practice when ECs consider trials related to children 
and young people” and to develop proposals to disseminate those examples. Enpr-EMA, Mandate of the Enpr-EMA working 
Groups, EMA/493016/2013Rev.1, 2014, p. 4. 
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her informed consent to participate in the clinical trial to consent to the use of his or her data 
outside the protocol of the clinical trial exclusively for scientific purposes. That consent may be 
withdrawn at any time by the subject or his or her legally designated representative”178. 
98. This new provision seems to be helpful to avoid unnecessary replications of trials 
and develop useful epidemiological studies, especially for generating data on children179. 
However, this “broad consent”, given in advance, will never be as precise and informed as a 
repeated informed consent procedure. Even if doing so proves to avoid additional risks to 
children, because the samples are already obtained, a broad parental consent deprives the child 
of the opportunity to exercise autonomy, by not allowing his/her ratification of the parental 
consent at a later date. This problem could be particularly relevant in longitudinal studies that 
imply a potentially lengthy period of involvement of children. Moreover, if the minor keeps the 
right to withdraw his/her consent, notably when becoming legally competent, he/she has to be 
able to exercise this right. This means that he/she has to be informed of the existence of a new 
study. Thus it implies that re-identification of his/her data must be possible.  
99. Furthermore, different legislations have adopted different definitions to guarantee 
the confidentiality of personal data180. Terms such as “anonymization”, “pseudonymisation”, 
“codification”, and “de-identification” are indiscriminately used in guidelines and legal texts to 
indicate similar concepts as different requirements and level of confidentiality protection have 
been identified taking into account the notion of “reversibility” within the data processing 
procedures181. That’s why it is important to have clear definitions and frameworks, so that 
parents and minors know exactly what they consent to when they are told that their child’s 
information will be coded or anonymized. Finally, specific requirements must be established 
with reference to specific data, such as genetic data, which can raise concerns in terms of equity 
and discrimination especially for children. Precise definitions and provisions need to be 
developed, guaranteeing transparency to minors and legal representatives, and assuring legal 
certainty. Perhaps the forthcoming reform of the EU data protection legal framework will bring 
some answers to these questions182. 
                                                                    
178 Regulation 536/2014, Article 28.2. 
179 Regulation 1901/2006, Article 41; Recommendations of the Ad hoc group, Ethical considerations for clinical trials 
performed in children,  op. cit., §19. 
180 Canadian guidelines differentiate between directly identifying information, indirectly identifying information, coded 
information, anonymized information and anonymous information. For more details: Centre of Genomics and Policy (CGP), 
Maternal Infant Child and Youth Research Network (MICYRN), Best Practices for Health Research Involving Children and 
Adolescents, 2012, p. 92.  
181 Global Research in Paediatrics (GRiP), Report on ethical and governance issues related to processing of healthcare data, 
D.2.04, 2015. 
182 European Commission Website, http://ec.europa.eu/justice/data-protection/review/index_en.htm. 
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6 Other Relevant Ethical Standards Impacting Paediatric 
Research 
100. There are other issues that require attention towards paediatric research. All of 
these are included in the EU Ethical Recommendations, and often correspond to internationally 
recognised ethical and methodological standards. Here we address those issues that require 
specific mention within the framework of the new EU Regulation. 
6.1 ASSENT/DISSENT AND COMPENSATION: A STEP FORWARD WITH 
NEED OF CLARIFICATION 
101. The notion of assent, introduced by the Declaration of Helsinki183 and mentioned in 
the WHO-CIOMS184 and ICH-E11 guidelines185, was introduced into the EU legal framework only 
with Regulation 536/2014186. Nevertheless, Member States still have a large margin within which 
to manoeuvre in applying this principle, again possibly leading to some disparities, especially 
with multinational trials.  
102. The new Regulation is significantly progressive with respect to “dissent” of the child. 
While Directive 2001/20/EC notes that dissent of the child has to be “considered”187, the new 
Regulation now expects it to be “respected”: “the explicit wish of a minor who is capable of 
forming an opinion and assessing the information referred to in Article 29(2) to refuse 
participation in, or to withdraw from, the clinical trial at any time, is respected by the 
investigator”188.  
103. Best-practice guidelines that take into account national legislations and are based on 
a well-sustained methodological approach should be developed. Specific requirements to obtain 
the child’s assent, adapted to different age-ranges, provided in the EU Ethical 
Recommendations189, as well as international provision related to the respect of refusal190 could 
be an important starting point for the implementation of these guidelines. Regarding 
                                                                    
183 Declaration of Helsinki, §29. 
184 2002 CIOMS Guidelines, Guideline 14. 
185 ICH E11, §2.6.3, p. 11. 
186 EU Member States may foresee, in their national law, that the «minor who is capable of forming an opinion and 
assessing the information given to him or her, should himself or herself assent in order to participate in a clinical trial». 
Regulation 536/2014, Recital 32 and Article 29.8. 
187 Directive 2001/20/EC, Article 4.c. 
188 Regulation 536/2014, Article 32.1.c  
189 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children, op. cit., §5.7, §6.1, 
§6.4 and §7. 
190 Oviedo convention, Article 17.1.v; United Nations Commission on Human Rights (UNCHR), Convention on the Rights of 
the Child of 20 November 1989, Article 12.1.  
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compensation, the new Regulation changes the provision applicable in the EU, stating that “no 
incentives or financial inducements are given to the subject or his or her legally designated 
representative except for compensation for expenses and loss of earnings directly related to the 
participation in the clinical trial”191.  
104. This provision is quite progressive compared to the Directive 2001/20/EC, which 
forbade financial incentives but allowed “compensation” without further detail on the nature 
and extent of this compensation192. The new Regulation implements and supplements the EU 
Ethical Recommendations193. The EU framework on clinical trials might now be stricter than the 
Council of Europe Conventions194 and U.S. legislation195. 
105. However, questions remain concerning the definitions of “inducement” or 
“incentive”196. It is not clear what the two terms in the new Regulation really entail. Therefore, it 
is also not clear which exact elements ECs should examined when reviewing payments. What 
constitutes an undue influence can be very different depending on the age of the minor, familial 
background and his/her financial or social situation197. 
6.2 MEASURES TO MINIMIZE PAIN, RISK MONITORING AND USE OF 
PLACEBOS: MISSED CHANCES FOR IMPROVEMENT 
106. Directive 2001/20/EC required trials with minors and incapacitated adults to be 
“designed to minimise pain, discomfort, fear and any other foreseeable risk in relation to the 
disease and developmental stage (…) Both the risk threshold and the degree of distress have to 
be specially defined and constantly monitored”198. With the new EU Regulation, this is now a 
general provision for all participants and not only children and incapacitated persons199. 
                                                                    
191 Regulation 536/2014, Article 32.1.d). 
192 Directive 2001/20/EC, Article 4.d. 
193 The EU Ethical Recommendations are stating that this ban of financial incentives should concern not only the child but 
also the parents / legal representatives, and that compensation was only related to the time and expenses of the latter. 
Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §21. 
194 The Oviedo Convention only forbids in its Additional Protocol on Biomedical Research «undue influence, including that 
of financial nature» on the potential participant. Additional Protocol, Article 12. 
195 The CFR provides that the IRBs is responsible of assessing «the amount of payment and the proposed method and timing 
of disbursement to assure that neither are coercive or present undue influence». 21 CFR 50.20 
196 Canadian guidelines give precise and clearly distinguished definitions of reimbursement, compensation, appreciation 
and incentive. According to those, reimbursement would concern transportation, parking, meals, lodging or babysitting 
whereas compensation would rather be for time and inconvenience. Appreciation could be toys, gift certificate, books, 
movie coupons etc. and finally incentive could take the form of a draw, lottery or community service credit. CGP & MICYRN, 
Best Practices for Health Research Involving Children and Adolescents, op. cit., p. 114. 
197 Since an increasing proportion of clinical trials are conducted in developing countries, the prohibition of (hidden) 
remuneration is particularly important for the protection of participants, i.e. with socially and financially disadvantaged 
populations who hope either for health care or for payment when they take part in a clinical trial. Regulation 536/2014; A 
Altavilla A., “Ethical standards for clinical trials conducted in third countries: The new strategy of the European Medicines 
Agency”, European Journal of Health Law, Vol. 18, 2011, pp. 65-75. 
198 Directive 2001/20/EC, Article 4. 
199 Regulation 536/2014, Article 28. 
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107. Yet the EU Ethical Recommendations give thoroughly detailed guidelines on how to 
minimise pain, distress and fear in children, taking into account age and condition-appropriate 
validated scales. Furthermore, the document underlines the requirement to limit 
investigations/interventions to the minimum necessary for obtaining valid data (e.g., using size-
/age-appropriate material and devices, including limiting in advance the number of attempts for 
sampling). Surprisingly, the new EU Regulation does not mention any of these recommendations 
or even the fact that children deserve specific attention and care to prevent physical and 
emotional pain and distress. 
108. Furthermore, whereas the EU Ethical Recommendations expressly recommend to 
monitor the level of risk especially for paediatric populations200 and to use a Data and Safety 
Monitoring Board (DSMB), the new EU Regulation only requires investigators to monitor three 
elements201, including risks but only indirectly202. Using a DSMB for paediatric research is not 
mentioned. However, it would be useful to expressly address monitoring of risks, instead of 
leaving it up to the sponsor to decide the extent and nature of that. It would also be useful to 
mention that monitoring of risks should be specific to vulnerable groups, including children. The 
constant update of risk/benefit evaluation, in light of scientific developments during research, 
should be particularly important for the paediatric population, particularly if we take into 
account the fact that children are constantly developing themselves.  
109. Finally, regarding control groups and placebos, although Directive 2001/20/EC does 
not contain specific requirements, the EU Ethical Recommendations give precise guidelines on 
the use of placebos and paediatric control groups203. Placebo is not acceptable when it implies 
that an effective and available treatment be withheld, especially for life-threatening conditions. 
There might be some occasions where its use is permissible but must be discussed, and then 
harm and exposure to harm should be avoided or minimised as much as possible, and ‘rescue 
treatments and escape procedures’ organised. However, none of these recommendations were 
included or mentioned in the new Regulation, not even in a general manner, despite the fact 
that various institutions, like the EMA204, and guidelines, such as the WHO-CIOMS guidelines205 
or the Declaration of Helsinki206 require as much207. 
                                                                    
200 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §9. 
201 Monitoring of the objective and methodology, monitoring of low-intervention trials, and monitoring of the degree of 
deviation from normal clinical practice. Regulation 536/2014, Article 48. 
202 The monitoring of the “objective and methodology” does not necessarily include the monitoring of the risks. As for the 
other elements, one of them only concerns the monitoring of low-intervention trials, and only the last element could lead 
to monitoring the risks: “degree of deviation of the intervention from normal clinical practice”. Ibid., Article 48. 
203 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §9.2.1. 
204 The EMA warned against the danger to justify the use of placebos when the standard treatment is not available in the 
country where the trial is conducted. EMA, Reflection paper on ethical and GCP aspects of clinical trials of medicinal 
products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU 
regulatory authorities, EMA/121340/2011, London, 2012, §4.6, p. 26-27. 
205 By principle, the use of placebo is forbidden, and only acceptable by exception: “- when there is no established effective 
intervention; - when withholding an established effective intervention would expose subjects to, at most, temporary 
discomfort or delay in relief of symptoms; - when use of an established effective intervention as comparator would not 
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6.3 PROVISIONS FOR TRIALS CARRIED OUT OUTSIDE THE EU: 
INADEQUATE IMPLEMENTATION FOR PAEDIATRICS 
110. The new Regulation, which confirms existing rules adopted at the international208 
and European209 level, introduces an equivalence criterion and specifies that clinical trials 
conducted outside the EU shall be conducted in accordance with principles equivalent to those 
in the Regulation, with regard to the rights and safety of a subject and the reliability and 
robustness of data210. As with any type of clinical trial, paediatric trials performed in non-EU 
countries should be conducted in accordance to the laws and regulations of the country of 
conduct, most importantly, in accordance to all ethical standards and good clinical practice 
applicable in the European Union, regardless of any goal for obtaining a Marketing 
Authorization211. 
111. Nevertheless, as demonstrated, many aspects especially related to ethical and 
methodological standards for paediatric research are not clear and harmonised in Europe. 
Hence, the criterion of equivalence could be interpreted in various and broad ways leading to an 
increasing shift of paediatric trials outside Europe, especially in low-income and emerging 
countries that, as many reports show, are particularly attractive for sponsors212.  
                                                                                                                                                                                                                   
yield scientifically reliable results and use of placebo would not add any risk of serious or irreversible harm to the subjects”. 
2002 CIOMS Guidelines, Guideline 11. 
206 The Declaration of Helsinki only allows the use of placebo when there is no proven intervention available, when it is 
indispensable to assess the safety and efficacy of the trial, or when the use of placebo does not expose the participant “to 
additional risks of serious or irreversible harm as a result of not receiving the best proven intervention”. WMA, Declaration 
of Helsinki, §33. 
207 Regulation 536/2014, Recital 80. 
208 2002 CIOMS Guidelines, Guideline 3.  
209 Directive 2001/83/EC, as amended by Directive 2004/27/EC, established that clinical trials performed in third countries 
(non-EU countries) and submitted in a Marketing Authorisation application in the EU should be conducted in accordance 
with the principles of Good Clinical Practice and the ethical requirements equivalent to the provisions of Clinical Trials 
Directive and should comply with Good Manufacturing Practices of EU countries. In this sense, the EMA Reflexion Paper, 
released in 2012, proposed that EU competent authorities should refuse to consider data obtained that is not in accordance 
with ethical standards. EMA, Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human 
use conducted outside of the EU/EEA, op. cit. 
210 Regulation 536/2014, Article 25.5. 
211 Recommendations of the Ad hoc group, Ethical considerations for clinical trials performed in children,  op. cit., §23. 
212 Low-income and emerging countries are particularly attractive for sponsors because less stringent regulation and/or 
weak enforcement can result in a faster approval of protocols and recruitment of subjects, for which participation in a trial 
may be the only option for access to medication and treatments. For more see: Koski G. and Nightingale S. L., “Research 
involving human subjects in developing countries”, NEJM, Vol. 345, 2001, pp. 136-138; Hawkins J.S. and Emanuel E.J., 
Exploitation and Developing Countries. The Ethics of Clinical Research, Princeton, NJ: Princeton University Press, 2008; I. 
Schipper and F. Weyzig, “Ethics for drug testing in low and middle income countries, considerations for European market 
authorisation”, SOMO, 2008,  p. 77 . 
  61 
7 Conclusion 
 
112. Regulating paediatric research in the European Union and implementing the 
Regulation 536/2014 represent a particularly difficult challenge that requires clarity, 
transparency and legal certainty. As underlined, many notions actually need to be clarified 
because current discrepancies will lead to uncertainties in the assessment of paediatric 
protocols, especially in multicentre trials and trials conducted outside of the EU. Particular clarity 
is needed for the concepts of minimal risk and low-intervention trials, but also for issues 
concerning the role and paediatric expertise of ECs and their interaction with the Paediatric 
Committee (PDCO), as well as the conditions for processing paediatric data (especially in the 
case of secondary use of data in children) and compliance with other internationally recognized 
ethical standards. 
113. Furthermore, current uncertainties and disparities in the EU Regulation are not 
tempered by any reference to international ethical guidelines that could provide a basis for 
greater harmonisation. It is unclear as to what is the current status of the EU Ethical 
Recommendations for paediatric research since they were not repealed, but might still be 
obsolete because of their strong link to the provisions of Directive 2001/20/EC. All the relevant 
guidelines and recommendations are expected to be revised and updated so as to be in line with 
the changes and requirements of the Clinical Trials Regulation, but since ethical aspects are not 
adequately addressed in the Regulation and are instead left to national provisions, clarifications 
of those issues are necessary in order to ensure equal treatment of children across Europe. The 
Oviedo Convention and its Additional Protocol on Biomedical Research are not mentioned once 
in the whole text of the Regulation213 and the legal status of the Declaration of Helsinki and the 
ICH guidelines is vague214. The revision process of paediatric ICH guidelines currently continues 
and an addendum will be developed including, among others, an enhancement of the ethical 
considerations in paediatric studies within a global context215. 
114. In the light of this analysis, we wonder if the new Regulation represents a step 
forward for paediatric research. Since further clarifications are needed, the implementation 
                                                                    
213 The Oviedo Convention has been ratified by 29 countries to this date, Website of the Treaty Office from the Council of 
Europe, http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?NT=164&CM=8&DF=23/02/2015&CL=ENG. The 
Additional Protocol to the Oviedo Convention on Biomedical Research has been ratified by 9 countries to this date, Website 
of the Treaty Office from the Council of Europe, http://conventions.coe.int/Treaty/Com 
mun/ChercheSig.asp?NT=195&CM=8&DF=23/02/2015&CL=ENG [15 June 2018]. 
214 Their status is vague whereas their clarification was one of the claims in the responses to the public consultations as well 
as in literature on the proposal for the Regulation released by the European Commission. European Commission, 
Assessment of the functioning of the “Clinical Trials Directive” 2001/20/EC. Summary of the responses to the public 
consultation paper, op. cit., p. 15. 
215 ICH Steering Committee, Final Concept Paper E11(R1): Clinical Investigation of Medicinal Products in the Pediatric 
Population, 2014. 
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process of the new Regulation, carried out under supervision of the European Commission, will 
be a crucial step. All main stakeholders engaged in paediatric trials must play a major role in this 
process with the aim to facilitate and foster ethically sound paediatric research. 
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1 Introduction 
115. Over the past decade, significant efforts have been made in Europe to promote 
patients’ self-determination. An important step in this direction was the explicit support given by 
the Council of Europe and several European countries to the use of advance directives to specify 
healthcare preferences in case of future incapacity216. In contrast, the possibility of using 
advance directives to prospectively consent to research participation remains largely unexplored 
in Europe. Moreover, legal instruments in the area are virtually silent. However, despite the 
current regulatory vacuum, the use of advance research directives (ARDs) is gradually drawing 
interest among scholars217. In addition, non-governmental organisations promoting the care of 
patients suffering from dementia have, in recent years, given their explicit support to the use of 
ARDs, provided that certain safeguards are in place218.  
116. ARDs can serve as a useful tool for patients in the early stage of dementia who are 
still capable of consenting to research participation. These documents allow them to express 
their preferences about their participation in future or ongoing clinical trials should they lose 
decision-making capacity. Without such directives, family members are placed in the difficult 
role of having to make a decision based on the presumed wishes of the patient or on the 
assessment of his or her best interests, which are not obvious when no direct benefit is 
expected. Several studies show that proxies cannot reliably guess patients’ preferences: they are 
either too reluctant to authorise their enrolment in clinical trials, or consent to studies that do 
not really correspond to the preferences and values of the persons they represent219.  
117. The current situation is challenging since there is a crucial need to conduct research 
involving dementia patients to better understand the conditions that cause dementia (in 
particular Alzheimer’s disease), and to develop more effective therapeutic or preventive 
measures. Dementia is at present one of the greatest global health challenges as the number of 
people suffering from this condition worldwide is estimated at 44 million and is set to almost 
                                                                    
216 Andorno R., Biller-Andorno N. & Brauer S., “Advance Health Care Directives. Towards a Coordinated European Policy?”, 
European Journal of Health Law, Vol. 16, n°3, 2009, pp. 207-227; Negri S. (ed.), Self-Determination, Dignity, and End-of-Life 
Care. Regulating Advance Directives in National and International Law, Leiden: Brill Academic Publishers, 2012; Goffin T., 
“Advance Directives as an Instrument in an Ageing Europe”, European Journal of Health Law, Vol. 19, n°2, 2012, pp. 121-
140; Veshi D. & Neitzke G., “Advance Directives in Some Western European Countries: A Legal and Ethical Comparison 
between Spain, France, England, and Germany”, European Journal of Health Law, Vol. 22, n°4, 2015, pp. 321-345.  
217 Lötjönen S., “Medical research on patients with dementia: the role of advance directives in European legal instruments”, 
European Journal of Health Law, Vol. 13, n°3, 2006, pp. 235-261; Helmchen H., “Ethics of clinical research with mentally ill 
persons”, European Archives of Psychiatry and Clinical Neuroscience, Vol. 262, 2012, pp. 441-452; Jongsma K. and van de 
Vathorst S., “Advance directives in dementia research: The opinions and arguments of clinical researchers – an empirical 
study”, Research Ethics, 2014, published online 8 August 2014: doi: 10.1177/1747016114523422. 
218 Alzheimer Europe, Position paper on the use of advance directives, 2009, §31. 
219 Stocking C.B. et al., “Speaking of research advance directives: planning for future research participation’”, Neurology, 
Vol. 66, n°9, 2006, pp. 1361-1366.  
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double by 2030220. Rates increase significantly with age, as dementia affects 5 per cent of the 
population older than 65 and 25-50 per cent of those older than 85221. 
118. The moral advantage of ARDs, if compared to the current practice of proxy consent, 
is that participants themselves, while still competent, provide their consent to research 
participation. This possibility can be regarded as a mechanism of empowerment222. Like advance 
directives for healthcare, advance directives for research can be justified on the grounds that 
they offer a tool for prospective self-determination to those individuals who anticipate 
incapacity: if autonomous choices regarding one’s own healthcare can be applied beyond one’s 
competence, why should it be different for participation in clinical trials? From a more practical 
perspective, ARDs have the advantage of helping to solve the problem posed by the lack of 
information about the willingness of dementia patients to be enrolled in clinical trials. ARDs can 
facilitate the task of proxies in making decisions, while ensuring a greater respect for the 
personal preferences and values of participants223. These documents also have the potential to 
increase the participation of dementia patients in clinical trials and consequently, contribute to 
the development of specific treatments for this group of people. 
119. It should be noted that it is beyond the scope of this article to address the 
philosophical objection, sometimes levelled against advance directives, that there is no 
continuity of identity before and after the onset of dementia224. We assume, as legal norms do, 
that people affected by dementia should still be regarded as the same persons they were before 
the onset of the cognitive impairment, no matter how serious their loss of memory or cognitive 
capacities. This is to say that advance directives should not be automatically disqualified as 
legally invalid on the ground that they were made by a different person to the one who is now 
suffering from dementia.  
120. The article begins by exploring the place that ARDs have in the European legal 
framework governing biomedical research. The discussion then proceeds to consider the 
possibility of integrating them more explicitly into the existing European norms. The central 
questions addressed in the article are: What is the legal status of ARDs in Europe? What 
possibilities does the European legal framework offer for using ARDs? In addressing these 
questions, special focus is placed on issues regarding informed consent, the role of proxies, and 
the level of acceptable risks and burdens. 
                                                                    
220 Alzheimer’s Disease International, World Alzheimer Report 2014, Dementia and Risk Reduction: An Analysis of 
Protective and Modifiable Factors, www.alz.co.uk/research/world-report-2014 [14 July 2015]. 
221 Yudofsky S. and Hales R. (eds.), The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral 
Neurosciences, Washington, DC, Psychiatric Publishing, 2008, p. 452. 
222 Pierce R., “A changing landscape for advance directives in dementia research”, Social Sciences and Medicine, Vol. 70, 
2010, p. 624. 
223 Abdoler E. and Wendler D., “Using data to improve surrogate consent for clinical research with incapacitated adults”, 
Journal of Empirical Research on Human Research Ethics, Vol. 7, n°2, 2012, pp. 37-50. 
224 See for instance Dresser R., “Dworkin on Dementia: Elegant Theory, Questionable Policy”, Hastings Center Report, Vol. 
25, n°6, 1995, pp. 32-38. 
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2 European Legal Framework for ARDs 
121. The concept of advance directives for research has been discussed in the US since 
the end of the 1980s225. Some American scholars have emphasized the potential utility of these 
documents to facilitate research involving people with mental disorders226. As a result of these 
discussions, several proposals for the regulation of ARDs have been made in the US227. In 
Canada, the regulations governing research involving human subjects make explicit mention of 
advance directives for research228. In contrast, no proposals for guidelines or legislation in this 
area have been brought forward in Europe, and the European literature on ARDs is almost non-
existent. The legal frameworks on biomedical research adopted by European bodies, namely the 
Council of Europe and the European Union, are ambiguous in this respect229. Similarly, European 
domestic laws are virtually silent about the possibility of consenting to research participation in 
the event of future mental incapacity.  
122. It is important to stress that research involving persons unable to consent is not per 
se prohibited in Europe, but subject to additional safeguards, such as the requirement that the 
research poses no more than minimal risk and minimal burden to participants in circumstances 
where no direct benefit to them is expected, that the legally authorised representatives give 
their consent, and that the research protocol is approved by an independent ethics committee. 
The legal basis for such safeguards can be found in the 1997 European Convention on Human 
Rights and Biomedicine230, and in the 2014 EU Regulation on Clinical Trials231, which will replace 
the currently applicable 2001 EU Clinical Trials Directive232 in 2016. 
                                                                    
225 Levine R., Ethics and Regulation of Clinical Research, Baltimore, MD: Urban and Schwarzenberg, 1986, pp. 270-274; 
National Institutes of Health, Consent Process in Research Involving Impaired Human Subjects, 1987, Clinical Center Policy 
and Communications Bulletin, n87-4; National Bioethics Advisory Commission (NBAC), Research Involving Persons with 
Mental Disorders That May Affect Decisionmaking Capacity, Report and Recommendations, vol. I, Washington, DC: US 
Government Printing Office, 1998, chapter 3. 
226 Moorehouse A. and Weisstub D., “Advance directives for research: ethical problems and responses”, International 
Journal of Law and Psychiatry, Vol. 19, n°2, 1996, p.107; Backlar P., “Anticipatory planning for research participants with 
psychotic disorders like Schizophrenia”, Psychology, Public Policy, and Law, Vol. 4, n°3, 1998, pp. 829-853. 
227 Pierce R., “A changing landscape for advance directives in dementia research”, op. cit., p. 624. 
228 Canadian Institutes of Health Research, National Science and Engineering Research Council of Canada, and Social 
Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving 
Humans, December 2014, Articles 3.10 and 3.11, www.pre.ethics.gc.ca/pdf/eng/tcps2/TCPS_2_FINAL_Web.pdf [14 July 
2015]. 
229 Lötjönen S., “Medical research on patients with dementia: the role of advance directives in European legal instruments”, 
op. cit. 
230 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology 
and Medicine: Convention on Human Rights and Biomedicine, Oviedo, 4. IV. 1997, ETS 164 (hereinafter “Oviedo 
Convention”), Article 17. 
231 Council Regulation 536/2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 
2001/20/EC, 2014 OJ (L 158) 1 (hereinafter “Regulation 536/2014”), Article 31. 
232 Council Directive 2001/20 on the Approximation of the Law, Regulations and Administrative Provisions of the Member 
States relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for 
Human Use, OJ L 121/34 (2001) (hereinafter “Directive 2001/20/EC”).   
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2.1. COUNCIL OF EUROPE 
123. The Council of Europe’s Convention on Human Rights and Biomedicine 1997 
(hereinafter Biomedicine Convention) includes only one provision relating to advance directives, 
which stipulates that “[t]he previously expressed wishes relating to a medical intervention by a 
patient who is not, at the time of the intervention, in a state to express his or her wishes shall be 
taken into account”233. It is important to point out that this provision was exclusively developed 
in relation to advance directives for healthcare. The Convention’s drafters did not have in mind 
the use of these documents for research purposes. This is clear not only from the Explanatory 
Report to the Convention, which in its commentary on Article 9 refers to the “patient” and the 
“practitioner”234, but also from the fact that Section V of the Convention, which specifically deals 
with biomedical research, does not mention the possibility of making advance directives in this 
context. Interestingly, the Convention does not say anything about positive advance directives 
for research. But it can be argued that refusals to participate in research, made either before or 
after the onset of the mental incapacity, would be binding. This can be inferred from Article 
17.1(v), which enumerates, among the conditions for conducting research involving persons 
unable to consent, that “the person concerned does not object”235.  
124. In comparison to the Biomedicine Convention, the Convention’s Additional Protocol 
on Biomedical Research 2005 takes a step towards the recognition of ARDs. Article 15, 1.iv 
indirectly refers to ARDs stipulating that the consent of the legal representative must be given 
“taking into account the person’s previously expressed wishes or objections”. This means that 
although prior wishes -including written wishes and objections- are regarded by the Protocol as 
relevant, they are not accepted as a stand-alone requirement. Instead, a kind of double 
safeguard mechanism for the protection of incapacitated research subjects is suggested. 
Therefore, the previously expressed wishes have to be assessed by the proxy decision-maker, 
who can eventually overrule them (as they need only to be “taken into account”, and not strictly 
followed). Indeed, these instructions seem to be considered as an element that might complete 
the consent given by the legal representative of the incapable person, as opposed to an 
independent basis for the decision, and not as instructions documents that can operate 
independently. When such documents exist, the decision of the legal representative cannot be 
exclusively based on his or her own personal opinion, but should be guided by the preferences 
expressed by the individual before the onset of the incapacity.  
                                                                    
233 Oviedo Convention, Article 9. 
234 Explanatory Report to the Additional Protocol to the Convention on Human Rights and Biomedicine, Concerning 
Biomedical Research, Strasbourg, 25 I. 2005, ETS 195 [hereinafter Explanatory Report to the Additional Protocol], §62. 
235 Lötjönen S., “Medical research on patients with dementia: the role of advance directives in European legal instruments”, 
op. cit., p. 243. 
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2.2. EUROPEAN UNION 
125. At the level of the European Union, the 2001 Clinical Trials Directive refers only 
indirectly to ARDs. Article 5 reads: “In the case of other persons incapable of giving informed 
legal consent, all relevant requirements listed for persons capable of giving consent shall apply. 
In addition to these requirements, inclusion in clinical trials of incapacitated adults who have not 
given or not refused informed consent before the onset of their incapacity shall be allowed only 
if…” [the list of additional requirements follows]. Since advance consent to participation in 
research is only mentioned in passing as a negative condition for the application of the general 
rules for conducting research involving incapacitated persons, it is hard to draw from this norm 
any positive conclusion about the general conditions for making ARDs and about their efficacy. 
Therefore, it seems excessive to deduce from this provision that “the effect of a valid previously 
given informed consent or refusal is that the potential research participant is legally treated as a 
competent research subject and therefore, the additional safeguards listed in the latter part of 
Article 5 (including consent given by a legal representative) need not be applied”236.  
126. In April 2014, a new Regulation on Clinical Trials was adopted by the EU to replace 
the 2001 Clinical Trials Directive. The Regulation, which will become directly applicable to 
Member States no earlier than on May 2016, uses almost the same wording as the 2001 
Directive to refer -indirectly- to ARDs in Article 31. The only novelty of the new Regulation in this 
regard concerns research in emergency situations and the need for the researcher to ensure that 
the potential participant has not previously expressed objections to participate in the clinical 
trial (Article 35, d). However, advance directives as envisaged by the Regulation, expressing a 
wish not to be involved in specific emergency trials, seems very unlikely. Therefore, it is difficult 
to draw from this provision any conclusions that could be applicable to advance consent to 
clinical trials in the event of mental incapacity.  
127. In short, the current European legal framework neither explicitly mentions the 
possibility of using ARDs nor forbids them. Concerning domestic regulations, the Swiss Law on 
Research Involving Human Beings 2011 is, to our knowledge, the only legal instrument in Europe 
that explicitly refers to the possibility of using advance directives to prospectively consent to 
medical research237. The UK Mental Capacity Act 2005, covering England and Wales, mentions 
                                                                    
236 Lötjönen S., “Medical research on patients with dementia: the role of advance directives in European legal instruments”, 
op. cit., p. 246. 
237 Article 24, §1 stipulates that “[r]esearch projects involving persons unable to consent which offers prospects of direct 
benefit to participants can be conducted if the following conditions are met: 1. the subjects have given their consent when 
they were still competent and the consent is evidenced by a document; 2. in the absence of a document evidencing the 
consent, the legal representative, a trustworthy person or their relatives gave a written informed consent; 3. the subjects 
do not express in an identifiable manner, verbally or by a particular behavior, their refusal to participate in the research 
project”. Article 24, §2 provides that in the case of research not offering prospect of direct benefit to participants, two 
additional conditions must be met: “the risks and burden associated with the project are minimal” and “the project is 
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ARDs only as a means for objection to involvement in research, as it stipulates that research on 
incapacitated persons cannot be performed if, among other things, it is contrary to “an advance 
decision of his which has effect”238. The following section will discuss the conditions for 
integrating advance research directives into the European legal framework governing biomedical 
research.  
3 Challenges for Integrating ARDs into the European Legal 
Framework 
128. On the one hand, the need for some common European requirements for the 
validity of consent to research participation (including dementia research) is undeniable. 
Although only 24 per cent of all clinical trials applied for in the EU are conducted in more than 
one Member State, they involve approximately 67 per cent of all subjects enrolled in clinical 
trials. This is to say that in Europe the majority of trials involving a large number of research 
subjects (40 or more) are multinational239. On the other hand, when aiming at a regional 
consensus on the use of ARDs it should be acknowledged that these documents raise a variety of 
ethical and legal questions, especially regarding informed consent, the role of proxies, and the 
level of acceptable risks and burdens. These three topics are discussed in this section.  
3.1 INFORMED CONSENT 
129. In general, participation in clinical trials is subject to stringent conditions and 
additional safeguards that do not apply to healthcare. These specific requirements are 
understandable because clinical trials do not generally aim to improve the health of research 
participants, but are primarily conducted to gain scientific knowledge that can potentially 
benefit future patients. In giving their consent, it is important that potential research subjects 
understand the altruistic nature of their involvement. Obviously, this must also be understood 
by those who give consent in the form of an ARD. In this regard, it has been argued that, in such 
                                                                                                                                                                                                                   
expected to offer long-term benefit to people suffering from the same disease, or having a comparable health condition” 
(Article 24, §2). 
238 Mental Capacity Act 2005, s 33(2). 
239 European Commission, Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on 
Medicine Products for Human Use, and Rrepealing Directive 2001/20/EC, Brussels, 17 July 2012, p. 2,  
http://ec.europa.eu/health/files/clinicaltrials/2012_07/proposal/2012_07_proposal_en.pdf, [14 July 2015].  
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a context, the individual must, at least, be able to understand the distinction between being a 
“patient” and a “research subject”240.  
130. Rebecca Dresser has pointed out how demanding it is to ask people at risk of 
dementia to imagine how it would be to participate in research after the onset of cognitive 
impairment. She even notes that “it may be a rare person who can genuinely achieve this level 
of understanding”241. In addition, although therapeutic misconception is not the prerogative of 
only dementia patients, Dresser reports empirical results demonstrating how frequently 
potential dementia research participants misunderstand the proposed study, notably the fact 
that it is not another treatment option, but principally aims to produce generalizable 
knowledge242. This “therapeutic misconception” can be even greater if the same advance 
directives combine treatment and research purposes243. This kind of misunderstanding is more 
likely to happen if the research subjects are already mildly affected by dementia. The 
assessment of the decision-making capacity of such individuals poses a significant ethical and 
legal challenge244, and should be exercised with caution, in order to prevent any misuse or 
deception of potential research subjects.  
131. It is generally accepted that participants in medical research “must be adequately 
informed of the aims, methods, sources of funding, any possible conflicts of interest, 
institutional affiliations of the researcher, the anticipated benefits and potential risks of the 
study and the discomfort it may entail, post-study provisions and any other relevant aspects of 
the study (…)”245. There are in principle no reasons for departing from these requirements in the 
case of prospective consent to dementia research. This is certainly the case for ongoing clinical 
trials, providing that there are no changes in the protocol. However, it should be noted that it 
may be more difficult when dealing with future clinical trials, the design of which are not 
finalized. In any case, it is crucial that ARDs are very specific about the procedures to which 
participants will be exposed (for instance, taking blood samples, monitoring blood pressure, 
testing new drugs, etc.), as well as about the risks and burdens associated with these 
procedures246. 
                                                                    
240 Backlar P., “Anticipatory planning for research participants with psychotic disorders like Schizophrenia”, op. cit., p. 842; 
Alzheimer Europe, “The Ethics of Dementia Research”, 2011, chapter 4, www.alzheimer-europe.org/Ethics/Ethical-issues-
in-practice/Ethics-of-dementia-research [14 July 2015]. 
241 Dresser R., “Advance directives in dementia research. Promoting Autonomy and Protecting Subjects”, IRB. Ethics & 
Human Research, Vol. 23, n°1, 2001, p. 4.  
242 Ibid. 
243 Pierce R., “A changing landscape for advance directives in dementia research”, op. cit., p. 624. 
244 Trachsel M., Hermann H., and Biller-Andorno N., “Cognitive Fluctuations as a Challenge for the Assessment of Decision-
Making Capacity in Patients with Dementia”, American Journal of Alzheimer’s Disease and Other Dementias, Vol. 30, n°4, 
2015, pp. 360-363. 
245 World Medical Association (WMA), Declaration of Helsinki: Ethical Principles for Medical Research Involving Human 
Subjects, 2013 (hereinafter “Declaration of Helsinki”), §26. 
246 Regarding the importance of the specificity of the consent, see Gevers S., “Dementia and the Law”, European Journal of 
Health Law, Vol. 13, n°3, 2006, p. 217. 
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132. Even though ARDs are defendable as an initial authorisation for research 
participation, and are a valuable means to promote patients’ autonomous decisions, other 
safeguards remain necessary to ensure the well-being of cognitively impaired participants. It has 
been pointed out that in practice, at any sign of distress, dissent or discomfort, incompetent 
participants are excluded from clinical trials247. Nevertheless, the protection of incapacitated 
subjects cannot merely depend on the good will of researchers but should be ensured by legal 
mechanisms. It is important to guarantee that the well-being of participants is constantly 
monitored from both the researchers’ side and also from the participant’s side (i.e. the proxy). 
Physicians, researchers and ethics committees, due to the regular assessment of any changes in 
the protocol and in the balance benefit/risk, have to make sure that the participation of 
incapacitated subjects is in conformity with the prior consent and with the legal requirements. 
Such consent should therefore not be understood as a simple authorisation at the start of the 
study, but as a continuous process throughout the trial248. This is why the involvement of a legal 
representative is crucial in terms of monitoring and accountability. The proxy, who is someone 
close to the participant and has no personal interest in the research, is in a good position to 
assess the burdens that may result from research participation, and evaluate the subject’s 
willingness to continue participation in the trial. 
133. Concerning the possibility of withdrawal from research trials by participants after 
the onset of their incapacity, it has been argued that ARDs can be revoked at any time, even 
when the individual has already lost his or her decision-making capacity249. This means that “the 
threshold for the capacity to revoke or refuse to participate should be lower than the capacity to 
consent”250. Similarly, Alzheimer Europe lists among the conditions for the implementation of 
ARDs that the person “does not show any sign of unwillingness to participate at the start of the 
research, e.g. refusing to take medication when offered, obvious distress when interviewed, etc., 
and that the participant does not display signs of unwillingness to continue participating and/or 
experience distress as a result of the research”251. These conditions are in conformity with the 
European Biomedicine Convention, which requires that the incompetent individual “does not 
object”252. Similarly, the 2014 EU Regulation on Clinical Trials expressly gives incapacitated 
persons the right to withdraw from trials, independently from the opinion of their legal 
representatives253. However, this right to withdraw is rather demanding in the Regulation, as the 
                                                                    
247 Jongsma K.  and van de Vathorst S., “Dementia research and advance consent: it is not about critical interest”, Journal of 
Medical Ethics, 2014, published online 19 September 2014; doi:10.1136/medethics-2014-102445.  
248 See Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, 25.I. 
2005 (hereinafter “Additional Protocol”), Article 24.2. 
249 Backlar P., “Anticipatory planning for research participants with psychotic disorders like Schizophrenia”, op. cit., p. 842. 
250 Moorehouse A. and Weisstub D., “Advance directives for research: ethical problems and responses”, op. cit., p. 133. 
251 Alzheimer Europe, Position paper on the use of advance directives, op. cit., §32. 
252 Oviedo Convention Article 17.1.v; Additional Protocol, Article 15 1.v. 
253 Regulation 536/2014, Article 31. 
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patient has to express an “explicit wish” and must be “capable of forming an opinion and 
assessing the information”254.  
134. The right to withdraw from research can be compared to the way in which advance 
treatment refusals operate. Incapacitated patients who ask for life-saving treatments, which 
they have refused in an advance directive, would probably be treated, even if they have already 
lost their decision-making capacity255. This is because priority is given to the least harmful 
alternative, which is non-refusal of life-saving treatments, and in the case of ARDs, non-
participation in research, even when the risks and burdens are very low. In other words, the 
initial consent given by means of ARDs is not sufficient to continue research procedures when 
participants show clear signs of unwillingness to continue participating in the trial. 
3.2 THE ROLE OF PROXIES   
135. Legal instruments in Europe state explicitly that the consent of the legally authorised 
representatives or proxies is absolutely required to enrol incapacitated adults in research 
trials256. However, from a theoretical perspective one may wonder whether such consent is 
necessary when the patient had consented in advance to research participation at a time when 
he or she was still competent. In this regard, Pierce suggests that ARDs can operate without the 
involvement of a proxy257. She argues that there are individuals who do not wish to defer the 
decisions concerning their participation in research to a surrogate decision-maker258. Therefore, 
she claims that, for reasons of equality, ARDs should be available to all competent individuals 
who wish to prospectively consent to research, regardless of whether they appoint a proxy259. 
136. This proposal is problematic, at least for practical reasons. It is difficult to imagine 
how a cognitively impaired individual could participate in clinical trials without the assistance of 
a trusted, independent caretaker. It must be noted that the proxy does not necessarily have to 
be a family member but could be any trusted person, including the treating physician, insofar he 
or she does not have any direct interest in the clinical trial. Proxies are in a better position than 
researchers to detect any discomfort or adverse reaction that the demented person may 
experience as result of his or her participation in the trial. Furthermore, proxies can be consulted 
by researchers about the interpretation of the directives and about any possible change in the 
original protocol that may imply additional risks or burdens for participants. 
                                                                    
254 Regulation 536/2014, Article 31.1.c. 
255 Lemmens T., “End-of-life decisions and demented patients. What to do if patient’s current and past wishes are in 
conflict with each other?”, European Journal of Health Law, Vol. 19, n°2, 2012, pp. 177-186. 
256 Oviedo Convention, Articles 6.3 and 17.iv; Regulation 536/2014, Article 31.1.a. 
257 Pierce R., “A changing landscape for advance directives in dementia research”, op. cit., p. 627. 
258 Ibid., p. 627. 
259 Ibid. 
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137. A related question is whether the proxy should be allowed to override the advance 
consent of the participant. As Pierce has pointed out, there could be situations in which this 
would be acceptable, for instance, a change in protocol that results in an alteration in the 
research experience, a change in patient behaviour with assessment by an independent 
behavioural psychologist, or a change in risk exposure, either as a result of a change in protocol 
or in the participant’s health condition260. Certainly, those changes have to be relevant enough 
to justify overriding the consent of the participant. This can be the case, for instance, if the 
changes in the protocol or in the health condition of participants create unanticipated burdens 
and risks for them, or if the subjects show clear signs of distress, fear or pain as a result of their 
participation in the trial. These situations show how important the involvement of an 
independent, trusted person to ensure the well-being of the incapacitated subject. 
3.3. LEVEL OF ACCEPTABLE RISKS AND BURDENS 
138. It has been pointed out that “perhaps one of the most complex issues in the use of 
ARDs is whether it should be acceptable to prospectively consent to the full spectrum of risk, 
including risky research”261. Some scholars claim that it is permissible to consent to more than 
minimal risk and minimal burden on the grounds that the advance directive reflects the 
autonomous decision of the individual at a time when he or she was still competent262. But it can 
also be legitimately argued that ARDs are subject to the general limit of minimal risk and 
minimal burden that applies to all research studies involving incapacitated subjects. The reason 
for this is that the participant is especially vulnerable when the research is conducted and 
therefore deserves special protection at the time of the trial, it being irrelevant whether he or 
she was competent when the advance directive was made. 
139. The current European legal framework on biomedical research clearly follows this 
second position: incapacitated subjects can be enrolled in research that does not offer the 
prospect of direct benefit only when it poses minimal risk and minimal burden263. There is no 
exception to this rule based on the circumstance that the individual had previously made an 
advance directive and accepted levels of risk and burden higher than minimal. In the European 
regulations, the “minimal risk and minimal burden” limit seems to have the status of an ordre 
public rule, which means that it cannot be the subject of renunciation. In this respect, it must be 
mentioned that the Biomedicine Convention prescribes that some of the protective provisions it 
                                                                    
260 Pierce R., “A changing landscape for advance directives in dementia research”, op. cit., p. 627. 
261 Ibid. 
262 See Buller T., “Advance consent, critical interests and dementia research”, Journal of Medical Ethics, 2014, published 
online 12 August 2014, doi: 10.1136/medethics-2014-102024); Pierce R., “A changing landscape for advance directives in 
dementia research”, op. cit., p. 628. 
263 Oviedo Convention, Article 17; Additional Protocol, Article 15; Regulation 536/2014, Article 31.
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contains cannot be set aside by the states’ domestic laws264. Interestingly, Article 17, which sets 
the “minimal risk and minimal burden” limit, is explicitly mentioned as one of those non-
negotiable provisions265.  
140. In the past, several American experts have favoured the first position mentioned 
above. They have argued that an advance consent would be an acceptable basis for allowing the 
incompetent individual to be involved in research with higher risk than the one permitted for 
other incompetent subjects266. More recently, Buller claims that advance directives for research 
and for treatment are similar and therefore, the level of acceptable risks should be similar as 
well267. Based on the comparison with advance refusals of life-sustaining treatments, he argues 
that a person has the right to expose herself to high risks, including the risk of death. Therefore a 
person should equally be able to decide in advance to expose oneself to risky research, and not 
be limited to research involving minimal risk.  
141. However, leaving aside the current legal obstacles to the use of ARDs for research 
involving risks higher than minimal, there are reasons to remain sceptical about this possibility. 
The analogy with advance directives for healthcare is not satisfactory. There is a crucial 
difference between prospectively consenting to treatment and to participation in research. 
Preferences regarding healthcare, including the refusal of treatments that the patient considers 
to be too burdensome or useless, are directly related to the well-being of that same patient who 
made the advance directive. On the contrary, research studies are normally not designed to 
benefit participants themselves, but to gain scientific knowledge that may eventually help future 
patients. The altruistic nature of research participation explains why research involving human 
beings is subject to conditions that do not apply to treatment, not even to treatment refusals. 
These additional safeguards concerning research need to be taken particularly seriously when 
participants are cognitively impaired at the time the research is carried out.  
142. Moreover, from a practical point of view, there are reasons to believe that most 
individuals consenting to research participation by means of advance directives would prefer not 
to be exposed to risks higher than minimal. In this regard, it is interesting to note an empirical 
study in which patients were asked to complete a research advance directive and to express 
their preferences regarding participation in clinical trials268. Only 11 per cent of patients 
accepted to complete a research advance directive. The great majority of them (76 per cent) 
were not willing to be exposed to more than minimal risk, while 49 per cent were also willing to 
take part in research without direct benefit, but which only posed minimal risk. Only 9 per cent 
                                                                    
264 Oviedo Convention, Article 26. 
265 Oviedo Convention, Article 26.2. 
266 American College of Physicians (ACP), ‘Cognitively Impaired Subjects. Position Paper’, Annals of Internal Medicine, Vol. 
111, n°10, 1989, p. 843; National Bioethics Advisory Commission (NBAC), Research Involving Persons with Mental Disorders 
That May Affect Decisionmaking Capacity, Report and Recommendations, op. cit., chapter 3. 
267 Buller T., “Advance consent, critical interests and dementia research”, op. cit., p. 6.  
268 Muthappan P., Foster H., and Wendler D., ‘’Research advance directives: protection or obstacle?”, American Journal of 
Psychiatry, Vol. 162, n°12, 2005, pp. 2389-2391.  
  76 
of those who were in favour of making an ARD (that is, 1 per cent of the total of patients who 
were initially invited to complete an ARD) would accept to participate in research that would not 
help them and posed greater than minimal risk. 
4 Conclusion 
 
143. This article has sought to draw attention to the fact that the European legal 
framework for biomedical research, as well as most European domestic laws, are virtually silent 
about the use of advance directives for research purposes. At the same time, it has shown that 
these same norms do not explicitly exclude the possibility of prospective consent to research 
participation. Considering that ARDs are perfectly in line with the commitment of European 
institutions to support patients’ self-determination, we think that these tools could be 
integrated into the existing European norms relating to biomedical research. However, essential 
questions remain to be explored in greater depth. These include questions around how detailed 
the trial information which is given to potential participants must be, the role of the proxy 
before and during the trial, and the level of acceptable risk and burden which should be 
permitted in the context of ARDs. 
144. As mentioned above, the use of ARDs can be justified in moral terms on the grounds 
that they contribute to patients’ self-determination. Besides, ARDs could help to increase the 
amount of clinical trials with dementia patients and facilitate the development of specific drugs 
for this population. On the one hand, ARDs could do more justice to the patient’s prior wishes 
than proxy consent does. On the other hand, it is unlikely that ARDs without the appointment of 
a proxy can offer a stand-alone solution to the requirement of informed consent. The 
involvement of a proxy seems indispensable to implement the advance directives in the light of 
the complete information at the time the research is conducted. In addition, other safeguards 
are necessary to ensure the well-being of incompetent participants, for example the right to 
withdraw or to be withdrawn from the trial at any time. Another question concerns the level of 
risks that can be accepted by means of ARDs. From the legal point of view, current regulations 
clearly forbid exposing incompetent participants to more than minimal risk and minimal burden, 
regardless of whether they have consented to them in advance or not. But from an ethical point 
of view, the question remains open for discussion. 
145. In conclusion, it is desirable to clarify the legal status of ARDs and the conditions for 
their use in Europe. This would not only help to satisfy the wish of potential participants in 
dementia research, but also benefit future dementia patients by developing more effective 
therapeutic or preventive measures. This clarification would also facilitate the task of 
researchers and ethics committees. In this regard, it would be appropriate for the Council of 
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Europe, for instance, to address the use of ARDs, at least in their Guide for Research Ethics 
Committees269. Similarly, the European Commission could include guidance on ARDs while 
revising and updating the current guidelines and recommendations on clinical trials in the light 
of the new Clinical Trials Regulation270. In the context of an increasingly ageing population, the 
incidence of dementia is expected to grow in the coming years. Therefore, the need for research 
with incapacitated elderly patients will become more and more pressing. In this scenario, ARDs 
could turn out to be a useful tool to both empower potential research participants and 
contribute to the development of more effective treatments for dementia. 
  
                                                                    
269 See Council of Europe’s Steering Committee on Bioethics, Guide for Research Ethics Committee Members, Strasbourg: 
Council of Europe, 2012, www.coe.int/t/dg3/healthbioethic/activities/02_biomedical_research_en /guide/Guide_EN.pdf 
[14 July 2015]. 
270  See European Commission, Clinical Trials. General Information, http://ec.europa.eu/health/human-use/clinical-
trials/information/index_en.htm#ct4 [14 July 2015]. 
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Chapter 4: Les personnes âgées vulnérables dans les 
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ABSTRACT 
As the main medications consumers, elderly persons are estimated to represent up to 30% of 
the European population in 2050. Paradoxically there is a considerable lack of information about 
drug prescription in older persons, which is compromising the quality of treatments, and leaving 
to physicians the considerable responsibility of improvised prescriptions, which are potentially 
either dangerous or ineffective. In fact, the geriatric population is either excluded from clinical 
trials or represented by relatively healthy elderly persons who do not accurately represent real 
world patients. Despite repeated demonstrations of the need to include frail elderly persons in 
clinical trials in the medical literature, European law only offers disappointing responses to the 
problem. The frequent decline in older persons’ cognitive capacities makes the task even more 
difficult (cognitive frailty, early dementia like Alzheimer’s disease or psychiatric disorders). Many 
older persons have reduced decision making capacity without benefiting from legal protection 
yet. Surprisingly, ethics guidelines as well as European law are not very sensitive to the phases 
before legal incompetence, and do not consider alternative ways to obtain informed consent as 
suggested in medical and ethical literature. Although these questions fall under national 
competencies, the issue is common to Europe and solutions will necessarily have to go beyond 
state borders. Involving the European legislator is essential in order to at least act as an incentive 
for a better inclusion of frail elderly persons in biomedical research, and for a better promotion 
of their autonomy.  
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1 Introduction 
146. Les recherches biomédicales permettent d’améliorer les traitements, de réagir aux 
nouvelles maladies271, et de s’adapter aux évolutions globales de la société, tel le vieillissement 
de la population. Car en effet, les personnes âgées sont estimées représenter 30% de la 
population européenne d’ici 2050272, alors qu’elles sont les principales consommatrices de 
médicaments273. Par personnes âgées, on entend habituellement les personnes de plus de 65 
ans274, sachant que le critère de l’âge a pu montrer ses limites. Pour le thème des essais 
cliniques, c’est plutôt la prise en compte de leur vulnérabilité qui va conditionner leur statut 
juridique. Et pourtant, le droit européen275 relatif à la recherche biomédicale ne donne pas de 
définition de la vulnérabilité ni de la personne vulnérable, mais liste seulement les personnes 
considérées comme vulnérables 276 . De manière générale, une personne est vulnérable 
lorsqu’elle est en état de faiblesse et qu’elle est exposée à des risques accrus de souffrances277. 
En matière d’essais cliniques, nous classerons la vulnérabilité en deux types principaux : la 
vulnérabilité physique et mentale et la vulnérabilité décisionnelle278. La première désigne une 
vulnérabilité aux effets secondaires ou indésirables des essais cliniques, une vulnérabilité qui est 
donc liée à la condition ou à l’état de santé du participant (enfants, femmes enceintes, 
personnes âgées fragiles, malades…). Le second type de vulnérabilité, la vulnérabilité 
                                                                    
271 Elles permettent de « comprendre les causes, le développement et les effets des maladies et améliorer les interventions 
préventives, diagnostiques et thérapeutiques ». Association Médicale Mondiale (AMM), Déclaration d’Helsinki - Principes 
éthiques applicables à la recherche médicale impliquant des êtres humains, adoptée par la 18ème Assemblée générale à 
Helsinki (Finlande), en juin 1964 et telle qu’amendée lors de l’Assemblée général à Fortaleza (Brésil), en Octobre 2013, § 6. 
272 Site Web d’Eurostat, http://ec.europa.eu/eurostat/statistics-explained/index.php/File:Population_structure_by_major_ 
age_groups,_EU-28,_2014%E2%80%9380_%28%C2%B9%29_%28%25_of_total_population%29_YB15.png [14 août 2015], 
Figure 6. 
273 Berdeu D. et al., « Clinical trials in the elderly : Ethical and methodologic considerations », La Revue de médecine interne, 
Vol. 21, n°7, 2000, p. 616. 
274 Comme par exemple c’est le cas dans certaines lignes directrices internationales spécialisées sur les questions 
gériatriques ICH, Studies in support of special populations: Geriatrics E7, Conférence internationale sur l'harmonisation des 
exigences techniques pour l'enregistrement des médicaments à usage humain, 1993, p. 2 ; ou encore comme c’est le cas 
dans la prise en compte des personnes âgées par les études démographiques de l’Union européenne, Site Web d’Eurostat 
http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_structure_and_ageing [13 août 2015]. 
275 Nous entendons par droit européen, le droit du Conseil de l’Europe et celui de l’Union européenne ainsi que les 
principales lignes directrices éthiques applicables en Europe.  
276 Union Européenne, Règlement (UE) n° 536/2014 du Parlement européen et du Conseil du 16 avril 2014 relatif aux essais 
cliniques de médicaments à usage humain et abrogeant la directive 2001/20/CE, J.O., L 158, 27 mai 2014, Article 10 ; La 
Convention d’Oviedo du Conseil de l’Europe n’inclut même pas l’expression « personne vulnérable » et se contente de 
protéger les personnes qui n’ont pas la capacité de consentir. Conseil de l’Europe, Convention pour la protection des Droits 
de l’Homme et de la dignité de l’être humain à l’égard des applications de la biologie et de la médecine : Convention sur les 
Droits de l’Homme et la biomédecine, STCE N°164, Oviedo, 4 avril 1997, Article 17. 
277 Sur la définition de la vulnérabilité : Fiechter-Boulvard F., « La notion de vulnérabilité et sa consécration par le droit », in 
Cohey-Cordet F. (dir.), Vulnérabilité et droit. Le développement de la vulnérabilité et ses enjeux en droit, Presses 
Universitaires de Grenoble, Grenoble, 2000, p. 14 ; Paillet É. et Richard P. (dir.), Effectivité des droits et vulnérabilité de la 
personne, Bruylant, Bruxelles, 2014, p. 2 ; Enfin et surtout : Bergouignan C., « Mesurer la vulnérabilité ? », in Paillet É. et 
Richard P. (dir.), Effectivité des droits de l'homme et vulnérabilité de la personne, Bruylant, 2014, p. 12. 
278 Gennet É., Andorno R. et Elger B., « Does the new EU Regulation on clinical trials adequately protect vulnerable research 
participants ? », Health Policy, 2015, n°119, 2015, p. 925-931. 
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décisionnelle, vise le risque d’exploitation, le risque pour les participants de donner leur 
consentement sous une influence indue. Si cette vulnérabilité décisionnelle peut être d’origine 
relationnelle279 et circonstancielle280, nous nous focaliserons ici sur son origine cognitive : les 
mineurs, les adultes incapables, mais surtout les personnes âgées atteintes de maladies 
psychiatriques, troubles cognitifs ou encore démences telles la maladie d’Alzheimer281. Il est 
fréquent que ces deux types de vulnérabilités – physique et décisionnelle – se croisent et donc 
soient présents chez une seule et même personne, en particulier chez les personnes âgées. Si 
ces doubles vulnérabilités sont fréquentes, il n’en est pas moins important de les distinguer d’un 
point de vue méthodologique et argumentaire, car les réponses normatives découlant des 
différents types de vulnérabilités auront, si ce n’est une issue différente, au moins des 
justifications différentes. 
147. Quels sont les enjeux de la participation des personnes âgées vulnérables aux 
recherches biomédicales et comment le droit européen y répond-il? Comment prend-t-il en 
compte l’avis des principaux acteurs intéressés comme les médecins, les industries 
pharmaceutiques ou tout professionnel de santé impliqué dans l’éthique ? Deux enjeux distincts 
sont ainsi à analyser : celui de promouvoir la qualité des soins de santé des personnes âgées 
vulnérables par une meilleure inclusion dans les essais cliniques (2), et celui de protéger et de 
promouvoir l’autonomie des personnes âgées vulnérables dans le cadre des essais cliniques (3). 
2 La promotion de la qualité des soins de santé des 
personnes âgées vulnérables 
148. Les patients âgés sont très souvent exclus des essais cliniques alors qu’il y a un 
important besoin d’information sur les effets des médicaments sur ce type particulier de 
patients. L’enjeu principal pour promouvoir la santé des personnes âgées vulnérables est donc 
de mieux les inclure dans les recherches biomédicales (2.1). Toutefois, la réponse du droit 
européen à ce besoin n’est que partiellement satisfaisante (2.2).  
                                                                    
279 Les relations avec le médecin ou la famille – notamment les enfants -, les traditions religieuses ou encore les relations 
hiérarchiques comme par exemple les étudiants ou les militaires. Gennet É., Andorno R. et Elger B., « Does the new EU 
Regulation on clinical trials adequately protect vulnerable research participants ? », op. cit., p. 927. 
280 Les classes socio-économiques défavorisées ou encore les personnes privées de liberté comme les détenus ou encore les 
personnes en institutions d’hébergement ou de soins. Ibid. 
281 Berr C., Wancata J., Ritchie K., « Prevalence of dementia in the elderly in Europe », European Neuropsychopharmacology, 
n° 15, 2005, pp. 463-471. 
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2.1 LE BESOIN D’UNE MEILLEURE INCLUSION DANS LES RECHERCHES 
BIOMÉDICALES 
149. S’il est difficile de trouver un juste milieu entre protection des participants aux essais 
et promotion de la santé des futurs patients, la protection actuelle de la vulnérabilité physique 
des personnes âgées peut paraître trop stricte (2.1.1) si on la compare aux recommandations 
scientifiques, médicales et éthiques en matière d’essais cliniques (2.1.2). 
2.1.1 Entre protection et surprotection de la vulnérabilité physique 
150. La fragilité physique des personnes âgées oblige à les protéger des recherches 
biomédicales (2.1.1.1), mais cette protection est à double tranchant puisqu’elle surprotège et 
marginalise les personnes âgées fragiles (2.1.1.2). 
2.1.1.1 LA FRAGILITÉ PHYSIQUE DES PERSONNES ÂGÉES 
151. Les personnes âgées présentent des différences notables par rapport à une 
personne jeune. Elles vont absorber, transporter et éliminer les médicaments différemment, 
subir un déclin général de leur condition physique, souffrir d’affections multiples voire de 
maladies qui leur sont propres282. Ces caractéristiques sont un véritable challenge pour les 
médecins prescripteurs, que ce soit dans le cadre du traitement comme de celui de la recherche, 
car le rapport bénéfice-risque d’un traitement (expérimental ou non) est peut varier chez les 
personnes âgées selon leur condition de santé. Elles vont réagir différemment aux effets 
indésirables, secondaires, aux interactions médicamenteuses, ou de manière générale à 
l’efficacité du médicament283. Il est indispensable de déterminer ce rapport bénéfice risque de 
manière différenciée pour les personnes âgées en bonne santé, ainsi qu’aux différents stades de 
la fragilité. 
152. La fragilité est un concept de médecine gériatrique et une condition clinique qui 
regroupe ces symptômes principalement physiques284, liés à la vieillesse et à un déclin général 
                                                                    
282 Certaines maladies cardiaques, osseuses ou mentales. EMA, ICH Topic E7. Studies in support of special populations: 
Geriatrics. Questions and answers., EMA/CHMP/ICH/604661/2009, Agence Européenne du Médicament, Londres, 2010, p. 
2 ; Pour une explication claire et détaillée des problèmes associés aux changements physiologiques et maladies liés à la 
vieillesse, ainsi que les problèmes associés à la polymédication lire Piette F. et Le Quintrec J.-L., « L'emploi d'un médicament 
nouveau chez les personnes âgées : Terra incognita », Gérontologie et société, Vol. 4, n°103, 2002, pp. 73-92, p. 80 et 81. 
283 Bortz W., « Understanding frailty », J Gerontol A Biol Sci Med Sci, Vol. 65, n°3, 2010, pp. 255-257. 
284 « Frailty was defined as a clinical syndrome in which three or more of the following criteria were present : unintentional 
weight loss (10lbs in past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical 
activity ». Fried L. P. et al., « Frailty in older adults : Evidence for a phenotype », The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences, Vol. 56, n°3, 2001, pp. M146-M157. 
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de l’état de la personne âgée285. S’il est tentant d’utiliser vulnérabilité et fragilité comme 
synonymes286, il faut préciser que la fragilité se limite à un état de faiblesse intrinsèque avec des 
critères essentiellement physiques, biologiques voire cognitifs287, là où la vulnérabilité inclut 
aussi des caractéristiques extrinsèques comme les circonstances économiques ou relationnelles. 
Ainsi, la fragilité physique est la faiblesse de la personne âgée qui, due à ses réserves 
physiologiques diminuées et lorsqu’exposée à un risque accru de dommage (des recherches 
biomédicales), la rend vulnérable et nécessite qu’on l’en protège. 
2.1.1.2. LA MARGINALISATION DES PERSONNES ÂGÉES PHYSIQUEMENT FRAGILES 
153. Aux fins de protection, beaucoup de comités d’éthiques refusent les recherches 
incluant des personnes âgées fragiles car le risque pour leur santé est très élevé288. Pour les 
promoteurs, industriels comme académiques, non seulement l’approbation du comité d’éthique 
est très incertaine, mais en plus, l’inclusion de personnes âgées fragiles est complexe289. Mais le 
problème vient aussi en grande partie des investigateurs eux-mêmes. Ces derniers pêchent 
souvent par timidité et ne proposent pas de protocoles incluant des sous groupes de personnes 
âgées fragiles de peur d’essuyer un refus du comité d’éthique. Voire, c’est par stratégie que les 
investigateurs excluent les personnes âgées fragiles de leurs protocoles. Cela leur permet 
d’éviter les complications et investissements en temps et en argent, et de favoriser l’obtention 
de résultats favorables, homogènes, et ainsi en permettre une publication plus rapide. En effet, 
comme les personnes âgées constituent un groupe très hétérogène, il faudra beaucoup plus de 
participants afin d’avoir des groupes homogènes et générer des données fiables sur le 
médicament testé290. Ensuite, c’est la fragilité même qui pose des problèmes pour les résultats 
des essais cliniques qui, forcément compteront plus de cas d’effets indésirables, secondaires, ou 
d’inefficacité du médicament, diminuant les chances d’obtention d’une autorisation de mise sur 
le marché. Il est donc économiquement et statistiquement plus intéressant de mener des essais 
cliniques sur des patients jeunes « monopathologiques et monomédiqués », que sur le double 
                                                                    
285 Fried L. P. et al., « Frailty in older adults : Evidence for a phenotype », op. cit.; Voir aussi Clegg A. et al., « Frailty in elderly 
people », Lancet, Vol. 381, n°9868, 2013, pp. 752-762 ; et Van Kan G. A. et al., « The assessment of frailty in older adults », 
Clin Geriatr Med, Vol.  n°26, 2010, pp. 275-286. 
286 Clegg A. et al., « Frailty in elderly people », op. cit. 
287 Michel H., « La notion de fragilité des personnes âgées : Apports, limites et enjeux d'une démarche préventive », 
Retraite et société, Vol. 62, n°1, 2012, p. 175. 
288 Quelques exemples non exhaustifs : Aapro M. S. et al., "Never too old ? Age should not be a barrier to enrollment in 
cancer clinical trials », Oncologist, Vol. 10, n°3, 2005, pp. 198-204 ; Kaźmierska J., « Do we protect or discriminate ? 
Representation of senior adults in clinical trials », Reports of Practical Oncology & Radiotherapy, Vol. 18, n°1, 2013, pp. 6-
10. 
289 Par exemple : Ridda J. et al., « Difficulties in recruiting older people in clinical trials : An examination of barriers and 
solutions », Vaccine, Vol.  n°28, 2010, pp. 901-906 ; Marcantonio E. R. et al., « Maximising clinical research participation in 
vulnerable older persons : Identification of barriers and motivators », Journal of the American Geriatrics Society, Vol. 56, 
n°8, 2008, pp. 1522-1527 ; Townsley C. A. et al., « Systematic review of barriers to the recruitment of older patients with 
cancer onto clinical trials », Journal of Clinical Oncology, Vol. 23, n°13, 2005, pp. 3112-3124. 
290 Piette F. & Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », op. cit., 
p. 78. 
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de participants hétérogènes d’une population âgée fragile291. Et il est facile d’exclure les patients 
âgés des essais en instaurant des critères d’inclusion limitatifs, par exemple en exigeant des 
patients monopathologiques292.  
154. Or, leur exclusion a pour conséquence le manque de données adaptées sur la 
prescription de médicaments aux futurs patients âgés fragiles293. Les risques engendrés par un 
essai clinique seront les mêmes pour les patients âgés fragiles une fois le médicament 
commercialisé, mais sans la surveillance rapprochée d’un essai clinique, ce qui maintient voire 
aggrave la situation des patients âgés fragiles et les marginalise294. Lorsque les participants âgés 
ne sont pas exclus, ils sont très différents des patients réels des services de gériatrie : moins de 
75 ans, aucune comorbidités, peu de traitements concomitants ou encore absence de problèmes 
cognitifs295. Ces patients même âgés ne représentent pas fidèlement les réels patients296, et ne 
permettent pas non plus d’obtenir les informations nécessaires à une prescription éclairée par 
les médecins297. Seuls les gériatres sont spécialement formés sur ces questions de l’adaptation 
des posologies aux personnes âgées. Or le manque de gériatres, associé à la croissance rapide de 
la proportion de personnes âgées, fait que la majorité des patients âgés est traitée par des 
médecins non gériatres 298 . Ces derniers dénoncent les prescriptions improvisées par 
extrapolation des données disponibles299. Au lieu de pouvoir anticiper les effets indésirables, ils 
les découvrent au fur et à mesure de l’utilisation300.  
                                                                    
291 Piette F. & Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », op. cit., 
p. 79 ; Cherubini A. et al., « Fighting against age discrimination in clinical trials », Journal of the American Geriatrics Society, 
Vol. 58, n°9, 2010, p. 1792. 
292 Piette F. et Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », op. cit., 
p. 84. 
293 Dudeja V. et al., « Guideline recommended gastric cancer care in the elderly : Insights into the applicability of cancer 
trials to real world », Ann Surg Oncol, Vol. 18, n°1, 2011, pp. 26-33. 
294 Par exemple : Davidoff A. J. et al., « Prevalence of potentially inappropriate medication use in older adults using the 
2012 Beers criteria », J Am Geriatr Soc, Vol. 63, n°3, 2015, pp. 486-500 ; Cherubini A. et al., « The persistent exclusion of 
older patients from ongoing clinical trials regarding heart failure », Arch Intern Med, Vol. 171, n°6, 2011, pp. 550-556. 
295 Cherubini A. et al., « Fighting against age discrimination in clinical trials », op. cit., p. 1792. 
296 Par exemple : Lloyd-Williams F. et al., « Why are patients in clinical trials of heart failure not like those we see in 
everyday practice ? », Journal of Clinical Epidemiology, Vol.  n°56, 2003, pp. 1157-1162. 
297 EMA, Geriatric Medicines Strategy, EMA/CHMP/137793/2011, Agence Européenne du Médicament, Londres, 2011, p. 3. 
298 Une piste en dehors du domaine de la recherche biomédicale pourrait également être celle de la formation continue des 
médecins de toute spécialité sur les questions de médecine gériatrique, difficile à imposer à un niveau européen. 
299 « Nous ne pouvons pas cautionner le scandale du décalage constaté actuellement. On ne peut pas en effet admettre que 
la prescription se fasse dans une attitude d’improvisation compassionnelle, parfois à des doses non validées pour 30% des 
patients ». Piette F. et Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », 
op. cit., p. 83. 
300 Sur le long terme, cela pourrait également poser la question de la responsabilité des institutions qui émettent les 
autorisations de mise sur le marché de médicaments qui n’ont pas été suffisamment testés pour avoir des données fiables 
sur leur administration aux patients réels, l’EMA, mais aussi les agences nationales comme en France l’Agence Nationale de 
Sécurité du Médicament et des produits de santé (ANSM). 
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2.1.2 Recommandations scientifiques, médicales et éthiques 
155. La doctrine médicale (2.1.2.1) comme les lignes directrices éthiques (2.1.2.2) 
affirment le besoin, pour la promotion de la santé des personnes âgées, de mieux les 
représenter dans les essais cliniques. 
2.1.2.1 LA DOCTRINE MÉDICALE 
156. La recommandation majeure de la doctrine médicale à l’échelle européenne301 est 
d’inclure plus systématiquement les personnes âgées fragiles dans les essais. Cette 
recommandation ancienne semble être aujourd’hui toujours et encore d’actualité302, montrant 
ainsi la difficulté de la tâche303. Trois propositions plus modestes pourraient potentiellement 
être plus réalisables.  
157. La première serait celle de l’élaboration d’une liste européenne médicaments 
potentiellement inappropriés (PMI) pour les personnes âgées, et de faire des suggestions 
d’adaptation des posologies ou de traitements alternatifs. Ces listes existent déjà au niveau 
national304, et une liste européenne a même été débutée avec 7 États membres de l’Union 
européenne305, mais dont le champ reste encore à élargir. Si les gériatres sont déjà sensibilisés à 
ces questions, il reste aussi à en diffuser les résultats aux médecins des autres spécialités 
amenés à prescrire des médicaments à des patients âgés. Il pourrait par exemple être pertinent, 
pour l’EMA ou les autorités nationales compétentes, d’imposer aux industries pharmaceutiques 
de fournir ces informations sur la notice du médicament. 
                                                                    
301 Une étude a même été menée à l’échelle de 9 Etats de l’Union européenne afin de dénoncer le manque d’essai clinique 
sur les personnes âgées, et d’en analyser les causes et possibles solutions. Crome A. et al, « Exclusion of older people from 
clinical trials. Professional views from nine EU countries participating in the PREDICT study », Drugs Aging, Vol. 28, N°8, 
2011, pp. 667-677 ; PREDICT, European charter for older people in clinical trials, 2010, 
http://ec.europa.eu/research/health/medical-research/human-development-and-ageing/projects/predict_en.html [6 août 
2015]. 
302 Piette F. et Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », op. cit., 
p. 89 ; Cherubini A. et al., « Fighting against age discrimination in clinical trials », op. cit., p. 1791 ; Autres exemples non 
exhaustifs de doctrine dans ce sens : Blozik E. et al., « Prescription of potentially inappropriate medication in older persons 
in Switzerland : Does the dispensing channel make a difference? », Risk Manag Healthc Policy, Vol. 8, 2015, pp. 73-80 ; Büla 
C., « Médicaments et personnes âgées : S'indigner… et se réjouir », Revue Médicale Suisse, 2011, pp. 2163-2164 ; Dauerman 
H. L. et al., « Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients », Am 
Heart J, Vol. 159, n°4, 2010, pp. 508-517 ; Fitzsimmons P. R. et al., « Older participants are frequently excluded from 
Parkinson's disease research », Parkinsonism Relat Disord, Vol. 18, n°5, 2012, pp. 585-589 ; Lang K. J. et Lidder S., « Under-
representation of the elderly in cancer clinical trials », British Journal of Hospital Medicine, Vol. 71, n°12, 2010, pp. 678-681. 
303 Payne J. K. et Hendrix C. C., « Clinical trial recruitment challenges with older adults with cancer », Applied Nursing 
Research, Vol.  n°23, 2010, pp. 233-237 ; Masoudi F. A. et al., « Most hospitalized older persons do not meet the enrollment 
criteria for clinical trials in heart failure », Am Heart J, Vol.  n°146, 2003, pp. 250-257. 
304 Par exemple en Allemagne avec la liste PRISCUS : Holt S. et al., « Potentially inappropriate medications in the elderly : 
The priscus list », Dtsch Arztebl Int, Vol. 107, n°31-32, 2010, pp. 543-551 ; Hefner G. et al., « Side effects related to 
potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy », Eur J Clin 
Pharmacol, Vol. 71, n°2, 2015, pp. 165-172. 
305 Renom-Guiteras A. et al., « The EU(7)-PIM list: A list of potentially inappropriate medications for older people consented 
by experts from seven European countries », European Journal of Clinical Pharmacology, Vol. 71, n°7, 2015, pp. 861-875, p. 
13. 
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158. La seconde proposition, plus ambitieuse, serait de systématiser la conduite d’essais 
cliniques additionnels et spécifiques aux personnes âgées pendant la pharmacovigilance. L’idée 
serait ici pour l’EMA de donner une autorisation de mise sur le marché soumise à la condition de 
la conduite de ces essais supplémentaires dans un certain délai. Cette proposition a le mérite de 
ne pas retarder inutilement la mise sur le marché306, tant pour des raisons économiques, que 
pour des raisons de santé publique.  
159. Enfin, la troisième proposition vise à systématiser la tenue de registres de patients 
âgés vulnérables, au lieu de s’en remettre aux seules obligations des professionnels de santé de 
déclarer les effets non mentionnés dans la notice aux autorités de santé. La systématisation de 
tels registres nécessiterait cependant l’intervention, notamment financière, des autorités 
publiques nationales, éventuellement en collaboration avec les industries pharmaceutiques. 
2.1.2.2 LES LIGNES DIRECTRICES INTERNATIONALES 
160. La Déclaration d’Helsinki et les lignes directrices du CIOMS ne mentionnent pas 
directement la population gériatrique, mais prévoient des recommandations dans ce sens. Dans 
les deux cas, elles attirent l’attention sur les groupes sous représentés pour lesquels des 
recherches seraient bénéfiques, obligeant à une meilleure justification de leur exclusion307. 
161. En revanche, la Conférence internationale sur l’harmonisation des exigences 
techniques pour l’enregistrement des médicaments à usage humain (ICH) consacre aux 
recherches biomédicales sur la population gériatrique des travaux entiers depuis 1993308. Selon 
ces lignes directrices, les participants aux essais cliniques doivent représenter la population 
destinée à être traitée, notamment par groupe d’âge et y compris pour les personnes âgées309. 
Ces dernières doivent être incluses en proportion suffisante310 voire majoritaire311, si la maladie 
visée est directement liée au vieillissement (e.g. maladie d’Alzheimer), ou si la population à 
traiter inclut une grande proportion de personnes âgées (e.g. hypertension). Ces 
recommandations devraient s’appliquer aux nouveaux médicaments, comme à ceux déjà sur le 
marché312.  
                                                                    
306 Piette F. et Le Quintrec J.-L., « L'emploi d'un médicament nouveau chez les personnes âgées : Terra incognita », op. cit., 
p. 89. 
307 WMA, Déclaration d’Helsinki, op. cit., § 13 ; CIOMS, Lignes directrices internationales d’éthique pour la recherche 
biomédicale impliquant des sujets humains, élaborées par le Conseil des Organisations internationales des Sciences 
médicales (CIOMS) avec la collaboration de l’Organisation mondiale de la santé, Genève, 2002, Ligne directrice 12. 
308 ICH, Studies in support of special populations: Geriatrics E7, Conférence internationale sur l'harmonisation des exigences 
techniques pour l'enregistrement des médicaments à usage humain, 1993. 
309 Ibid., p. 1. 
310 En 1993, il avait été estimé qu’un nombre de 100 personnes âgées pourrait suffire à procurer des données fiables sur les 
effets d’un médicament sur les personnes âgées, mais ce nombre ne paraît plus adéquat à ce jour. ICH, Final concept paper 
E7(R1) : Studies in support of special populations: Geriatrics, Conférence internationale sur l'harmonisation des exigences 
techniques pour l'enregistrement des médicaments à usage humain, 2008, p. 1. 
311 ICH, Studies in support of special populations: Geriatrics E7, op. cit., p. 2. 
312 ICH, Studies in support of special populations: Geriatrics E7, op. cit., p. 1. 
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162. En 2008, cette ligne directrice a été actualisée, exposant les problèmes non 
résolus313 et concluant par trois recommandations314 : 1) mieux justifier le nombre, l’âge et la 
répartition des participants âgés selon l’indication du médicament expérimental ; 2) prévoir le 
développement de tests de sécurité sur la population gériatrique pendant la pharmacovigilance ; 
3) indiquer des éléments précis à examiner spécifiquement dans le cas de comorbidités et de 
traitements multiples. Il y est précisé à plusieurs reprises qu’étant donnée la difficulté de la 
tâche, les essais peuvent être repoussés à après la mise sur le marché afin de ne pas retarder 
démesurément la mise à disposition des médicaments aux patients315. 
2.2 LES RÉPONSES DU DROIT EUROPÉEN 
163. La notion de fragilité est une notion médicale et non juridique, mais qu’il serait utile 
de reconnaître en droit comme une condition qui nécessite l’inclusion des personnes âgées 
fragiles dans les essais cliniques. Là où le dynamisme de l’Union est inégal mais présent (2.2.1), 
le Conseil de l’Europe est en revanche étonnamment silencieux (2.2.2). 
2.2.1 L’Union européenne : une réponse à deux vitesses 
164. Si l’Agence européenne du médicament (EMA) est depuis 2006 très active dans la 
promotion de la recherche en gériatrie 316 (2.2.1.1), le nouveau Règlement 536/2014 relatifs aux 
essais cliniques n’offre que quelques timides concrétisations de l’activité de l’EMA (2.2.1.2). 
2.2.1.1 LE DYNAMISME DE L’AGENCE EUROPÉENNE DU MÉDICAMENT 
165. L’EMA est une agence décentralisée de l’Union responsable de l’évaluation 
scientifique des médicaments en vue de leur mise sur le marché. Ses avis ne sont que 
consultatifs, et elle n’a pas de compétence propre pour remettre les autorisations de mise sur le 
marché, ni pour imposer des lignes directrices scientifiques ou éthiques relatifs aux 
médicaments317. Mais de par l’indépendance et l’expertise de ses membres318, il paraît crucial 
d’étudier ses avis et conseils scientifiques. 
                                                                    
313 ICH, Final concept paper E7(R1) : Studies in support of special populations: Geriatrics, op. cit., p. 1-3. 
314 Ibid., p. 3. 
315 Ibid., p. 3. 
316 L’EMA a effectivement organisé plusieurs workshops sur des questions plus précises des médicaments administrés sur 
les personnes âgées et surtout, elle avait réagi dès 2006 en publiant un rapport sur les lignes directrices relatives aux 
médicaments pour les personnes âgées. EMA, Adequacy of guidance on the elderly regarding medicinal products for human 
use, Doc. Ref. EMEA/498920/2006, Agence Européenne du Médicament, Londres, 2006 ; Si elle conclut à la conformité de 
la plupart des dossiers soumis à l’EMA aux lignes directrices ICH E7, elle conclut également que ces lignes directrices 
nécessitent, pour être plus utiles, d’être développées plus en profondeur, notamment pour opérer une distinction entre 
« personnes âgées » et « personnes très âgées ». Ibid., p. 2. 
317 Site Web de l’EMA, http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_0000 
91.jsp&mid=WC0b01ac0580028a42 [20 août 2015]. 
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166. Le dynamisme de l’EMA en matière de gériatrie a été particulièrement remarqué en 
2011, avec la stratégie pour les médicaments gériatriques319. Elle vise à d’abord s’assurer que les 
médicaments administrés aux personnes âgées soient de haute qualité, et que leur usage chez 
ces dernières soit suffisamment étudié320. La stratégie vise aussi à améliorer les notices de 
médicament, qui devraient comprendre toutes les informations pertinentes à l’administration 
d’un médicament à la population gériatrique, y compris les limitations et carences, afin de 
promouvoir une prescription « éclairée » par les médecins321.  
167. Pour atteindre ses objectifs, l’EMA a défini deux domaines d’actions privilégiés. Le 
premier relève de l’expertise et du conseil, par la promotion des échanges scientifiques ; le but 
étant de procurer une assistance aux industries pharmaceutiques mais également d’identifier les 
points à améliorer dans la législation pertinente ou les lignes directrices en la matière322. Ce 
premier objectif implique aussi la création du Groupe Expert en Gériatrie (GEG) en 2011323. Il est 
chargé de conseiller l’EMA sur les problèmes liés aux personnes âgées, par exemple en donnant 
son avis sur les lignes directrices existantes, sur les aspects gériatriques du développement, de 
l’évaluation et de la pharmacovigilance des médicaments à usage gériatriques, et de manière 
plus générale aider à la mise en place de la stratégie et procurer son expertise lorsqu’il y en a 
besoin. L’EMA projette aussi d’élaborer des directives sur la sécurité et l’efficacité des 
médicaments sur les patients âgés fragiles324. Le second domaine d’action est plus concret 
puisqu’il vise à renforcer la sévérité des critères d’évaluation des demandes de conduite d’essai 
clinique. Les demandes devront présenter des données sur les personnes âgées qui soient 
fiables, en quantité suffisante, et présentées de manière claire et sans impasses325.  
168. En outre, l’EMA se réserve le droit de soumettre l’autorisation de mise sur le marché 
à des obligations spécifiques de pharmacovigilance pour compléter l’information concernant 
certaines comorbidités ou effets indésirables326. Pour le moment, seuls deux rapports d’activités 
relatent les conséquences précises de la stratégie encore en cours. Le premier décrit ainsi la 
révision des lignes directrices pertinentes qui, pour 93% d’entre elles, n’étaient pas conformes 
aux directives de la ICH E7327 . Dans un second rapport, l’EMA rapporte que 75% des 
médicaments nouvellement autorisés ne procuraient pas suffisamment d’informations relatives 
                                                                                                                                                                                                                   
318  Site Web de l’EMA, http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000 
092.jsp&mid=WC0b01ac0580028a43 [20 août 2015]. 
319 EMA, Geriatric Medicines Strategy, EMA/CHMP/137793/2011, Agence Européenne du Médicament, Londres, 2011. 
320 Ibid., p. 1. 
321 Ibid., p. 1. 
322 Ibid., p. 3. 
323 EMA, Mandates, objectives and rules of procedure for the CHMP Geriatric Expert Group (GEG), EMA/281009/2013, 
Agence Européenne du Médicament, Londres, 2013. 
324 EMA, Geriatric Medicines Strategy, op. cit., p. 2. 
325 Ibid., p. 3 
326 Ibid., p. 2. 
327 EMA, Report analysis of scientific guidelines. EMA Geriatrics Medicines Strategy, EMA/352591/2013, 2013, p. 2.  
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à l’usage sur les personnes âgées328. Les activités de recherches ont également permis 
l’élaboration d’un article sur la qualité des médicaments administrés aux personnes âgées329. À 
l’exception de ces rapports d’activité, il n’y a, à cette date, pas encore de bilan général des 
résultats de la stratégie. 
2.2.1.2 L’IMPLICATION TIMIDE DU NOUVEAU RÈGLEMENT 536/2014 
169. Le nouveau Règlement 536/2014 étend considérablement la protection des 
personnes vulnérables en comparaison à la Directive 2001/20/CE330. Mais malgré les efforts de 
l’EMA, aucun engagement n’a été pris vis-à-vis des personnes âgées. 
170. Et pourtant, les besoins des personnes âgées sont reconnus. L’alinéa 14 du 
Préambule indique que « sauf disposition dûment justifiée dans le protocole, les participants à 
un essai clinique devraient être représentatifs des catégories de populations, par exemple le 
sexe et le groupe d’âge, susceptibles d’utiliser le médicament faisant l’objet de l’investigation ». 
De même, l’alinéa 15 du Préambule soulève aussi la problématique : « Afin d’améliorer les 
traitements disponibles pour les populations vulnérables telles que les personnes de santé 
fragile ou les personnes âgées, les personnes atteintes de plusieurs maladies chroniques ou les 
personnes atteintes de troubles psychiques, il convient d’étudier intégralement et de façon 
adaptée les effets sur ces groupes particuliers de médicaments susceptibles de présenter un 
intérêt clinique significatif, notamment en ce qui concerne les exigences liées aux 
caractéristiques spécifiques de ces populations et à la protection de la santé et du bien-être des 
participants y appartenant ».  
171. Par conséquent, le besoin d’inclusion des personnes âgées fragiles, n’a pas été 
oublié. Il est simplement regrettable que le nouveau Règlement ne fasse suite à ce constat du 
problème à aucun moment dans tout le reste de ses dispositions. On pourrait interpréter l’article 
10.4 comme incluant implicitement les personnes âgées : « Si, conformément au protocole, un 
essai clinique prévoit la participation de groupes ou de sous-groupes spécifiques de participants, 
le cas échéant, la demande d’autorisation de cet essai clinique est évaluée de façon 
particulièrement attentive à partir des connaissance relatives à la population que représentent 
les participants concernés » 331. Mais même si cela était le cas, l’article reste vague et dépendant 
                                                                    
328 Ibid., pp. 2-3. 
329  EMA, Concept paper on the need for a reflection paper on quality aspects of medicines for older people, 
EMA/165974/2013, Londres, 2013, p. 2. 
330 Union européenne, Directive 2001/20/CE du Parlement européen et du Conseil du 4 avril 2001 concernant le 
rapprochement des dispositions législatives, réglementaires et administratives des États membres relatives à l’application 
de bonnes pratiques cliniques dans la conduite d’essais cliniques de médicaments à usage humain, J.O., L 121, 1er mai 
2001, pp. 34-44. Si la directive protégeait les mineurs et les adultes incapables, la protection des personnes vulnérables 
s’étend désormais en outre aux personnes inconscientes en situation d’urgence (Article 35), aux femmes enceintes (Article 
33), et selon les droits nationaux, elle peut également s’appliquer aux personnes en situation de dépendance 
institutionnelle ou hiérarchique (Article 34). Union Européenne, Règlement (UE) n° 536/2014, op. cit., pp. 32-34. 
331 Union Européenne, Règlement (UE) n° 536/2014, op. cit., Article 10.4. 
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d’une prémisse majeure : le fait que des essais soient conduits sur un groupe de personnes 
âgées. Or, c’est exactement dans cette prémisse que réside le problème, comme nous l’avons 
exposé au début de cette partie, un nombre insuffisant d’essais cliniques sont menés sur les 
personnes âgées. 
172. Cette timide implication est d’autant plus étonnante que les législateurs européens 
ont déjà, depuis 2006, poussé la réflexion et franchi le cap de la réglementation pour les enfants. 
Ils ont reconnu que leur exclusion des essais cliniques, à la fois par souci de protection mais aussi 
par manque d’attractivité du marché, avait comme conséquence l’absence de médicaments 
adaptés332. Le Règlement pédiatrique 1901/2006 met ainsi en place un système d’obligations et 
d’incitations afin de faciliter le développement et l’accessibilité de médicaments à usage 
pédiatrique333, et ce, sur la base juridique du rapprochement des législations nationales pour le 
fonctionnement du marché intérieur334. Le Parlement européen a d’ailleurs élaboré une 
résolution spécifique sur la maladie d’Alzheimer en 2011 témoignant du besoin des recherches, 
et notamment pour cela d’une « collaboration transnationale »335. En outre, il « insiste » pour 
que la problématique des essais thérapeutiques pour les patients atteints d’Alzheimer « trouve 
son prolongement dans la révision de la directive européenne portant sur les essais cliniques de 
médicaments (2001/20/CE) »336, en vain. 
2.2.2 Le silence étonnant du Conseil de l’Europe 
173. L’unique disposition pertinente dans la Convention d’Oviedo 337  concerne les 
personnes juridiquement incapables, pour lesquelles il existe, par exception, la possibilité de 
mener des recherches338. Cependant, les personnes âgées fragiles ne sont qu’indirectement 
concernées car elles ne sont pas nécessairement incapables. Fragilité physique ne veut pas 
nécessairement dire troubles cognitifs ni démence. Le Protocole additionnel à la Convention 
d’Oviedo relatif à la recherche biomédicale prévoit les mêmes règles339. Bien qu’il mentionne des 
                                                                    
332 Règlement (CE) N° 1901/2006 du Parlement européen et du Conseil du 12 décembre 2006 relatif aux médicaments à 
usage pédiatrique, modifiant le règlement (CEE) n° 1768/92, les directives 2001/20/CE et 2001/83/CE ainsi que le 
règlement (CE) n° 726/2004, J.O., L 378, 27 décembre 2006, pp. 1-19, Préambule, Considérants 2 et 3. 
333 Ibid., Préambule, Considérants 4 et 6. 
334 Règlement (CE) N° 1901/2006, op. cit., Considérant 1.. 
335 Union européenne, Résolution du Parlement européen du 19 janvier 2011 sur une initiative européenne pour faire face 
à la maladie d’Alzheimer et aux autres démences (2010/2084(INI)), P7_TA(2011)0016, §14, §20, §22 et §52. 
336 Ibid., §64. 
337 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit., Chapitre V. 
338 Si cela peut lui procurer un bénéfice direct (Article 17.1), ou exceptionnellement si la recherche ne comporte pas de 
bénéfices potentiels directs, l’essai clinique peut être effectué si cela va améliorer les connaissances sur cette condition en 
question et sur ce type de patient particulier (Article 17.2.ii). Ibid. 
339 Conseil de l’Europe, Protocole additionnel à la Convention sur les Droits de l’Homme et la biomédecine, relatif à la 
recherche biomédicale, STCE N°195, Strasbourg, 25 janvier 2005, Article 15. 
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groupes vulnérables supplémentaires340, là encore, aucune mention des personnes âgées 
fragiles. 
174. Cette absence quasi totale de reconnaissance du besoin des personnes âgées vis-à-
vis des recherches biomédicales est d’autant plus surprenante que le domaine des droits 
fondamentaux des personnes âgées est en plein développement341. Malgré tout, le dernier texte 
en date, une recommandation du Comité des Ministres adoptée le 19 février 2014 à propos de la 
promotion des droits de l’homme des personnes âgées342 ne fait aucune mention de leur 
vulnérabilité vis-à-vis du défaut d’information sur l’usage des médicaments, ni du manque 
d’essai clinique qui est à l’origine de ce défaut d’information. Là encore, pareillement à l’Union 
européenne, cette absence même de reconnaissance par le Conseil de l’Europe du manque 
d’information sur les personnes âgées fragiles est paradoxale car il reconnaît ce besoin pour les 
enfants343.  
175. Ainsi, la phase d’élaboration du médicament, la phase de recherche biomédicale, est 
sous-estimée par le droit européen dans l’appréhension des enjeux de santé des personnes 
âgées. Elle est sous-estimée pour toutes les raisons que nous venons d’exposer, mais également 
car s’ajoute fréquemment un obstacle supplémentaire : l’obtention du consentement. L’obstacle 
est plus souvent contourné qu’affronté, remettant en cause la promotion de l’autonomie des 
personnes âgées vulnérables. 
3 La promotion de l’autonomie des personnes âgées 
vulnérables 
176. L’autonomie est un principe omniprésent en éthique clinique 344  qui oblige à 
respecter les choix du patient, et donc à respecter son droit à l’autodétermination345. Le respect 
du principe d’autonomie exige donc que le patient (ou le participant à une recherche) donne son 
                                                                    
340 Conseil de l’Europe, Protocole additionnel à la Convention sur les Droits de l’Homme et la biomédecine, relatif à la 
recherche biomédicale, op. cit. : Personnes privées de liberté (Article 20 du Protocole), personnes en situation d’urgence 
(Article 19 du Protocole), et enfin les femmes enceintes ou allaitantes (Article 18 du Protocole additionnel). 
341 Rien qu’au niveau du Conseil de l’Europe : Résolution 1793 (2011) de l’Assemblée parlementaire « Pour une longévité 
positive : valoriser l’emploi et le travail des seniors » ; Recommandation 1796 (2007) sur la situation des personnes âgées 
en Europe, Recommandation 1591 (2003) sur les défis de la politique sociale dans les sociétés européennes vieillissantes, 
Recommandation 1619 (2003) sur les droits des migrants âgés… 
342 Conseil de l’Europe, Recommandation CM/Rec(2014)2 sur la promotion des droits de l’homme des personnes âgées du 
Comité des Ministres aux États membres, adoptée le 19 février 2014. 
343 Même si, au contraire de l’Union, il n’est pas allé jusqu’à élaborer d’instrument ni même de régime spécifique aux 
enfants. Conseil de l’Europe, Rapport explicatif au Protocole additionnel à la Convention sur les Droits de l’Homme et la 
biomédecine, relatif à la recherche biomédicale, Strasbourg, STCE N°195, 25 janvier 2005, §90 et §92. 
344 Lamau M.-L., « Le recours au principe d’autonomie en éthique clinique », Revue d’éthique et de théologie morale, Vol. 2, 
n°234, 2005, pp. 63-70. 
345 Le Coz P., « Les principes éthiques reconnus à l’échelle internationale », in Mattei J.-F. (dir.), Questions d'éthique 
biomédicale, Flammarion Coll Nouvelle Bibliothèque Scientifique, Paris, 2008, p. 77. 
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consentement. Mais surtout, ce consentement soit libre et éclairé, ce qui suppose que la 
personne soit en mesure de comprendre et d’évaluer les enjeux de sa décision, et qu’elle soit 
également en mesure de faire ce choix librement, sans mesure coercitive extérieure346. Or, 
l’obtention de ce consentement de la part de personnes âgées vulnérables pose de sérieux défis 
(3.1) qui ont pour le moment encore peine à trouver réponse dans le droit européen (3.2).  
3.1 LES DÉFIS DE L’OBTENTION DU CONSENTEMENT ÉCLAIRÉ 
177. Lorsque la personne âgée vulnérable n’est que partiellement autonome, des 
mécanismes sont mis en place pour la protéger, mais cette protection peut parfois devenir 
surprotectrice (3.1.1). Divers moyens sont utilisés dans la pratique médicale pour promouvoir 
leur capacité de décision, mais ces moyens ne sont ni harmonisés ni même reflétés dans les 
recommandations scientifiques et éthiques (3.1.2). 
3.1.1 Entre protection et surprotection de la vulnérabilité 
décisionnelle 
178. La fragilité cognitive des personnes âgées constitue un réel obstacle à l’obtention du 
consentement éclairé (3.1.1.1), de sorte que la prudence des médecins et chercheurs est contre-
productive lorsqu’elle marginalise les personnes âgées en les excluant soit des essais, soit du 
processus de consentement (3.1.1.2). 
3.1.1.1 LA FRAGILITÉ COGNITIVE DES PERSONNES ÂGÉES 
179. C’est sur la vulnérabilité cognitive que nous nous attarderons en ce qu’elle affecte la 
capacité de donner une décision éclairée par la personne âgée juridiquement capable. C’est le 
cas par exemple des maladies psychiatriques ou neurologiques, mais aussi d’une condition très 
fréquente chez la personne âgée : la fragilité cognitive347. Elle est un syndrome clinique 
hétérogène de troubles cognitifs entraînant une confusion chez les personnes âgées, qui est 
                                                                    
346 Le Coz P., « Les principes éthiques reconnus à l’échelle internationale », op. cit., p. 78. 
347 Hazif-Thomas C., Thomas P. et Walter M., « Motivation sociale, fragilité cognitive et assomption de la vieillesse », La 
Lettre du Psychiatre, Vol. VII, n°5-6, 2011, pp. 148-151.. 
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causé par leur (pré-)fragilité physique348, et qui se distingue de démences telles la maladie 
d’Alzheimer ou maladies associées349.  
180. En d’autres termes, la fragilité cognitive n’est que « vieillissement physiologique »350 
qui ralentit les capacités de compréhension et de mémorisation de l’information. Et ceci 
constitue un obstacle de taille pour obtenir le consentement éclairé des participants âgés. Une 
étude a rapporté que seule la moitié des participants âgés – jugés d’intelligence normale – 
avaient compris l’information qui leur avait été fournie à propos d’un protocole de recherche351. 
Et lorsqu’à la fragilité cognitive s’additionne une maladie neurologique ou psychiatrique, les 
résultats sont encore plus alarmants. Une étude a par exemple démontré que 70% des 
participants potentiels d’un essai clinique pour la maladie d’Alzheimer n’avaient été jugés que 
partiellement compétents352, et les illustrations sont nombreuses dans la littérature353. 
3.1.1.2 LA MARGINALISATION DES PERSONNES ÂGÉES COGNITIVEMENT FRAGILES 
181. Plus qu’une protection de l’autonomie, le processus du consentement éclairé est 
parfois un défi car il se perd entre les documents administratifs et le vocabulaire médical. Il 
découragerait parfois la recherche sur les personnes âgées, et d’autant plus si la personne âgée 
est atteinte de fragilité cognitive354, de dépression, maladie psychiatrique ou encore de la 
maladie d’Alzheimer ou autre démence355. 
182. Il relève du devoir des médecins de s’assurer au cas par cas que la personne est 
capable de prendre une décision 356 . Mais une tendance souvent dénoncée est de 
systématiquement considérer les personnes âgées comme trop vulnérables pour donner un 
consentement. On va alors, dans leur intérêt, les exclure de la recherche, faire appel à un 
                                                                    
348  EMA, Proposal for the development of a points to consider for baseline characterisation of frailty status, 
EMA/335158/2013, Agence Européenne du Médicament, Londres, 2013 ; Robertson D. A., Savva G. M. et Kenny R. A., 
« Frailty and cognitive impairment – a review of the evidence and causal mechanisms », Ageing Research Reviews, Vol. 12, 
2013, pp. 840-851. 
349 Qingwei R. et al., « Cognitive frailty, a novel target for the prevention of elderly dependency », Ageing Research Reviews, 
Vol. 20, 2015, p. 4 ; Kelaiditi E. et al., « Cognitive frailty : rational and definition from an (IANA/IAGG) international 
consensus group », The Journal of Nutrition, Health and Aging, Vol. 17, n°9, 2013, p. 731. 
350  Ce vieillissement physiologique induit un « ralentissement du traitement de l’information ainsi qu’un déclin 
attentionnel ». Krolak-Salmon P., « Cognition et fragilité chez la personne âgée », Les Cahiers de l’Année Gérontologique, 
Vol. 4, n°13, 2012, p. 14. 
351 Krolak-Salmon P., « Cognition et fragilité chez la personne âgée », op. cit., p. 13 ; Berdeu D. et al., « Clinical trials in the 
elderly : Ethical and methodologic considerations », op. cit., p. 618. 
352 Bayer A. et Fish M., « The doctor's duty to the elderly patient in clinical trials », Drugs Aging, Vol. 20, n°15, 2003, p. 1093. 
353 Ibid., p. 1092 à 1094 ; Ou encore Dunn L. B. et Misra S., « Research ethics issues in geriatric psychiatry », Psychiatr Clin 
North Am, Vol. 32, n°2, 2009, p. 4. 
354 Barron J. S. et al., « Informed consent for research participation in frail older persons », Aging Clin Exp Res, Vol. 16, n°1, 
2004, p. 79. 
355 Pour des résultats d’études empiriques en la matière, voir Dunn L. B. et Misra S., « Research ethics issues in geriatric 
psychiatry », op. cit., p. 4. 
356 Bayer A. et Fish M., « The doctor's duty to the elderly patient in clinical trials », op. cit., p. 1091 ; Meulenbroek O. et al., 
« Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent », 
European Geriatric Medicine, n°1, 2010, p. 58 ; Bayer A. et Fish M., « The doctor's duty to the elderly patient in clinical 
trials », op. cit., p. 1092 ; Bielby P., Competence and vulnerability in biomedical research, International Library of Ethics, Law 
and the New Medicine, Springer, 2008, p. 140. 
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représentant légal, ou bien limiter leur décision à ce que le comité d’éthique estime comme 
raisonnablement dans leur intérêt, ce qui est souvent très limitatif357. Cette tendance porte 
cependant atteinte à leur autodétermination par une ingérence surprotectrice358. Au contraire, il 
relève aussi du devoir du chercheur de tout mettre en œuvre pour l’optimiser et l’entretenir en 
faisant participer la personne au maximum359 car la capacité de décision doit être vue comme 
une qualité dynamique et développable, et non comme une caractéristique fixe360. 
3.1.2.Recommandations scientifiques, médicales et éthiques 
183. Là où la doctrine médicale propose des solutions pour promouvoir l’auto-
détermination des personnes âgées (3.2.1), ces propositions ne sont pas reflétées par les lignes 
directrices internationales majeures (3.2.1). 
3.2.1 LA DOCTRINE MÉDICALE  
184. S’il existe des grilles générales d’évaluation de la capacité de décision361 voire des 
instruments scientifiquement développés362, les pratiques diffèrent grandement selon les 
chercheurs et selon les types de patients. La doctrine réclame des instruments qui soient 
harmonisés et spécifiques par exemple à une démence légère363. 
185. Ensuite, il s’agit de surmonter d’éventuelles faiblesses dans la capacité de décision 
et promouvoir l’autonomie des personnes âgées. Par exemple, certains proposent toute une 
série de moyens comme les vidéos ou outils interactifs, la lecture à haute voix, une écriture plus 
grande, ou encore l’usage régulier de quizz pour vérifier la compréhension et la mémoire avant 
et pendant l’essai364. Cependant, ces recommandations alourdissent encore le processus 
                                                                    
357 Lacour C., « La personne âgée vulnérable : Entre autonomie et protection », Gérontologie et société, Vol. 4, n°131, 2009, 
p. 192. 
358 Barron J. S. et al., « Informed consent for research participation in frail older persons », op. cit., p. 79. 
359 Ibid.,  p. 81. 
360 Bielby P., Competence and vulnerability in biomedical research, op. cit., p. 142. 
361 Cinq critères majeurs guident généralement l’analyse : 1) la capacité à recevoir et à comprendre les informations ; 2) la 
capacité à les analyser ; 3) la capacité d’évaluer la situation et ses conséquences ; 4) la capacité de mettre en balance les 
bénéfices, risques et alternatives ; et 5) la capacité de prendre une décision et de l’exprimer. Meulenbroek O. et al., 
« Informed consent in dementia research. Legislation, theoretical concepts and how to assess capacity to consent », op. cit., 
p. 58 ; Voir aussi les 4 capacités de Dunn : 1) comprendre l’information, 2) appliquer l’information à sa situation 
personnelle, 3) analyser l’information de façon rationnelle, 4) exprimer un choix clair et cohérent. Dunn L. B. et Misra S., 
« Research ethics issues in geriatric psychiatry », op. cit., p. 2. 
362 Dunn L. B., Nowrangi M. A., Palmer B. W., Jeste D. V. et Saks E. R., « Assessing decisional capacity for clinical research or 
treatment : a review of instruments », American Journal of Psychology, n°163, 2006, pp. 1323-1334. 
363 Barron J. S. et al., « Informed consent for research participation in frail older persons », op. cit., p. 82. 
364 Bayer A. et Fish M., « The doctor's duty to the elderly patient in clinical trials », op. cit., p. 1087 et p. 1093 ; Dans 
le même sens, voir Berdeu D. et al., « Clinical trials in the elderly : Ethical and methodologic considerations », op. 
cit., Tableau I, p. 619 ; Dunn L. B. et Misra S., « Research ethics issues in geriatric psychiatry », op. cit., p. 5. 
  96 
d’obtention du consentement sans même de garantie de stabilité. C’est pourquoi les efforts 
doctrinaux portent plus souvent sur l’encadrement du rôle des représentants365. 
186. Lorsque la capacité de décision n’est pas suffisante, il sera fait appel à un 
représentant pour autoriser la participation366. Mais les personnes vulnérables, de facto 
incapables, ne sont pas nécessairement sous protection juridique. Pour une démence telle 
l’Alzheimer, la protection juridique n’est que rarement déjà en place à cause de la rapidité 
d’évolution de la maladie. Et lorsqu’il y a représentant, d’autres problèmes se posent car ce 
dernier a le pouvoir de soumettre la personne aux risques liés à la recherche sans jamais 
vraiment savoir de ce que la personne aurait décidé367. En outre, son opinion peut aussi être 
biaisée368, tout comme il peut présenter une vulnérabilité décisionnelle liée au vieillissement et à 
la fragilité cognitive369, par exemple s’il s’agit du conjoint. 
187. Enfin, une autre possibilité trop peu explorée est celle des directives anticipées. En 
matière de soins, elles servent aux patients à exprimer leurs souhaits en avance, pour un 
moment futur dans lequel ils ne seront plus capables de décider ou de s’exprimer. Elles 
pourraient être utiles avec les patients âgés pendant les stades précurseurs d’une démence370 
afin de leur donner un moyen supplémentaire de jouir de leur droit à l’auto-détermination. Mais 
plusieurs questionnements demeurent quant à leur éventuelle utilisation en matière de 
recherche : à quel point l’information doit-elle être détaillée ? À quel point la directive doit-elle 
être détaillée ? Les directives anticipées devraient-elles valoir consentement (si oui dans quelles 
conditions), ou ne devraient-elle être qu’un support pour les représentants légaux371 ? 
3.2.2 LES LIGNES DIRECTRICES INTERNATIONALES 
188. Les instruments éthiques internationaux n’offrent que peu de recommandations 
spécifiques au consentement éclairé des personnes âgées. Il faut donc se tourner vers les 
mécanismes communs.  
                                                                    
365 Bielby P., Competence and vulnerability in biomedical research, op. cit., p. 158 ; Lacour C., « La personne âgée vulnérable 
: Entre autonomie et protection », op. cit., p. 188. 
366 Barron J. S. et al., « Informed consent for research participation in frail older persons », op. cit., p. 82 ; Dunn L. B. et 
Misra S., « Research ethics issues in geriatric psychiatry », op. cit., p. 2 ; Meulenbroek O. et al., « Informed consent in 
dementia research. Legislation, theoretical concepts and how to assess capacity to consent », op. cit., p. 60. 
367 Meulenbroek O. et al., « Informed consent in dementia research. Legislation, theoretical concepts and how to assess 
capacity to consent », op. cit., p. 58. 
368 Bayer A. et Fish M., « The doctor's duty to the elderly patient in clinical trials », op. cit., p. 1095; Dunn L. B. et 
Misra S., « Research ethics issues in geriatric psychiatry », op. cit., p.7; Beattie B. L., « Consent in Alzheimer's disease 
research : Risk/benefit factors », Can J Neurol Sci, Vol. 34, Suppl 1, 2007, p. S27. 
369 Ibid., p. S28. 
370 Jongsma K. et van de Vathorst S., “Advance directives in dementia research : The opinions and arguments of clinical 
researchers – an empirical study”, Research ethics, publié en ligne le 8 août 2014: doi: 10.1177/1747016114523422 ; 
Helmchen H., « Ethics of clinical research with mentally ill persons », Eur Arch Psy Clin, Vol. 262, 2012, p. N441 ; Pierce R., « 
A changing landscape for advance directives in dementia research”, Soc Sci Med, Vol. 70, 2010, p. 623 ; Alzheimer Europe, 
Position paper on the use of advance directives, 2009, http://www.alzheimer-europe.org/Policy-in-Practice2/Our-opinion-
on/Advance-directives [22 mars 2015], § 31. 
371 Andorno R., Gennet É., Jongsma K. et Elger B., « Integrating Advance Research Directives into the European Legal 
Framework », European Journal of Health Law, Vol. 23, 2016, pp. 49-64. 
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189. Pour commencer, les trois lignes directrices éthiques majeures reconnaissent que la 
vulnérabilité va bien au-delà de la seule incapacité juridique. Elles définissent ainsi la 
vulnérabilité par ce que nous appelons ici la vulnérabilité décisionnelle, c’est-à-dire la difficulté 
de défendre ses intérêts et le risque accru de subir des influences extérieures qui modifieraient 
la décision de consentement 372 . Seules les lignes directrices du CIOMS mentionnent 
spécifiquement les personnes âgées vulnérables, en associant par exemple leur vulnérabilité à 
leur placement en institution ou au diagnostic d’une forme de démence373, sans plus de détails.  
190. En ce qui concerne l’évaluation de la capacité de décision et les moyens de 
l’améliorer, les lignes directrices restent générales. Globalement, elles exigent du médecin qu’il 
s’adapte aux besoins des participants potentiels374, sans préciser les moyens d’évaluation et 
d’adaptation. 
191. Si le consentement est donné par un représentant légal, la Déclaration d’Helsinki, les 
lignes directrices du CIOMS et de la ICH exigent le recueil de l’assentiment du participant375. 
Seuls le CIOMS et la Déclaration d’Helsinki précisent que toute objection du participant doit être 
respectée376. Le CIOMS met en garde contre les problèmes de partialité des membres de la 
famille ou amis mais ne donne pas de directives en la matière377. 
192. Pour finir, aucune des lignes directrices internationales ne traite explicitement de la 
possibilité d’utiliser des directives anticipées en matière de recherches biomédicales.  
                                                                    
372 Les personnes vulnérables sont celles qui ont « une plus forte probabilité d’être abusés ou de subir un préjudice 
additionnel » et qui ont donc besoin d’une « protection adaptée » (§19). AMM, Déclaration d’Helsinki, op. cit. ; Les sujets 
vulnérables sont les individus dont la volonté de participer à un essai clinique est susceptible d’être influencée à tort par 
l’espoir, qu’il soit justifié ou non, de bénéfices associés avec la participation, ou bien de représailles de la part de supérieurs 
hiérarchiques en cas de refus de participer. ICH, Final concept paper E7(R1) : Studies in support of special populations: 
Geriatrics, op. cit., §1.61, p. 8 ; Les personnes vulnérables sont « celles qui sont relativement (ou totalement) incapables de 
protéger leurs propres intérêts. Plus précisément, leur pouvoir, leur intelligence, leur degré d’instruction, leurs ressources, 
leur force ou autres attributs nécessaires pour protéger leurs intérêts propres, peuvent être insuffisants ». CIOMS, Lignes 
directrices internationales d’éthique pour la recherche biomédicale impliquant des sujets humains, op. cit., Ligne directrice 
13, Commentaire, p. 49.  
373 CIOMS, Lignes directrices internationales d’éthique pour la recherche biomédicale impliquant des sujets humains, op. 
cit., Ligne directrice 13, Commentaire « Autres groupes vulnérables », p. 50. 
374 ICH, Directive de bonne pratique clinique E6(R1) de la Conférence internationale sur l’harmonisation des exigences 
techniques pour l’enregistrement des médicaments à usage humain (ICH), 10 juin 1996, §4.8.12, p. 17 ; La Déclaration 
d’Helsinki exige du médecin engagé dans la recherche médicale qu’il protège, entre autres, le droit à l’autodétermination 
des participants, (§ 9), supposant aussi de s’adapter aux éventuels besoins spécifiques des personnes pour comprendre 
l’information (§ 26). WMA, Déclaration d’Helsinki, op. cit. ; Les lignes directrices du CIOMS mettent en garde contre les 
difficultés de compréhension du participant qui dépendent aussi « de la capacité et de la volonté de l’investigateur de 
communiquer avec patience et sensibilité ». CIOMS, Lignes directrices internationales d’éthique pour la recherche 
biomédicale impliquant des sujets humains, op. cit., Ligne directrice 4, Commentaire « Langue », p. 23. 
375 WMA, Déclaration d’Helsinki, op. cit., §29 ; CIOMS, Lignes directrices internationales d’éthique pour la recherche 
biomédicale impliquant des sujets humains, op. cit., Ligne directrice 15, Commentaire « Consentement de la personne », p. 
54 ; ICH, Directive de bonne pratique clinique E6(R1), op. cit., §4.8.12, p. 17. 
376 WMA, Déclaration d’Helsinki, op. cit., §29 ; CIOMS, Lignes directrices internationales d’éthique pour la recherche 
biomédicale impliquant des sujets humains, op. cit., Ligne directrice 15, Commentaires, p. 54. 
377 CIOMS, Lignes directrices internationales d’éthique pour la recherche biomédicale impliquant des sujets humains, op. 
cit., Ligne directrice 15, Commentaire « Consentement de la personne », p. 54. 
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3.2 LA RÉPONSE DU DROIT EUROPÉEN 
193. La protection de la vulnérabilité décisionnelle ne paraît en pratique que peu 
compatible avec la protection duelle classique des personnes capables et incapables. Il serait 
nécessaire de déterminer une catégorie intermédiaire afin de mieux adapter la protection des 
personnes dans ce cas, y compris des personnes âgées. Cependant, Union européenne comme 
Conseil de l’Europe semblent avoir une vision manichéenne de la capacité de consentir car les 
dispositions protectrices de la vulnérabilité décisionnelle, hors incapacité juridique, ne sont que 
marginales (3.2.1). Par conséquent, les dispositions applicables au consentement éclairé de la 
personne âgée vulnérable sont très limitées et seulement prospectives (3.2.2). 
3.2.1 Une reconnaissance marginale de la vulnérabilité 
décisionnelle 
194. L’éventuelle détermination d’une catégorie intermédiaire de capacité de décision 
des personnes relèverait des compétences nationales des États. Cependant, la reconnaissance 
de la vulnérabilité décisionnelle en tant qu’objectif éthique gagnerait à être ne serait-ce que 
reconnu au niveau européen afin d’inciter les États à mettre en place des dispositions 
spécifiques. Dans les développements suivants, nous exposerons dans quelle mesure l’Union 
(3.2.1.1) et le Conseil de l’Europe (3.2.1.2) reconnaissent la vulnérabilité décisionnelle. 
3.2.1.1 UNION EUROPÉENNE 
195. Le Préambule fait clairement référence à des cas qui relèvent de la vulnérabilité 
décisionnelle - les catégories socioéconomiques défavorisées et les personnes en situation de 
dépendance institutionnelle ou hiérarchique378 - mais sans les reprendre dans l’article dédié aux 
personnes vulnérables379. La spécificité de la situation des personnes âgées vulnérables n’est 
explicitement mentionnée à aucun moment du texte.  
196. Seule la vulnérabilité des personnes en établissement de soins est reconnue380 et 
pertinente pour les personnes âgées, mais elle ne suffit pas et ce, à plusieurs égards : d’une part, 
seule une partie des personnes âgées sont placées en établissement, d’autre part, le Règlement 
ne prévoit qu’une possibilité pour les Etats de mettre en place des dispositions supplémentaires, 
sans les y obliger pour autant381. Cette disposition risque donc de laisser libre court à une double 
                                                                    
378 Union Européenne, Règlement (UE) n° 536/2014, op. cit., Préambule, Considérant 31. 
379 En effet, l’article 10 traitant des personnes vulnérables mentionne les mineurs, les majeurs incapables, les femmes 
enceintes, les groupes ou sous-groupes spécifiques de participants, et enfin les personnes inconscientes en situation 
d’urgence. Ibid., Article 10. 
380 Ibid., Article 34. 
381 Ibid. 
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inégalité : inégalité entre les personnes âgées à domicile et les personnes âgées placées en 
établissement au sein même des États ; mais aussi une inégalité entre les personnes âgées 
placées en établissements dans des États différents, selon qu’ils auront mis en place ou non des 
dispositions plus protectrices. Laisser les États membres libres sur cette question risque donc de 
rendre encore la recherche biomédicale avec des personnes âgées vulnérables encore plus 
difficile, surtout lorsque les essais seront multinationaux. 
197. Et pourtant, le Parlement européen avait attiré l’attention des États membres et du 
Conseil dans sa résolution de 2011, les encourageant à « promouvoir une réflexion et une 
démarche éthique par rapport aux malades pour garantir la permanence et le respect de la 
personne humaine, et à lancer une réflexion sur le statut juridique de la personne souffrant de 
maladies neurodégénératives afin d’encadrer juridiquement le champ de la privation de liberté 
et de la protection juridique du malade »382, là encore, en vain. 
3.2.1.2 CONSEIL DE L’EUROPE 
198. Outre les majeurs incapables et les mineurs383, le Conseil de l’Europe reconnaît, dans 
le cadre des soins, une situation intermédiaire pour les personnes capables souffrant d’un 
trouble mental384. Pour pouvoir traiter la personne sans son consentement, il faut qu’il y ait 
altération des facultés mentales, que l’intervention ait comme but de traiter précisément ce 
trouble mental, et que l’absence de traitement soit préjudiciable à sa santé385. Ainsi, même s’il 
était techniquement possible de conduire des recherches sur des personnes souffrant d’un 
trouble mental sans leur consentement, ces cas se borneraient aux situations rares dans 
lesquelles les essais cliniques constituent la dernière option de traitement possible pour 
améliorer la santé du patient. En outre, cette option n’est que spéculative puisque la Convention 
d’Oviedo ne prévoit pas de dispositions spécifiques pour les personnes capables souffrant d’un 
trouble mental dans le cadre des recherches. Par conséquent, s’il l’on s’en tient au chapitre V de 
la Convention d’Oviedo sur la recherche scientifique, il n’est pas certain de savoir dans quelle 
catégorie classer les personnes âgées vulnérables. 
199. Le Protocole additionnel sur la recherche biomédicale fait référence à la « personne 
en situation de faiblesse »386 pour laquelle « des pressions très légères suffiront à vaincre sa 
volonté et à lui donner le sentiment qu’elle a l’obligation de donner son accord, même si tel 
n’est pas son souhait »387. Il distingue ainsi les personnes en situation de faiblesse des 
                                                                    
382 Union européenne, Résolution du Parlement européen du 19 janvier 2011, op. cit., §59. 
383 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit., Articles 6 et 17.1. 
384 Ibid., Article 7. 
385 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit., Article 7. 
386 Ibid., Article 12. 
387 Conseil de l’Europe, Rapport explicatif au Protocole additionnel à la Convention sur les Droits de l’Homme et la 
biomédecine, relatif à la recherche biomédicale, op. cit., Article 12, § 62. 
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« personnes vulnérables ou en état de dépendance »388. Malheureusement encore, cette 
vulnérabilité n’est pas reconnue jusqu’au point de mentionner les vulnérabilités dues à des 
troubles cognitifs ou à des maladies psychiatriques ou neurologiques, ni au point pour les 
personnes âgées vulnérables de se voir reconnaître un statut spécifique. L’omission de cette 
particularité de la majeure partie des personnes âgées est d’autant plus étonnante que les 
législateurs européens ont en revanche pris le soin d’ajouter des catégories de personnes qui 
bénéficient d’une protection spécifique : les femmes enceintes, les patients en situation 
d’urgence et les personnes privées de liberté389. 
3.2.2 Le traitement prospectif du consentement de la personne 
âgée vulnérable 
200. Le droit de l’Union européenne comme celui du Conseil de l’Europe énoncent les 
règles essentielles qui entourent le régime du consentement éclairé, mais les conditions précises 
de son obtention relèvent des compétences nationales des États. L’étude du consentement de la 
personne âgée vulnérable n’y est ici donc que prospective. En effet dans un premier temps, nous 
étudierons les seules dispositions indirectement transposables à la situation des personnes 
âgées vulnérables (mais capables) : celles relatives à la promotion de l’auto-détermination du 
participant incapable (3.2.2.1). Dans un second temps, nous étudierons le statut d’éventuelles 
directives anticipées utilisées en matière de recherche (3.2.2.2). 
3.2.2.1 L’AUTO-DÉTERMINATION DU PARTICIPANT INCAPABLE 
201. Le participant incapable est dépendant de la décision de son représentant légal390, 
mais les textes européens imposent parfois de le faire participer puisqu’il doit « dans la mesure 
du possible » 391 être associé à la procédure, et son refus doit être respecté392. Toutefois, la 
formule apparaît trop vague pour pouvoir guider les États membres vers une harmonisation des 
                                                                    
388 Cependant en lisant le rapport explicatif, on constate que la distinction entre vulnérabilité et état de dépendance n’est 
pas bien établie, la définition donnée de la vulnérabilité semblant englober l’état de dépendance, tout en en étant 
explicitement séparée. Ibid., Article 12, § 67 et – 69. 
389 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit., respectivement les articles 18, 19 
et 20. 
390 Union Européenne, Règlement (UE) n° 536/2014, op. cit., Article 31; Conseil de l’Europe, Convention sur les Droits de 
l’Homme et la biomédecine, op. cit. Article 17. NB : Cependant, selon le Conseil de l’Europe, l’avis du médecin prévaudrait 
sur celui du représentant légal s’il estime la décision contre l’intérêt du patient incapable. Il reviendrait aux États de prévoir 
des recours appropriés pour ces situations. Rapport explicatif à la Convention sur les Droits de l’Homme et la biomédecine, 
op. cit.,, Article 6, § 48. 
391 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit. Article 6.3 ; Voir aussi Conseil de 
l’Europe, Protocole additionnel à la Convention sur les Droits de l’Homme et la biomédecine, relatif à la recherche 
biomédicale, op. cit., Article 15.1.iii ; Union Européenne, Règlement (UE) n° 536/2014, op. cit., Article 31.3. 
392 Conseil de l’Europe, Convention sur les Droits de l’Homme et la biomédecine, op. cit. Article 17.1.v ; Voir aussi Conseil de 
l’Europe, Protocole additionnel à la Convention sur les Droits de l’Homme et la biomédecine, relatif à la recherche 
biomédicale, op. cit., Article 15.1.v ; Union Européenne, Règlement (UE) n° 536/2014, op. cit., Article 31.1.c. 
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législations, notamment sur la manière dont on évalue si la personne est en mesure de 
participer à la décision et de se forger une opinion, laissant peu d’indices sur la marche à suivre 
avec des patients capables mais atteints de fragilité cognitive ou de démence. 
202. Le Conseil de l’Europe donne un peu plus de détails que l’Union en la matière. Par 
exemple le rapport explicatif de la Convention d’Oviedo indique que le participant incapable doit 
donner son consentement s’il est dans une phase d’amélioration de sa condition393. Cela 
pourrait être utile notamment pour les maladies psychiatriques, mais aussi et surtout pour les 
troubles cognitifs où les phases de lucidité alternent avec des phases de confusion. 
Malheureusement cette interprétation ne trouve aucun écho explicite dans le texte même de la 
Convention, notamment aucune obligation de réévaluer la capacité de décision du patient 
incapable. En revanche, le Protocole additionnel oblige implicitement à s’adapter aux capacités 
des participants en exigeant une information « adéquate, sous une forme compréhensible », 
exigence à laquelle le rapport explicatif du Protocole semble donner une dimension supérieure. 
Ainsi, sans figurer explicitement dans le Protocole additionnel, est amplement décrite dans le 
rapport explicatif toute une série de moyens pour pallier à diverses lacunes et faiblesses des 
participants potentiels comme l’usage de technologies audio-visuelles, l’allongement des délais 
de réflexion, l’adaptation aux troubles sensoriels ou au manque d’éducation394… Il est cependant 
dommage que les troubles cognitifs ne soient pas traités, laissant encore sans réponse la 
question de la protection pratique de la vulnérabilité décisionnelle de la plupart des personnes 
âgées. 
3.2.2.2 LES DIRECTIVES ANTICIPÉES 
203. Harmoniser les législations européennes sur ce point paraît presque impossible au 
vu des divergences entre droits nationaux sur ce sujet – par exemple en matière de fin de vie – 
et de l’absence de compétence du droit européen en la matière. Par conséquent, la position des 
institutions européennes reste floue. Ni le Conseil de l’Europe, ni l’Union n’autorisent 
explicitement les directives anticipées en matière de recherches. Pis encore pour le Conseil de 
l’Europe, le représentant légal n’a même pas l’obligation de respecter les « souhaits 
précédemment exprimés » par le participant, mais seulement de les « prendre en compte »395. 
204. Quant au nouveau Règlement UE 536/2014, il n’exclue pas explicitement les 
directives anticipées : « Dans le cas de participants incapables qui n’ont pas donné leur 
consentement éclairé ou qui n’ont pas refusé de le faire avant la survenance de leur incapacité, 
                                                                    
393 Rapport explicatif à la Convention sur les Droits de l’Homme et la biomédecine, op. cit., Article 6, § 43. 
394 Conseil de l’Europe, Rapport explicatif au Protocole additionnel à la Convention sur les Droits de l’Homme et la 
biomédecine, relatif à la recherche biomédicale, op. cit., Article 13, § 72. 
395 Conseil de l’Europe, Protocole additionnel à la Convention sur les Droits de l’Homme et la biomédecine, relatif à la 
recherche biomédicale, op. cit., Article 15.1.iv. 
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un essai clinique ne peut être conduit que si (…) »396. Si on peut aisément conclure qu’une 
directive anticipée négative aurait valeur de refus opposable au représentant légal, la question 
d’une directive anticipée positive pose plus de problèmes397. En outre, il resterait à déterminer 
quel régime s’appliquerait alors : celui des participants capables ou incapables, puisque le sujet 
devenu incapable a consenti à la recherche en tant que personne capable398. 
4 Conclusion 
205. Réglementer la recherche biomédicale sur les personnes âgées vulnérables implique 
des complexités pratiques auxquelles les textes européens ne sont pas encore adaptés. Afin de 
promouvoir la qualité de leurs soins de santé, la doctrine médicale et éthique démontre que les 
personnes âgées physiquement fragiles doivent – au lieu d’en être exclues – être incluses 
systématiquement dans les recherches biomédicales, avant et/ou après la mise sur le marché du 
médicament. Or le droit européen offre des réponses très inégales à ce besoin. Le droit du 
Conseil de l’Europe est totalement silencieux en la matière, tandis qu’en droit de l’Union 
européenne, les discussions au sein de l’Agence européenne du médicament n’ont pas suffit à 
faire intégrer de mesure spécifique aux personnes âgées dans le nouveau Règlement. Quant à la 
promotion de l’autonomie des personnes âgées, c’est surtout la doctrine médicale qui va alerter 
sur les challenges particuliers que représentent la fragilité cognitive, les maladies psychiatriques 
ou les démences comme la maladie d’Alzheimer. La plupart du temps, les personnes âgées ont 
une capacité de décision réduite sans encore bénéficier de protection juridique. Étonnamment, 
les lignes directrices éthiques ainsi que le droit européen sont plutôt manichéens et peu 
sensibles aux stades qui précèdent l’incapacité juridique. Une grande part de participants 
potentiels se trouve exclue de fait, là où des procédés intermédiaires pourraient encore être 
établis. 
206. Les solutions à apporter à ces deux problématiques devront être liées : favoriser 
voire inciter l’inclusion des personnes âgées fragiles dans les essais cliniques nécessite 
d’aménager des solutions pour le consentement des personnes âgées atteintes de fragilité 
cognitive, de la maladie d’Alzheimer, autres démences ou maladies psychiatriques, que ce soit 
par l’assistance et la promotion de leur capacité de décision, ou par des directives anticipées. Si 
ces questions relèvent des compétences nationales des États, la problématique est commune à 
l’Europe et la réunion d’un nombre suffisant de participants âgés pour des tests cliniques 
                                                                    
396 Ibid., Article 31.1. 
397 Andorno R., Gennet É., Jongsma K. et Elger B., « Integrating Advance Research Directives into the European Legal 
Framework », op. cit. 
398 Certains auteurs disent que c’est le cas : Lötjönen S., « Medical research on patients with dementia – the role of advance 
directives in European legal instruments », European Journal of Health Law, Vol. 13, n°3, 2006, p. 246. 
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présente un caractère nécessairement transfrontière399. L’implication du législateur européen 
est indispensable pour, si ce n’est imposer des règles communes, au moins donner une 
impulsion dans le sens d’une meilleure inclusion des personnes âgées dans les recherches 
biomédicales, et d’une meilleure promotion de leur autonomie. 
  
                                                                    
399 Par exemple pour la maladie d’Alzheimer et autres démences, le Parlement européen énonce : « Considérant qu’il 
s’impose désormais de plus en plus clairement à l’esprit que l’incidence de maladies neurodégénératives sur la population 
européenne est d’une ampleur telle qu’aucun État membre n’est capable d’y faire face seul, et qu’il est donc nécessaire de 
renforcer puissamment dans les États membres et dans l’Union européenne la coopération et la coordination des efforts de 
recherche clinique innovante et pluridisciplinaire portant sur les causes, la prévention et le traitement de la maladie 
d’Alzheimer, ainsi que le partage de l’information et le niveau d’investissement financier dans ce domaine, afin de lutter 
contre les maladies neurodégénératives, en particulier la maladie d’Alzheimer, devenues un défi majeur pour les sociétés 
européennes ». Union européenne, Résolution du Parlement européen du 19 janvier 2011, op. cit., §J et §M. 
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Discussion 
207. Instead of using lists of vulnerable categories or of factors of vulnerability, we are 
suggesting here to use another approach or at least to use it as a complement. A helpful 
perspective is to focus on the type of risks400 or on the type of damage the vulnerable person is 
exposed to401. Although it has not been often interpreted as such in the literature, this approach 
is actually suggested in the Declaration of Helsinki which evokes an “increased likelihood of 
being wronged or of incurring additional harm”402. It is further suggested in the CIOMS 
guidelines which emphasise the fact that consent violation is not the only type of harm 
vulnerable participants are exposed to 403 . This approach would allow clarification and 
systematisation of the definition of a vulnerable person and still allow adaptation to a specific 
area like clinical trials. Thus as outlined before, two main types of risks are emerging: risks to 
privacy (autonomy and private life) and risks to health404. The protection against those risks will 
tend to differ depending on the perspective of the trial participant (Section I) and of the future 
patient (Section 2). 
Section I: Vulnerable people and participation in clinical 
trials 
208. Being unable to defend one’s own interests creates a situation of vulnerability when 
the person is exposed to the risk of making a decision against her will. The extreme form of 
decisional vulnerability is legal incapacity (minors or incapacitated adults). However there are 
many other forms of decisional vulnerability, what we call de facto incapacity which includes 
persons in a coma, persons deprived of liberty, for which the European law foresees a specific 
                                                                    
400 “Each discipline reviewed tends to view vulnerability in a slightly different manner. Each uses different outcomes as its 
primary focus and is concerned with different forms of risk”. Alwang J., Siegel P. B. & Jørgensen S. L., "Vulnerability: a view 
from different disciplines", Social Protection Discussion Paper Series, n°0115, 2001, p. 4; Bergouignan C., "Mesurer la 
vulnérabilité ?", in Paillet É. & Richard P. (eds.), Effectivité des droits et vulnérabilité de la personne, Bruylant, Brussels, 
2014, p. 12. 
401 Hurst S., "Protéger les personnes vulnérables: Une exigence éthique à clarifier", Revue Médicale Suisse, Vol. 9, 2013, pp. 
1054-1057. 
402 WMA (World Medical Association), Declaration of Helsinki - Ethics principles applicable to medical involving human 
subjects, adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 64th WMA 
General Assembly, Fortaleza, Brazil, October 2013 (Hereafter “Declaration of Helsinki"), §19.  
403 CIOMS Guidelines, Guideline 15, Commentary. 
404 Schroeder D. & Genefas E., "Vulnerability: Too vague and too broad?", Cambridge Quarterly of Healthcare Ethics, n°18, 
2009, p. 119 ; Hurst S., "Vulnerability in research and health care ; describing the elephant in the room ?", Bioethics, Vol. 22, 
n°4, 2008, p. 198 (Figure 2). 
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status and protection (1). Decisional vulnerability also concerns persons who are less visibly 
vulnerable, who are unable to defend their interests, but whose vulnerability seems to not 
attract the attention it deserves, leading to neglected protection in European law (2). 
1 The strong protection of the autonomy of participants who are 
vulnerable because of their legal or de facto incapacity 
209. Interestingly enough the lists of vulnerable people in the European legal frameworks 
surrounding biomedical research and clinical trials are quite restricted in comparison to other 
legal areas. This is because the frameworks are limited to persons who have a legal or de facto 
incapacity (1.1). Vulnerable participants who are explicitly designated as such in European law 
now benefit from a strong protection regime thanks to the progressive harmonisation of the two 
European legal frameworks: the Additional Protocol on biomedical research from the Council of 
Europe and Regulation 536/2014 from the European Union (1.2). 
1.1 RESTRICTIVE VULNERABLE CATEGORIES IN CLINICAL TRIALS: LEGAL AND DE FACTO 
INCAPACITY 
210. The lack of theorisation of vulnerability at the beginning of its use may have led to 
partial or under-use of the protection that vulnerability should have entitled a person or a group 
(1.1.1). In fact, there are a lot of different risks that one can be vulnerable to, however, the 
protection in response is mainly focussed on restricted types of decision making vulnerabilities 
(1.1.2). 
1.1.1 The scattered use of the notion of vulnerability in European law 
and research ethics 
211. The notion of vulnerability can take several forms and in most cases, including 
clinical trials, normative instruments prefer having lists of vulnerable people than defining what 
constitutes vulnerability.  
212. In the legal framework of the European Union, the use of the explicit term 
“vulnerable” is very new. The former directive 2001/20/EC was protecting minors and 
incapacitated adults but without using the explicit term (articles 4 and 5). Regulation 536/2014 
now protects more groups of persons explicitly called “vulnerable” (article 10), including of 
course minors and incapacitated participants but also pregnant women, persons in emergency 
situations and “groups and subgroups of participants” which we will develop later on.  
213. The legal framework of the Council of Europe does not refer to “vulnerable” groups 
explicitly but it does offer a special status to similar groups: persons who are no able to consent 
(i.e. minors and incapacitated), pregnant women, persons in emergency situations and persons 
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deprived of liberty (articles 15, 18, 19 and 20 of the Additional Protocol on biomedical research). 
Interestingly enough, the same instrument does use the term “vulnerable” in a slightly different 
context, in article 12 emphasising on the need for ethics committee members to possible undue 
influences on consent, and giving a very long list of vulnerable people in that specific situation in 
the explanatory report which we will come back to. 
214. As specified above, the use of vulnerability is scattered as it can be implicit and most 
of all, there can be a “double” use of vulnerability for instance as observed in the Additional 
Protocol. It is also the case in the CIOMS guidelines: some groups benefit from a special status 
because of their special need of protection, and an unrelated article mentions other groups as 
“vulnerable”, including some of the groups that already benefit from a special status, but not all 
of them… This is quite confusing and indeed, the CIOMS guidelines even explicitly specify that 
pregnant women are not vulnerable, but are still devoting a special status to their protection 
(Guideline 15). 
215. The problems of using lists of different categories of vulnerable groups are 
numerous: stigmatisation, one size fits all protection, poor reflection of the complexity and 
variety of vulnerability situations, restricted access to protection, and slippery slope. Many 
authors in the literature as well as the CIOMS guidelines405 have sought to solve these problems 
by suggesting a different approach: defining the factors of vulnerability rather than vulnerable 
people406. However, this approach is not satisfying either. Even though it gives a better 
understanding and allows to efficiently improve protection, it does not help in defining 
vulnerability specifically for biomedical research or clinical trials. 
1.1.2 The partial use of the notion of vulnerability, mainly related to 
decision making 
216. Having clarified the type of risks vulnerable participants are exposed to, and before 
moving on to analyse the actual protection dedicated to them, it is evident that the European 
legal frameworks are making the risk of violation of autonomy, the determining criteria to 
designate the groups labelled as “vulnerable”. In law, designation of vulnerable groups is 
unfortunately often limited to the identification of those who will have difficulties in giving a 
valid consent407, be it legally or de facto: minors, incapacitated adults, people who are 
                                                                    
405 “A traditional approach to vulnerability in research has been to label entire classes of individuals as vulnerable. The 
account of vulnerability in this Guideline seeks to avoid considering members of entire classes of individuals as vulnerable”, 
CIOMS Guidelines, Guideline 15, Commentary.  
406 Luna F., “Not the usual suspect : addressing layers of vulnerability”, Bioethics, Vol. 27, n°6, 2013, pp. 325-332. 
407 For instance: Commission Nationale Consultative des Droits de l’Homme (CNCDH), Avis sur le consentement des 
personnes vulnérables. Plenary Assembly of 16 Avril 2015, J.O., n°0158, 10 July 2015, Text n°126. 
  108 
unconscious but in an emergency situation, persons deprived of liberty etc. Only the “usual 
suspects” as Florencia Luna would say408.  
217. On the contrary, persons who are “only” vulnerable to health risks are not among 
vulnerable groups whereas the list could be long: patients with orphan diseases, chronic disease, 
frail elderly patients to mention a few. There is only one exception which reflects the 
incoherence of legislators’ choices: pregnant and breast feeding women. Even if this could be 
deemed as protection of legal incapacity of the foetus, embryo or breast-feeding children for 
obvious reasons, categorising pregnant women as vulnerable seems inconsistent with the rest, 
unless one would dare to say that pregnancy affects rationality409. The CIOMS guidelines even 
clearly state in their 2016 updated version that pregnant women are not to be considered as 
vulnerable because they can protect their interests410, showing once again the tendency for 
literature and legislators to link vulnerability to only decisional vulnerability. This confusion 
between vulnerability and decisional vulnerability is frequent and also present in European law 
as we just showed, but it is also the case in the guidelines from the European Medicines 
Agency411, in the CIOMS guidelines on vulnerability412 and as well as in the ICH guidelines: 
“vulnerable subjects: Individuals whose willingness to volunteer in a clinical trial may be unduly 
influenced”413. 
1.2 THE STRONG PROTECTION OF PARTICIPANTS FOR THEIR LEGAL OR DE FACTO 
INCAPACITY 
218. The protection of vulnerable participants has a strong base in the general regime 
applicable to all participants that we will present here (1.2.1) before examining the specific rules 
for vulnerable categories (1.2.2). 
1.2.1 The general regime applicable to all participants 
219. Most rules from the general regime are similar between the legal frameworks of the 
Council of Europe and of the European Union. Pursuant to our suggestion to develop 
vulnerability through the different types of risks or damages, this work will distinguish between 
                                                                    
408 Luna F., “Not the usual suspect: addressing layers of vulnerability”, op. cit. 
409 Coleman C. H., "Vulnerability as a regulatory category in human subject research", The Journal of Law, Medicine & Ethics, 
Vol. 37, n°1, 2009, p. 12. 
410 CIOMS Guidelines, Guideline 15, Commentary. 
411 EMA, Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted 
outside of the EU/EEA and submitted in marketing authorisation applications to the EU regulatory authorities, 
EMA/121340/2011, London, 2012, p. 24. 
412 CIOMS Guidelines, Guideline 15. 
413 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH), Guideline for Good Clinical Practices, E6(R1), Geneva, 1996, §1.61 
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risks for health and safety of participants and risks for privacy, and thereafter move to some 
additional guarantees thanks to procedural obligations.  
220. Against risks for health and safety, several principles are applicable in European law 
and research ethics. First, primacy of individual has to be respected: their interests must prevail 
over those of science or society414. Second, no other alternative to clinical research should be 
possible before carrying out the research with human participants415. The third principle 
concerns the need of scientific quality of the research protocol and expertise of the 
investigators416. Last but not the least, there is a balance to be found between risks involved in 
the research and potential benefits417. The European Union does not distinguish between 
therapeutic and non-therapeutic research, direct and indirect benefits, but the Council of Europe 
does: risks should not be “disproportionate” regarding direct benefits, and they should not be 
“inacceptable” when no direct benefit is foreseen418. This distinction has been criticised because 
it is difficult to apply in practice419, leading to its withdrawal from the Helsinki Declaration in 
2000420. 
221. Against risks for privacy we can also find common general rules between European 
law and research ethics. Protection against risks for private life and confidentiality exists both in 
the law of the Council of Europe and the European Union, but is not specifically adapted or 
strengthened for vulnerable people. Rather, specific protection against risks to privacy for 
vulnerable people is focused on strengthening the protection of autonomy, thanks to the 
obligation to obtain informed consent from each participant421. First, this consent has to be free, 
it has to be voluntary and free from undue influences422 and it has to be continuous, i.e. the 
participant can reconsider any time423. Second, this consent has to be informed, which implies 
that the participant received comprehensive but comprehensible information, including for 
instance when the person does not speak the same language or cannot read424. 
222. Finally, some other obligations are additional procedural guarantees that make sure 
all previously mentioned safeguards are actually respected. First of all, the previous approval of 
                                                                    
414 Regulation 536/2014, Article 3, Article 28.1.e., Article 28.1.f ; Oviedo Convention, Article 2 ; Additional Protocol, Article 
3, Article 21.1, Article 23.1. 
415 Oviedo Convention, Article 16.i ; Additional Protocol, Article 5. 
416 Regulation 536/2014, Article 28.1.f ; Additional Protocol, Articles 8 et 21.2 ; Oviedo Convention, Article 4. 
417 Regulation 536/2014, Article 28.1.a 
418 Additional Protocol, Article 6. 
419 "When we evaluate entire protocols as either therapeutic or nontherapeutic, as required by the Declaration of Helsinki, 
we end up with what I call the ‘fallacy of the package deal’. Those who use this distinction typically classify as “therapeutic 
research” any protocol that includes one or more components that are intended to be therapeutic; therefore, the 
nontherapeutic components of the protocol are justified improperly according to the more permissive standards developed 
for therapeutic research”, Levine R. J., “Some Recent Developments in the International Guidelines on the Ethics of 
Research Involving Human Subjects”, Annals of the New York Academy of Sciences, Vol. 918, 2000, p. 172. 
420 Poisson D., "Déclaration d'Helsinki. Quelles nouveautés ?", Laennec, Vol. 1, n°50, 2002, p. 48. 
421 Oviedo Convention, Article 16.v ; Regulation 536/2014, Article 28.1. & Article 29.1 
422 Regulation 536/2014, Article 28.1.h et Article 28.3 ; Additional Protocol, Article 12, Article 13.3, Article 14.2. 
423 Additional Protocol, Article 13.3. 
424 Oviedo Convention, Article 16.iv ; Additional Protocol,  Article 13.1  et 13.2 ; Explanatory report to the Additional 
Protocol, § 72 ; Regulation 536/2014, Article 29. 
  110 
the research protocol by an ethics committee is now an obligation in research ethics as well as in 
European law425. And although there has been some criticism on the differences of status, 
composition as well as functioning of ethics committees between and even within European 
countries, this is quite an undisputed requirement. Second, there are also specific obligations 
related to transparency, for instance with regular mandatory reports, notifications of adverse 
events or any event worthy of mention and in relevance with the scientific or ethical 
acceptability of the clinical trial426. Member states can thus suspend or even completely stop a 
clinical trial according to the continuous updates they receive427. Finally, Regulation 536/2014 of 
the European Union foresees inspections to be organized by Member States, all being 
coordinated by the European Medicines Agency428. These inspections are another way to make 
sure rights and well-being of participants are being respected, quality and integrity of data is 
being guaranteed and good clinical practices as well as ethics principles are being 
safeguarded429. Those inspections can take place before, during or after the clinical trial, with or 
without previous warning430. 
1.2.2 Stricter safeguards for vulnerable participants in European law 
223. The rules of protection of vulnerable participants are similar to those in the general 
regime, mainly just reinforced. The distinction between types of risks is important to present the 
specific regime applicable to vulnerable populations: risks to health and safety as opposed to 
risks to autonomy. For the sake of clarity, we will present those provisions in two separate tables 
which depict the double comparison: a comparison between each vulnerable group, and a 
simultaneous comparison between the frameworks of the Council of Europe and of the 
European Union. Table I is thus dedicated to provisions on the protection of vulnerable 
participants regarding health and safety risks of clinical trials, whereas Table II is dedicated to 
risks for autonomy. Regarding risks for privacy, the focus, for vulnerable participants, is on 
autonomy and not privacy in general. This is mainly because there are no stricter or specific rules 
on confidentiality for vulnerable categories. Their specific protection regarding privacy thus 
mainly concerns the protection of their autonomy during decision making. 
224. There are a few significant elements to point out from these tables. The main 
element to highlight is the tremendous improvement of the legal framework of the European 
Union and its increasing harmonisation with the Council of Europe. The former European Union 
                                                                    
425 Oviedo Convention, Article 16.iii ; Additional Protocol, Article 7 ; Regulation 536/2014, Article 4 ;  
426 Additional Protocol, Article 24 ; Regulation 536/2014, Article 77.1. 
427 They inform other Member States concerned via the Union portal. Regulation 536/2014, Article 77.3. 
428 Regulation 536/2014, Article 78, Recitals 64 & 72 ; Commission Implementing Regulation (EU) 2017/556 of 24 March 
2017 on the detailed arrangements for the good clinical practice inspection procedures pursuant to Regulation (EU) No 
536/2014 of the European Parliament and of the Council (Hereafter Regulation 2017/556), Article 6 & Article 7. 
429 Regulation 2017/556, Article 6. 
430 Regulation 2017/556, Article 2 et 8. 
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instrument, Directive 2001/20/EC, was for instance only protecting minors and incapacitated 
adults, and was not obliging investigators to “respect” but only to “consider” their opinion. It 
was also only requiring risks to be minimised, which is a lot less protective than the current new 
formulation of “minimal risk”. The new regulation is definitely inspired by the Additional 
Protocol on biomedical research from the Council of Europe, as is visible in the tables.  
225. On some issues, Regulation 536/2014 even seems more protective, for instance on 
questions related to direct benefit needing to “outweigh” the risks whereas they need only to 
not be disproportionate according to the Additional Protocol. Moreover, Regulation 536/2014 is 
more restrictive regarding trials in emergency situations, which has been criticised for blocking 
innovative medicines431.  
226. In sum, vulnerability if viewed as a normative notion is meant to protect a lot of 
different aspects in a person’s life, including health and autonomy. Similarly, legal and ethical 
frameworks of clinical trials are also meant to protect health and safety of participants as well as 
their autonomy. Although European law does protect both of these aspects for all participants 
including vulnerable ones, it looks like the decisive criteria to be part of a “vulnerable group” lies 
in a lack of autonomy. However, it does not mean that all participants lacking autonomy are 
adequately protected in European law as will be developed further in §2. 
                                                                    
431 “applying this derogation to trials which pose only a minimal risk is too restrictive and would be a backward step for 
some Member States. In practice, this would rule out many forms of research relating to resuscitation and innovative 
products”. Willmott G., Committee on the Environment, Public Health and Food Safety (ENVI), Report on the proposal for a 
regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and 
repealing Directive 2001/20/EC (COM(2012)0369 – C7 0194/2012 – 2012/0192(COD)), A7-0208/2013, Strasbourg, 7 June 
2013, Amendment 91. 
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2 The neglected protection of participants who are unable to 
defend their interests  
227. Besides legal or de facto incapacity, other contexts put participants into a situation 
of decisional vulnerability, into a situation where they are not able to defend their interests. 
However in a lot of those situations, participants are not categorised as vulnerable although they 
would need protection. In this paragraph, we will see that European law only marginally 
recognises other decisional vulnerabilities (2.1) and that the elements of protection it offers to 
them are very insufficient (2.2). 
2.1 THE MARGINAL RECOGNITION OF THE DECISIONAL VULNERABILITY OF 
PARTICIPANTS UNABLE TO DEFEND THEIR INTERESTS 
228. Other situations of decisional vulnerabilities can stem either from individual 
factors432 (2.1.1) or systemic i.e. structural factors433 (2.1.2). Often both are combined. For 
instance, a psychiatric patient who would be hospitalised against his will already has individual 
factors of vulnerability, but there could also be a national or local context of a lacking legal 
framework, of a faulty implementation thereof or even of a history of corruption and abuse as it 
was in the ECHR court case Bataliny versus Russia434. However, the type of protection needed for 
those two different factors of vulnerability will be different, hence the importance of 
distinguishing and explaining both separately is great. 
2.1.1 The cautious recognition of individual factors of decisional 
vulnerability in European law 
229. There are plenty of individual factors potentially making a person unable to defend 
her interests, as highlighted in Guideline 15 of the CIOMS, in paragraph 1.61 of the ICH Guideline 
on Good Clinical Practice or in §27 of the Declaration of Helsinki. Here we will distinguish 
cognitive factors (2.1.1.1) and relational or social factors (2.1.1.2). 
 
 
 
 
                                                                    
432 CNCDH, Avis sur le consentement des personnes vulnérables, op. cit., al. 11. 
433 The expression “systemic” factors as a reference to the use that is made in the case law of both European Courts.  
434 A psychiatric patient had tried to commit suicide and was thus involuntarily hospitalised. Furthermore, he had been 
treated against his will, and with a drug that was only experimental. ECtHR, First Section, Case of Bataliny v. Russia, 
Application n°10060/07, 23 July 2015. 
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2.1.1.1 Cognitive factors of decisional vulnerability in clinical trials 
230. Suffering from acute pain435 or from a life-threatening condition can have an impact 
on the ability to consent436, even outside obvious cases of incapacity where the patient would be 
sedated or unconscious. Most of all, acute pain or a life-threatening condition can also trigger a 
“therapeutic misconception”437. Mental and psychiatric disorders, even when not leading to a 
legal incapacity, can also have an impact on the ability to consent. Along this line, literature has 
emphasised the case of suicidal patients438 or patients suffering from depression439, where it 
sometimes has an impact on decision making capacity or on the emotional perception of risks440, 
although controversial441. A key disorder among the older adults that raises similar questions is 
Alzheimer’s disease and dementia which triggers a progressive decline of cognitive capacities. 
This case leads us to frailty442 which is a clinical condition that usually comes with ageing, and 
that also affects cognitive capacities without necessarily being due to dementia443. 
231. In Regulation 536/2014 of the European Union, all these persons with a decisional 
vulnerability are not part of vulnerable categories. However, as we said before, article 10.4 
foresees a generic category called “specific groups and subgroups”, which could be meant to 
                                                                    
435 Dick B. D. & Rashiq S., “Disruption of attention and working memory traces in individuals with chronic pain”, Anesthesia 
& Analgesia, Vol. 104, n°5, 2007, pp. 1223-1239 ; Tait R. C., “Vulnerability in clinical research with patients in pain: A risk 
analysis”, Journal of Law, Medicine and Ethics, Vol. 37, 2009, pp. 59-72 ; Blacksher E., “Hearing from pain : using ethics to 
reframe, prevent, and resolve the problem of unrelieved pain”, Pain Medicine, Vol. 2, n°2, 2001, p. 170. 
436 Schaeffer M. H. et al., “The impact of disease severity on the informed consent process in clinical research”, The 
American Journal of Medicine, Vol. 100, n° 3, 1996, pp. 261-268; Menikoff J., “The vulnerability of the very sick”, Journal of 
Law Medicine and Ethics, Vol. 37, n°1, 2009, p. 53 ; Helmchen H. et al., From exclusion to inclusion. Improving clinical 
research in vulnerable people, Berlin-Brandenburgische Akademie der Wissenschaften (BBAW), Berlin, 2014, p. 41; 2003 
CIOMS Guidelines, Guideline 9, Commentary. 
437 Durand-Zaleski I. S. et al., “Informed consent in clinical research in France : assessment and factors associated with 
therapeutic misconception”, Journal of Medical Ethics, Vol. 34, 2008, p. e16; Joncas D. & Philips-Nootens S., “Le malentendu 
thérapeutique: un défi pour le consentement en recherche Clinique”, Revue de Droit de l’Université de Sherbrooke, Vol. 6, 
n°36, 2005, pp. 134-163. 
438 Lakeman R. & Fitzgerald M., “The ethics of suicide research. The views of ethics committee members”, Crisis, Vol. 30, 
n°1, 2009, p. 16 ; Rudd M. D. et al., “Informed consent with suicidal patients; rethinking risks in (and out of) treatment”, 
Psychotherapy Theory, Research, Practice, Training, Vol. 46, n° 4, 2009, pp. 459-468. 
439 Applebaum P. S. et al., “Competence of depressed patients for consent to research”, American Journal of Psychiatry, 
n°156, 1999, pp. 1380-1384 ; Elliott C., “Caring about risks: are severely depressed patients competent to consent to 
research ?”, Archives of General Psychiatry, Vol. 54, n°2, 1997, p. 113. 
440 Pereira M., Shah N. & Desousa A., “Decisional capacity for research in schizophrenia: a review”, Indian Journal of Applied 
Research, Vol. 5, n°12, 2015, p. 376 ; Palmer B. W. & Jeste D. V., “Relationship of individual cognitive abilities to specific 
components of decisional capacity among middle-aged and older patients with schizophrenia”, Schizophrenia Bulletin, Vol. 
32, n°1, pp. 98-106. 
441 On the controversy: Bielby P., Competence and vulnerability in biomedical research, International Library of Ethics, Law 
and the New Medicine, Springer, 2008, pp. 115-120. 
442 “Frailty was defined as a clinical syndrome in which three or more of the following criteria were present : unintentional 
weight loss (10lbs in past year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical 
activity”. Fried L. P. et al., “Frailty in older adults: Evidence for a phenotype”, The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences, Vol. 56, n°3, 2001, pp. M146-M157 ; Clegg A. et al., “Frailty in elderly people”, 
Lancet, Vol. 381, n°9868, 2013, pp. 752-762 ; Van Kan G. A. et al., “The assessment of frailty in older adults”, Clin Geriatr 
Med, Vol.  n°26, 2010, pp. 275-286. 
443  EMA, Proposal for the development of a points to consider for baseline characterisation of frailty status, 
EMA/335158/2013, London, 2013 ; Robertson D. A., Savva G. M. et Kenny R. A., “Frailty and cognitive impairment – a 
review of the evidence and causal mechanisms”, Ageing Research Reviews, Vol. 12, 2013, pp. 840-851; Hazif-Thomas C., 
Thomas P. & Walter M., “Motivation sociale, fragilité cognitive et assomption de la vieillesse”, La Lettre du Psychiatre, Vol. 
VII, n°5-6, 2011, pp. 148-151. 
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include all the previously mentioned persons. In fact, the legislators have left a few indications in 
that direction in recitals 15 and 19 of the regulation. Recital 15 talks about “vulnerable groups 
such as frail or older people, people suffering from multiple chronic conditions, and people 
affected by mental health disorders”, and recital 19 about “subjects in emergency situations, 
minors, incapacitated subjects, pregnant and breastfeeding women and, where appropriate, 
other identified specific population groups, such as elderly people or people suffering from rare 
and ultra rare diseases”. 
232. In the Additional Protocol to the Oviedo Convention, on biomedical research, article 
12 warns against undue influences especially regarding vulnerable people. The explanatory 
report does provide for a lot more details, including cognitive and medical factors of 
vulnerability444. This shows that the Council of Europe actually acknowledges, even if only in the 
explanatory report, the existence of those other types of decisional vulnerabilities.  
2.1.1.2 Social and relational factors of decisional vulnerability in clinical 
trials 
233. Decisional vulnerability can also stem from relational factors. Inability to protect 
one’s interests can be triggered by social disadvantages, poverty or a lack of access to health 
care, a perfect example for this would be the famous Tuskegee study445. Unfortunately, this type 
of exploitation has not disappeared even in Europe446, some authors even call this type of 
vulnerable participants “the invisible vulnerable”447. 
234. Inability to protect one’s interest can also stem from relationships, especially when 
it triggers a feeling of coercion, manipulation or persuasion448. This can happen in cases where 
the person is institutionalised and dependant on others for decisions: detainees, soldiers in the 
military, a resident of home for handicapped or elderly persons. Furthermore, this is the case 
when the person is highly dependent on family, carer, physician, teacher, employer or in any 
                                                                    
444 Explanatory report to the Additional Protocol, §69. 
445 This study was conducted in the United States of America between 1932 and 1972 on an isolated population of black 
farmers, poorly educated and lacking access to health care. It was examining the naturel evolution of Syphilis until death, 
which means that many participants were deprived of treatment although researchers knew the cure existed. Chiu C. T. & 
Katz R. V., “Identifying the ‘vulnerables’ in biomedical research: The vox populis from the Tuskegee legacy project”, Journal 
of Public Health Dentistry, n°71, 2011, pp. 220-228 ; Cuerda-Galindo E., Sierra-Valenti X., González-López E. & López-Muñoz 
F., “Syphilis and human experimentation from World War II to the present: a historical perspective and reflection on 
ethics”, Actas Dermosifiliográficas, Vol. 105, n°9, 2014, p. 850. 
446 Bern Declaration, Clinical drugs trials in Ukraine: myths and realities, Lausanne/Zurich, 2013 ; Bern Declaration, Russia: 
The mirage of Swiss clinical trials, Lausanne/Zurich, 2013 ; Waligora M., “Failures in clinical trials in the European Union: 
Lessons from the Polish experience”, Science and Engineering Ethics, Vol. 19, 2013, pp. 1087-1098. 
447 Stone T. H., “The invisible vulnerable: The economically and educationally disadvantaged subjects of clinical research”, 
The Journal of Law, Medicine & Ethics, Vol. 31, n°1, 2003, p. 150 ; Bustillos D., “Limited english proficiency and disparities in 
clinical research”, Journal of Law, Medicine and Ethics, Vol. 37, n°1, 2009. 
448 Coercion is “a credible threat of harm or force to a research subject”, manipulation consists in “influencing a research 
subject’s decision by altering the available options or information”, and persuasion consists in “guiding a research subject 
to your way of thinking through the disclosure of truthful information, but in a manner that is meant to get the person to 
think or act in a preferred manner”. Schwenzer K. J., “Protecting vulnerable subjects in clinical research: Children, pregnant 
women, prisoners, and employees”, Respiratory Care, Vol. 53, n°10, 2008, p. 1343. 
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case of subordination or deference, which are often underestimated449. This influence is not 
necessarily badly intentioned, but has to be recognised and taken into account to avoid the 
participant feeling a pressure from outside in one direction or another. 
235. European law is alluding to relational and social factors of vulnerability only in a 
subtle way. In Regulation 536/2014 of the European Union, article 28.1.h cautions against undue 
influences, including those of financial nature, as part of the general protection regime, and 
again for certain vulnerable groups but curiously not for all of them: incapacitated adults, 
minors, pregnant women but not for emergency situations. In addition, recital 31 alludes to ”all 
relevant circumstances which might influence the decision of a potential subject to participate in 
a clinical trial, in particular whether the potential subject belongs to an economically or socially 
disadvantaged group or is in a situation of institutional or hierarchical dependency that could 
inappropriately influence her or his decision to participate”. Interestingly, this recital can be 
indirectly linked to vulnerable groups, as article 34 acknowledges the possibility for Member 
States to add other categories like “persons performing mandatory military service, persons 
deprived of liberty, persons who, due to a judicial decision, cannot take part in clinical trials, or 
persons in residential care institutions”. 
236. Regarding the Council of Europe, article 12 of the Additional Protocol does warn 
against “undue influence, including that of a financial nature”, with special considerations to 
vulnerable and dependent persons, which apply exactly to all the examples of decisional 
vulnerability, which were mentioned above. It does recognise economic and social 
vulnerability450, as well as vulnerabilities linked to institutionalisation, deference, and hierarchy. 
However, it is unfortunate that the protection stops here, as no other provision develops 
safeguards for those vulnerabilities, then again, only the explanatory report does. 
2.1.2 The lack of recognition of systemic factors of decisional 
vulnerability in European law: low resource settings 
237. Systemic or structural factors refer to elements that are extrinsic to the participants 
and related to national or local system, cultural or political context, quality of the law and 
effectiveness of its application. Typically, this concerns clinical trials when they are conducted, 
for instance in poor, emerging or developing countries. However, as stated in the CIOMS 
guidelines and as one can notice in the literature, these systemic vulnerabilities are not 
necessarily related to a whole country nor are they necessarily found only in emerging 
countries451, although most authors will rather use the expression “developing countries” than 
“low resource settings”. There is an increasing tendency for trial sponsors to conduct trials in low 
                                                                    
449 Bell E. et al., “Beyond consent in research. Revisiting vulnerability in deep brain stimulation for psychiatric disorders”, 
Cambridge Quarterly of Healthcare Ethics, Vol. 23, n°3, 2014, pp. 362-365. 
450 Explanatory report to the Additional Protocol, §69. 
451 CIOMS Guidelines, Guideline 2, Commentary, p. 3. 
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resource settings452 in order to reduce costs (sometimes by 90%)453, to find naïve participants 
(who has never had a treatment)454, and finally to find a great number of volunteers ready to 
participate455. We will further define systemic vulnerabilities and present their apprehension by 
European law. 
238. Systemic vulnerability can take the form of exacerbated social vulnerability. When 
poverty and lack of access to health care can be observed at the scale of a whole country or 
region, the individual vulnerability actually becomes a structural and thus systematic 
vulnerability. Be it for the money or in the hope of getting health care, participants in low 
resource settings are easier to recruit, especially when exploitation is systematically organised. 
For instance, the Wemos Foundation reported that a clinical trial had been conducted in a rural 
area, offering financial incentives and an experimental treatment for HIV knowing well that the 
next door over-crowded nurses’ office had run out of treatment456. As the European Group on 
Ethics notes, participation in a clinical trial is too often the only opportunity for those persons to 
get some kind of treatment457. 
239. Additionally, systemic vulnerability can stem from cultural or structural factors. To 
begin with, informed consent is always an issue, especially in some cultures where the group, 
rather than the individual, is paramount, making authorisation from a spouse, priest, or any 
other authoritative figure an indispensable stage458. The CIOMS particularly insists on the social 
vulnerability of women towards masculine figures 459 . These problems in general are 
compounded with the behaviour of some investigators. Many NGO’s report that lying, pressures 
and intimidations used in these contexts to obtain (many time incomplete) informed consent 
                                                                    
452 Altavilla A., “Ethical standards for clinical trials conducted in third countries: The new strategy of the European 
Medicines Agency”, European Journal of Health Law, Vol. 18, 2011, p. 66; Bern Declaration Website, 
https://www.ladb.ch/themes-et-contexte/sante/essais-cliniques/ [22 May 2016]. 
453 Wemos Foundation Interview, https://www.youtube.com/watch?v=aoMnvUyCPuE [20 May 2016] ; Hervey T. K. & 
McHale J. V., Health law and the European Union, Law in Context, Cambridge University Press, Cambridge, 2004, p. 238 ; 
Wemos Foundation, Clinical trials realities in Zimbabwe. Dealing with possible unethical research, 2015, p. 7. 
454 European Group on Ethics in Science and Technologies (EGE), Opinion n°17 on ethical aspects of clinical research in 
developing countries, 2003, p. 5. 
455 In South Africa, an NGO reported that 3000 participants had been recruited within 9 days. Couderc M., Enjeux et 
pratiques de la recherche médicale transnationale en Afrique. Analyse anthropologique d’un centre de recherche clinique 
sur le VIH à Dakar (Sénégal), Université d’Aix-Marseille, Anthropologie sociale et ethnologie, 2011, p. 163 
456 Wemos Foundation, The clinical trials industry in South Africa: Ethics, rules and realities, 2013, p. 7. 
457 EGE, Opinion n°17 on ethical aspects of clinical research in developing countries, 2003, op. cit., p. 13. 
458 Vray M., Simon F., Bompart F. et al., “Recommandations pour la recherche clinique dans les pays en développement”, 
Thérapie, Vol. 62, n°3, 2007, p. 219 ; Caballero B., “Ethical issues for collaborative research in developing countries”, The 
American Journal of Clinical Nutrition, Vol. 76, 2002,  p. 718 ; EGE, Opinion n°17 on ethical aspects of clinical research in 
developing countries, 2003, p. 12. 
459 « In many societies women remain socially vulnerable in the conduct of research. For example, they may suffer 
negligence or harm because of their submission to authority, their hesitancy or inability to ask questions, and a cultural 
tendency to deny or tolerate pain and suffering.(…) Some women become vulnerable in research because of heightened 
psychological, social, physical, or legal risks. Examples include surveys and interviews regarding intimate partner violence 
and rape; social and behavioural research involving sex workers or women who inject drugs; and studies that solicit 
information about sexual behaviour ». CIOMS Guidelines, Guideline 18, Commentary, p. 69. 
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sheet signed460. In Argentina for instance, a study on neonates had become famous for 
numerous abuses461. Some infants were included although the parents had explicitly refused 
participation; other parents didn’t even receive the information sheet and consent-form before 
the vaccination of their baby with the experimental drug ; others received intimidations and 
threats of refusing further care. 
240. Those problems are also linked to the failure of local ethics committees to guarantee 
protection462. They often do not have enough human or financial resources to function correctly, 
to make time for evaluations and to have the expertise to conduct ethics review463. Even well 
intentioned ethics committees do not necessarily have the power to stop the violations they 
observed, for instance like in Zimbabwe when they are reportedly refused the access to the trial 
site for inspection, when rejected applicants conduct their trial anyway, or when investigators do 
not even apply for authorisation464. This leads us to another serious issue reported too often in 
literature: the frequency of conflict of interests and corruption in low resource settings: from 
politics, sponsors, and even the investigators465, who are paid proportionately to the number of 
participants they manage to recruit466.  
241. European law does not explicitly acknowledge the general vulnerability of 
participants in low resource settings, outside from occasional mentions in work-documents or 
debates. This does not mean legislators won’t try to offer some protection through more general 
means as « exporting research to the south is in itself a context of vulnerability and exploitation 
that requires more than protecting specifically vulnerable groups »467. Unfortunately it may not 
be sufficient. 
                                                                    
460 Bern Declaration, Exploratory study on clinical trials conducted by Swiss pharmaceutical companies in India: issues, 
concerns and challenges, Lausanne/Zurich/New Delhi, 2013, p. 32. 
461 Bern Declaration, Clinical drug trials in Argentina: Pharmaceutical companies exploit flaws in the regulatory system, 
Lausanne/Zurich, 2013, pp. 16-18. 
462 Emanuel E. J., Wendler D., Killen J. & Grady C., “What makes clinical research in developing countries ethical? The 
benchmarks of ethical research”, Journal of Infectious Diseases, Vol. 189, n°5, 2004, p. 934. 
463 Famenka A., “Ethical review of biomedical research in Belarus: current status, problems and perspectives”, Romanian 
Journal of Bioethics, Vol. 9, n°2, 2011, pp. 75-79 ; Public Eye, Industry-sponsored clinical drug trials in Egypt: ethical 
questions in a challenging context, Étude conjointe de Public Eye, la Fondation Somo (Centre for Research on Multinational 
Corporations), la Fondation Wemos, & Egyptian Initiative for Personal Rights and Shamseya for Innovative Community 
Healthcare Solutions, 2016, p. 51 ; Bern Declaration, Exploratory study on clinical trials conducted by Swiss pharmaceutical 
companies in India, op. cit., p. 30 et p. 37; Bern Declaration, Clinical drugs trials in Ukraine: myths and realities, op. cit., p. 5. 
464 Emanuel E. J., Wendler D., Killen J. & Grady C., “What makes clinical research in developing countries ethical? The 
benchmarks of ethical research”, op. cit., p. 930. 
465 European Commission, Directorate General for research, Conference proceedings, Brussels, 14-15 May 2007 : Ethics, 
research and globalisation. Europe and its partners building capacity in research ethics, Publications Office, 2007, p. 48; 
Benatar S. & Fleischer T., “Ethical issues in research in low-income countries”, The International Journal of Tuberculosis and 
Lung Disease, Vol. 11, n°6, 2007, p. 617;  
466 Bern Declaration, Exploratory study on clinical trials conducted by Swiss pharmaceutical companies in India, op. cit., p. 
28; Bern Declaration, Clinical drug trials in Argentina: Pharmaceutical companies exploit flaws in the regulatory system, op. 
cit., p. 17 ; Bern Declaration, Russia: The mirage of Swiss clinical trials, op. cit., pp. 6-7. 
467 Botbol-Baum M., “Care beyond autonomy : the recognition of our vulnerable capabilities”, International Journal of 
Bioethics, Vol. 27, n°3, 2016, p. 39. 
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2.2 THE INSUFFICIENT PROTECTION OF THE DECISIONAL VULNERABILITY OF 
PARTICIPANTS UNABLE TO DEFEND THEIR INTERESTS 
242. CIOMS Guidelines are suggesting a number of ways to avoid facing these systemic 
problems, for instance by collaborating with the local community to negotiate and elaborate the 
trial processes including the conditions of obtention of the informed consent, the functionnig of 
local ethics committees or the prevention of conflicts of interests468. 
243. Instruments of protection are enacted in every European country to comply with the 
European law. However, the content of protections and their implementation are sometimes 
insufficient to protect participants who do not constitute a classical vulnerable “group” but who 
are vulnerable nonetheless because of their inability to protect their interests. There are two 
explanations for this shortcoming: (2.2.1) it is limited in its possibilities to delve deeper into the 
ethical issues that are normally legally restricted to national competencies, which makes it 
particularly difficult to provide protection from individual factors of decisional vulnerability;  
(2.2.2) the European law is also limited in its territorial application, which makes it very 
challenging to protect participants from systemic deficits in the local legal framework when the 
setting is situated outside Europe. 
2.2.1 Protection of individual decisional vulnerability and limited 
competence of European law 
244. There is definitely a pressure from scientific and ethical literature to better promote 
autonomy and means to enhance it whatever the level of capacity. This literature inspires 
different theories and suggestions around ethics of care, which would imply to better evaluate 
decision making capacity and its variations in time or according to context. Doing so will put in 
place appropriate measures of protection and still make sure the person participates as much as 
possible in the decision-making process. 
245. Persons who are vulnerable yet not vulnerable “enough” to benefit from a 
protective status in European law related to clinical trials need safeguards to prevent harmful 
decisions and/or informally forced decisions. First it is important to make a clear distinction 
between the (even if unrealistic) will of the person, the possible and realistic options and the 
objectively least harmful option469. Paternalistic approaches would tend to make vulnerable 
people choose the least harmful option; the more vulnerable, the more this option will be 
                                                                    
468 For more details : CIOMS Guidelines, Guideline 7 on community engagement, guideline 8 on collaborative partnership 
and capacity-building for research and research review, guideline 23 on requirements for establishing research ethics 
committees and for their review of protocols and guideline 25 on conflicts of interests. 
469 Frison-Roche M.-A., "Distinction entre volonté et consentement en droit des contrats", RTD Civ., 1995, p. 573 ; Roman 
D., "Leçon 4 : Droit de la santé : la décision revient-elle au patient ou au médecin ? ", Vulnérabilité et droit, 5 lessons from 
13 February to 8 May 2017, http://www.unamur.be/droit/chaire-francqui-diane-roman [29 Avril 2017]. 
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commanded to them even against their will470. However, in order to respect autonomy, a 
compromise has to be found between the three options471. Several authors criticise the 
tendency to suspend capacity when a capable person is partially or temporarily vulnerable, 
without making the effort to evaluate decision-making capacity: “le paternalisme de la décision 
compatissante « pour autrui » transformant la bienveillance en violence par l’occultation de 
l’évaluation fine des capacités du patient“472. Ethics of care offers a compromise between 
oblivious autonomy and oppressive paternalism. It promotes interdependence, the support of 
the carer in favour of the autonomy of the vulnerable person with three ideas: information, 
support and participation473. 
246. A strong case is made for continuous evaluation of decision-making capacity and 
most of all of a specific evaluation according to the area in the corpus of literature on the topic 
of research474, as well as in the CIOMS guidelines475. There are a lot of different sets of criteria 
for analysing decision-making capacity in the literature, and methods are quite varied even only 
in the medical context according to local practices476, to the medical specialisation or to the 
patient’s medical condition477. Evaluation of decision-making capacity goes hand-in-hand with 
the perspective of assisting the vulnerable person in the informed-consent process, which has 
especially been developed around the topic of older adults478.  
247. The legal framework of the European Union is silent about such an issue, but the 
Council of Europe does offer a rich variety of provisions or even guiding instruments. The 
explanatory report to the Oviedo Convention specifies the precise motives that national law can 
use to determine if someone is legally competent or not: mental disorder, disease or similar 
                                                                    
470 Elger B. S. & Anderes C., Le paternalisme médical : mythe ou réalité ?: aspects philosophiques et empiriques d’un 
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Juridique Personnes et Famille, n°4, 2010, p. 2. 
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International Journal of Bioethics, Vol. 27, n°3, 2016, p. 18. 
473 Maillard N., La vulnérabilité. Une nouvelle catégorie morale?, Le champ éthique n°56, Labor et Fides, Geneva, 2011, p. 
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474 Bielby P., Competence and vulnerability in biomedical research, op. cit., p. 142. 
475 CIOMS Guidelines, Guideline 9 and guideline 16. 
476 Dunn L. B., Nowrangi M. A., Palmer B. W., Jeste D. V. & Saks E. R., "Assessing decisional capacity for clinical research or 
treatment: a review of instruments", American Journal of Psychology, n°163, 2006, pp. 1323-1334; Dunn L. B. & Misra S., 
"Research ethics issues in geriatric psychiatry", op. cit., p. 2; Meulenbroek O. et al., "Informed consent in dementia 
research. Legislation, theoretical concepts and how to assess capacity to consent", European Geriatric Medicine, n°1, 2010, 
p. 58. 
477 Barron J. S. et al., "Informed consent for research participation in frail older persons", Aging Clin Exp Res, Vol. 16, n°1, 
2004, p. 82. 
478 AGE Platform Europe & EDE (European Association for Directors of Residential Homes for the Elderly), European Charter 
of rights and responsibilities of older people in need of long-term care and assistance, June 2010, Article 2-1 ; Favier Y., 
"Vulnérabilité et fragilité : réflexion autour du consentement des personnes âgées", RDSS, 2015, p. 702 ; Bayer A. & Fish M., 
"The doctor's duty to the elderly patient in clinical trials", Drugs Aging, Vol. 20, n°15, 2003, p. 1087 et p. 1093 ; Berdeu D. et 
al., "Clinical trials in the elderly: Ethical and methodologic considerations", La Revue de Médecine Interne, Vol. 21, n°7, 
2000, Tableau I, p. 619. 
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motives479. Article 14 of the Additional Protocol on biomedical research requires investigators to 
actively verify that the participant is competent, especially when there is a doubt. But it is rather 
with two separate instruments that the Council of Europe has expressed the importance of the 
evaluation of decision-making capacity and harmonisation of this evaluation, first with a 1999 
Recommendation on the legal protection of incapacitated adults480, and second with the 2014 
Guide on the decision-making process regarding medical treatment in end-of-life situations 
which goes into very much detail regarding the evaluation of capacity481. 
248. Regarding assistance in decision making in the European Union, the new Regulation 
536/2014 did improve participation and respect of the opinion of minors and incapacitated 
adults. However, there were several failed attempts to introduce potentially useful provisions in 
this regulation, for instance the creation of a vulnerable category for persons with specific 
needs, including needs regarding information and consent process482. In the law of the Council of 
Europe, there is lack of mention on assisted decision-making as such in the Oviedo Convention 
or its Additional Protocol on biomedical research, except for the obligation to respect any 
objection even when formulated in a different way483. However, it appears to be a significant 
and established principle in the instruments of the Council of Europe for instance with 
recommendations or strategies on dependence, older adults, mental disorders or disabilities484. 
249. Finally, research advance directives can be used to indicate someone’s wishes 
regarding potential participation in a clinical trial and according to the CIOMS, should be 
respected in the research setting as well485. It is not very clear to determine how the legal 
framework of the European Union would apprehend those should they exist, but it is safe to say 
that negative research advance directives would definitely be respected. The situation is similar 
regarding research advance directives in the legal framework of the Council of Europe, although 
there is a tendency and expertise that is a lot more developed and in favour of the general use of 
advance directives for research as studied earlier. 
                                                                    
479 Explanatory report to the Oviedo Convention, § 43. 
480 Recommendation N°R(99)4 on principles concerning the legal protection of incapable adults, Adopted by the Committee 
of Ministers on 23 February 1999, at the 660th meeting of the Ministers' Deputies, Principle 3.1. 
481 Council of Europe, Bioethics Unit, The Guide on the decision-making process regarding medical treatment in end-of-life 
situations, May 2014, pp. 16-17. 
482 Willmott G. (ENVI), Report on the proposal for a regulation of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, op. cit., Amendments 125 & 189. 
483 Explanatory report to the Additional Protocol, § 86. 
484 Recommendation (98)9 of the Committee of Ministers to member States on dependence, Adopted by the Committee of 
Ministers on 18 September 1998 at the 641st meeting of the Minister’s Deputies, Recital 5,  Principles 2 & 3 ; 
Recommendation (2004)10 of the Committee of Ministers to member States concerning the protection of the human rights 
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  123 
2.2.2 Protection of systemic vulnerabilities and limited applicability of 
European law 
250. The possibilities of protection from the Council of Europe with the Additional 
Protocol on biomedical research are quite limited regarding third countries. Article 29 does 
require research projects conducted in third countries to be in conformity with the provisions of 
the Additional Protocol. However, the explanatory report has quite a pessimistic (and rather 
realistic) stance: “while it may be impracticable to implement all the detailed provisions 
contained in this Protocol when a research project is carried out in a State that is not party to 
the Protocol, it is nevertheless mandatory to observe the principles that those provisions 
develop”486. Surprisingly, this report even states that “the article is not intended to discourage 
otherwise ethical research in less developed countries that might utilise less expensive 
treatment than that routinely utilised in wealthier countries”. However, it does require a double 
evaluation from the origin country in settings where ethical evaluation might be unreliable. 
251. The legal framework of the European Union offers more concrete ways to protect 
against systemic vulnerabilities, but is also quite limited. According to article 25 of the new 
Regulation, clinical trials conducted outside the European Union “shall have been conducted in 
accordance with principles equivalent to those of this Regulation as regards the rights and safety 
of the subject and the reliability and robustness of the data generated in the clinical trial”. 
However, no further detail is given on how to actually prove equivalent principles have been 
respected. Several organs within the European Union are putting pressure on the European 
Commission in favour of stricter ethical rules for trials conducted in low resource settings, 
notably the European Group on Ethics487, the European Medicines Agency488 as well as some 
parliamentary members and even directorates 489 . These pressures mainly concern the 
conditions around informed-consent procedures and the responsibility of European sponsors to 
guarantee ethical principles, for instance through a commercial sanction (some parliamentary 
members unsuccessfully suggested to not apply data protection related to results of trials when 
those were conducted unethically490, to not grant a marketing authorisation in those cases491, or 
                                                                    
486 Explanatory report to the Additional Protocol, § 138. 
487 EGE, Opinion n°17 on ethical aspects of clinical research in developing countries, 2003, pp. 14-15. 
488 EMA, Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted 
outside of the EU/EEA, op. cit., p. 16. 
489 Schipper I., Directorate-General for external policies of the Union (DG-EXPO), European Parliament, Clinical trials in 
developing countries: How to protect people against unethical practices?, EXPO/B/DEVE/2008/45 PE 406.974, Brussels, 
2009, p. 5.; See also repeated written questions of parliamentary members to the European Commission: Recours à des 
cobayes humains pour tester des médicaments européens dans des pays à bas ou moyens revenus, E-005984-15, 
Parliamentary written question, J. Sargentini J. (Verts/ALE) & M. Rivasi (Verts/ALE), 15 April 2015 ; Contrôle du caractère 
éthique de nouveaux médicaments : négligence des autorités d’enregistrement européenne, E-0777/2007, Parliamentary 
written question, M. Van den Berg (PSE), 19 February 2007 ; Lignes directrices contraignantes pour les tests 
pharmaceutiques réalisés à l’étranger, E-1805/2006, Commission response, M. Verheugen, 20 June 2006. 
490 Contrôle du caractère éthique de nouveaux médicaments : négligence des autorités d’enregistrement européenne, E-
0777/2007, Parliamentary written question, M. Van den Berg (PSE), 19 February 2007. 
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to systematically make public the proven violations of ethical principles492). The consequences of 
such violations, according to article 94 of the new Regulation, have to be decided and organized 
nationally by Member States. 
252. Nevertheless, Regulation 536/2014 does offer more ways to protect systemic 
vulnerabilities than Directive 2001/20/EC did, notably through improved provisions on 
transparency and inspections even outside European Union. In fact, after numerous pressures in 
that direction from parliamentary members493, a big progress with the new Regulation is the 
obligation for European sponsors to register all clinical trials, even when conducted in third 
countries494. But most of all, on-site inspections of clinical trials conducted outside of the 
European Union could be developed in the future. There has been a continuous pressure in this 
direction from the European Parliament but also from the European Medicines Agency495, which 
is particularly promising as the Agency is in charge of coordinating inspections by European 
Union Member States. In 2013 the Agency thus published criteria to be applied to choose the 
sites or clinical trials that should be inspected496, including participation of vulnerable categories 
and research conduct in low resource settings. Finally, Regulations 536/2014 and 2017/556 are 
facilitating those inspections outside European Union497, but most of all, the Commission has 
now the possibility to evaluate the legal framework of a third country to determine if it can 
safeguard research ethics principles from Regulation 536/2014498. 
253. Finally, another useful though indirect way for the European Union to avoid systemic 
vulnerabilities in clinical trials goes with framework programs which often promote capacity 
building in developing countries: scientific capacities but also institutional capacities and even 
ethics capacities and education. This was indeed the case with the first499 and especially with the 
second European & Developing Countries Clinical Trials Partnership (EDCTP) which emphasized 
even more the importance of and means for compliance to ethics principles, to European law as 
                                                                                                                                                                                                                   
491 EMA, Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted 
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well as national laws500. Regular calls for projects are thus published in order to finance, not 
directly clinical trials but projects that will improve ethics scrutiny in countries that need it 
most501. 
 
 
*** 
 
 
254. The above analysis in Section 1 leads to the conclusion that the European legal 
frameworks for clinical trials do protect vulnerable people when they participate in clinical trials. 
Vulnerable categories are quite restricted in comparison to other areas of European law and 
though vulnerable participants receive protection for their health and safety, it is clear that the 
main criterion in clinical trials to designate vulnerable categories is the need for protection of 
autonomy. Protection is relatively harmonised between the instruments of the European Union 
and of the Council of Europe. However, decisional vulnerability affects a lot more people than 
those included within the few vulnerable categories, and it is these who are excluded from these 
categories who only receive limited protection from European law. 
  
                                                                    
500 Decision n° 556/2014/EU of the European Parliament and of the Council of 15 May 2014 on the participation of the 
Union in a second European and Developing Countries Clinical Trials Partnership Programme (EDCTP2) jointly undertaken 
by several Member States (Hereafter “Decision 556/2014/UE”), Annex I, §1, p. 48. 
501 Website of the EDCTP, http://www.edctp.org/call/ethics-regulatory-capacities-3/ [16 March 2018]. 
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Section II: Vulnerable people and representation in clinical 
trials 
255. Clinical trials constitute a necessary tool to elaborate new and better drugs with 
increasing safety and efficacy. The perspective of vulnerability will change here from an inability 
to protect one’s own interests to a special medical need, a particular physical or psychological 
condition that changes the safety and efficacy of a medicine. Too many people are excluded 
from clinical trials because of their inability to defend their interests, because of their poor 
medical condition or because of commercial considerations. However, this exclusion, even if 
sometimes well intentioned, is harmful on the long term as it marginalises whole groups of 
people by excluding them from trials and thereby its potential health benefits. In this section we 
are not intending to raise the issue of individual access to a trial in the hope of direct benefits, 
nor the issue of compassionate use of unlicensed drugs. We will be dealing with representation 
of vulnerable groups in clinical trials in a public health perspective. 
256. In a first paragraph we will see that European law does protect some vulnerable 
patients against exclusion from clinical trials, but in a disordered manner (1). In a second 
paragraph we will adopt a prospective approach to examine ethical and legal principles that 
would legitimate a more general approach on health-vulnerability in clinical trials and adequate 
representation, or even rather equitable representation (2). 
1 The disordered health promotion of vulnerable patients against 
exclusion from clinical trials  
257. Vulnerable patients who are not represented in clinical trials are even more 
vulnerable when being administered a drug which, although in the market, has never been 
tested on persons representing their health vulnerability. European law provides for entire 
protection regimes against exclusion of (only) two groups of vulnerable patients from clinical 
trials (1.1), and provides for emerging processes which, although not comparable to the former 
palliative regimes, are also promoting representation of a few vulnerable groups in clinical trials 
(1.2).  
1.1 PROTECTION REGIMES AGAINST EXCLUSION OF VULNERABLE PATIENTS FROM 
CLINICAL TRIALS 
258. Because some vulnerable patients urgently need better medicines, because they are 
particularly excluded from trials or because this group as a market is particularly unattractive to 
pharmaceutical industry, the European Union provided two palliative regimes, first in 2000 for 
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clinical trials on orphan medicines (1.1.1) and in 2006 for clinical trials on paediatric medicines 
(1.1.2). 
1.1.1 Orphan medicines 
259. Orphan diseases marginalize patients due to their rarity (5 cases out of 10 000 
people502). For most rare diseases no treatments are available and diagnostic is yet to be 
mastered. Due to the difficulties in gathering sufficient participants who are even rarer than the 
patients themselves, and most of all due to the lack of commercial attractiveness of marketing 
orphan diseases, there is a significant lack of research and of clinical trials related to orphan 
medicines 503 . Considering the scattering of patients suffering from orphan diseases, of 
researchers with an expertise on orphan medicines and the colossal costs of fundamental 
research and clinical trials, the implication of European law was especially justified in order to 
coordinate and rationalise expertise, costs and patient participation in these trials. 
260. Hence the legislator of the European Union elaborated Regulation 141/2000504 in 
order to promote clinical trials for orphan medicines. Article 4 created an expert committee 
within the European Medicines Agency in order to evaluate the orphan medicine designation 
and to produce scientific expertise. There are three main incentives in the regulation. First, 
article 8 gives 10 years of commercial exclusivity which is meant to compensate the costs of 
research and development of an orphan medicine. Second, article 7 provided for a centralised  
authorisation procedure for orphan medicines, which at the time did not exist yet, with fees 
exemption to the European Medicines Agency505. Third, article 6 tasks the European Medicines 
Agency with offering free scientific advice, which later demonstrated to be a determining factor 
for obtaining marketing authorisation506.  
261. The initial success of this regulation has fallen short on the longer term. After a few 
years of implementation, applications for orphan medicines had significantly increased and some 
new treatments were developed507. However, these positive results were not sufficient to have a 
                                                                    
502 Regulation (EC) N° 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal 
products (Hereafter “Regulation 141/2000”), Recital 4. 
503 European Commission, Rare Diseases: Europe's challenges, Communication from the Commission to the European 
Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions, COM(2008) 679 
final, Brussels, 11 November 2008 (Hereafter “Communication from the Commission”); EURORDIS, EURORDIS’ position on 
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504 Regulation 141/2000. 
505 It was estimated in 2016 that the loss of the European Medicines Agency according to this fee exemption was around 
78,4 millions euros. European Commission, Inventory of Union and Member State incentives to support research into, and 
the development and availability of orphan medicinal products, State of play 2015, SWD(2015) 13 final, p. 4. 
506 European Commission, Commission staff working document on the experience acquired as a result of the application of 
Regulation (EC) No 141/2000 on orphan medicinal products and account of the public health benefits obtained, SEC(2006) 
832, Brussels, 20 June 2006, p. 8. 
507 European Commission, Inventory of Union and Member State incentives to support research into, and the development 
and availability of orphan medicinal products , op. cit., p. 13. 
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noticeable impact on the general quality of health protection for orphan diseases508. The 
European Commission tripled the amount of funding for rare diseases research between the 6th  
(2002-2007) and the 7th framework program (2008-2013) which attributed 620 million Euros for 
it509. Two committees were launched about rare diseases research: the EUCERD which later 
became CEG-RD and the IRDiRC. There has been an ongoing project of a European register for 
rare diseases notably in order to coordinate the 62 already existing ones in Europe510, which may 
be easier to put in place once the Union portal will be functioning. The 8th framework program 
Horizon 2020 is supporting research on rare diseases, notably through the funding of the E-RARE 
project trying to coordinate activities between research centres in Europe511. 
262. To date, 150 marketing authorisations have been granted for orphan medicines, 
however this represents only about 2% of the necessary medical treatments to the existing 8000 
orphan diseases as many of them target the same disease512. Moreover, as the European 
Parliament highlighted in its 2017 Resolution, Regulation 141/2000 is sometimes misused by 
sponsors who manage to develop an orphan medicine and benefit from the financial and 
marketing incentives, but already knowing that once on the market the medication will actually 
be used off label for another (non-orphan) disease513. The same year, the European Commission 
published a report entitled “Rare diseases. A major unmet medical need”, confirming that the 
incentives of Regulation 141/2000 are not enough to compensate the difficulties and costs 
related to the development of orphan medicines.  
263. A few years later, a similar regime for paediatric medicines has been elaborated, 
which added two more years of marketing exclusivity to the 10 already granted, when a 
marketing authorisation is for a both orphan and paediatric medicine514. 
1.1.2 Paediatric medicines 
264. The clear lack of research on paediatric medicines has lead the European Union 
legislators to elaborate Regulation 1901/2006515 (1.1.2.1). Results of the implementation of this 
regulation on paediatric trials and medicines have recently been evaluated after 10 years (2). 
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1.1.2.1 Incentives and obligations from Regulation 1901/2006 
265. Paediatric trials are more difficult due to legal incapacity of children but also due to 
their physical and physiological specificities compared to adults as well as in between different 
age subgroups from neonates to adolescents516. The lack of research has led to lack of 
treatments, and consequent frequent use of off label medications517. As the Regulation states in 
recital 3 : “Problems resulting from the absence of suitably adapted medicinal products for the 
paediatric population include inadequate dosage information which leads to increased risks of 
adverse reactions including death, ineffective treatment through under-dosage, non-availability 
to the paediatric population of therapeutic advances, suitable formulations and routes of 
administration, as well as use of magistral or officinal formulations to treat the paediatric 
population which may be of poor quality”. 
266. The Regulation 1901/2006 sets up obligations, rewards and incentives for 
development of paediatric medicines. According to articles 7, 8 and 17, at a very early stage of 
development of any medicine, sponsors have to elaborate, with the help and approval of the 
European Medicines Agency, a Paediatric Investigation Plan (PIP) which guarantees the 
paediatric application of any medicine under study. This applies to new medicine as well as 
already marketed medicines, unless a waiver has been agreed by the Agency for not testing a 
medication that will not benefit children. If sponsors comply with this obligation, they get a 
reward of six supplementary months of marketing exclusivity (article 36). If sponsors fail to 
comply, the Agency can block the corresponding marketing authorisation, financial sanctions can 
even be applied according to articles 49.4 and 50.1. Article 30 even created a new type of 
marketing authorisation, the paediatric use marketing authorisation (PUMA), meant to increase 
the development of paediatric indications for off-patent products with the perspective of getting 
a 10 year data exclusivity. 
267. Other measures also indirectly help raising attractiveness of paediatric trials: the 
creation of the Paediatric Committee within the European Medicines Agency in charge of 
evaluating the PIPs, of providing free scientific advice to sponsors, or of updating a Union 
inventory of paediatric needs (articles 6, 23 and 43). Finally, new transparency rules were 
created, for instance with obligations to declare through a public database the start, end and 
interruption of paediatric trials as well as the results or reasons for interruptions. Sponsors also 
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have to communicate to national regulatory authorities any data related to clinical practice or 
phase IV trials on children (articles 45 and 46). Finally, a European network has been created 
within the Agency in order to coordinate all existing networks related to paediatric research, the 
European network for paediatric research. 
268. In conclusion, the system elaborated in the paediatric regulation goes far beyond 
the orphan regulation as the latter only provides for incentives, which has shown in the results 
related to ten years of implementation of the paediatric regulation. 
1.1.2.2 10 years-assessment of the paediatric regulation 
269. Early on, the implementation of the paediatric Regulation was already deemed as a 
success518. For instance in 2012, 18 000 existing studies about 2200 marketed medicines had 
been communicated, showing how much information can be gathered just by sharing and 
centralising data, all the more than those information lead to the marketing of 16 new paediatric 
indications. Both the European Medicines Agency519 and the European Commission520 have 
published 10 years reports which summarize the main achievements, deficiencies and the way 
forward. For instance, the number of orphan diseases related PIPs are growing every year: 2 in 
2008, 13 in 2012, 29 in 2013 and 49 in 2015. Another progress concerns neonates for which 
there has always been a particular reluctance to conduct clinical trials: from 470 in 2009, 13 000 
neonates had been included in trials in 2015521. The Regulation has had some very successful 
results (see Table III). In a more general perspective, there are definitely more paediatric trials 
and more medicines that have been authorised for children thanks to the paediatric Regulation, 
and these numbers will grow further as a lot of PIPs have been agreed but not yet implemented. 
270. The reports further show some pitfalls and new goals to be achieved as the 
European Parliament observed in its 2017 Resolution on the access to medicines in the European 
Union522. The PUMA for instance have constituted the greatest disappointments for the 
European legislators: only three PUMAs have been granted to date523. Moreover, the European 
Medicines Agency has highlighted the fact that there are still some areas where there are almost 
no PIPs, for instance in paediatric oncology for which, when there are treatments, some of them 
date from the 90’s524. In general, the Agency has also expressed worries regarding the small 
percentage of PIPs that are actually fully conducted: a lot of trials are interrupted because PIPs 
                                                                    
518 EMA, Successes of the Paediatric Regulation after 5 years. August 2007-December 2012, EMA/250577/2013, London, 
2013. 
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523 European Commission, State of Paediatric Medicines in the EU. 10 years of the EU Paediatric Regulation, Report from 
the Commission to the European Parliament and the Council, COM (2017) 626, p. 13. 
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are elaborated very early in the process, and most of the time too early for sponsors and 
investigators to predict the paediatric relevance525. 
                                                                    
525 European Commission, Better medicines for children - from concept to reality, op. cit., p. 88. 
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1.2 EMERGING PROCESSES AGAINST EXCLUSION OF VULNERABLE PATIENTS FROM 
CLINICAL TRIALS 
271. Apart from the previously mentioned palliative regimes against exclusion from 
clinical trials, there are other emerging processes that have the same goal but they lack a proper 
regime of incentives and obligations. The two types of vulnerable populations who could benefit 
from diverse provisions preventing their exclusion from clinical trials are the older adults (1.2.1) 
and those in developing countries (1.2.2). 
1.2.1 Older adults 
272. In 2050, people older than 65 will constitute 28% of the population (18% in 2013), 
and among those, people aged over 80 will double in number 526. Older adults are the largest 
consumers of medicines, 90% of adults aged over 80 consume over 10 medicines per day527. 
Needless to say it would be very important for those medicines to be tested on frail older 
people, which is better acknowledged now in European law but unfortunately has not resulted 
much progress yet, as extensively demonstrated before. 
273. Older adults have a declining condition often accompanied with physical528 as well as 
cognitive frailty529. The specific characteristics, when not studied, mean that physicians have no 
indications, which impedes informed prescription530. However, frailty makes clinical trials much 
more complicated, expensive, time consuming and above all, much more uncertain regarding 
ethical and scientific acceptability531. The PREDICT study at the scale of the European Union532, 
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ICH guidelines since 1993533 which were then updated in 2008534, and multiple scientific papers 
have denounced this deficiency and analysed its reasons for a long time. In spite of these 
repeated denunciations, there continues to be a lack of representation of older adults in clinical 
trials, which worsens even more the quality of treatment of this already vulnerable 
population535. 
274. The Council of Europe, although more and more interested in human rights of older 
adults for instance with the 2014 Recommendation536, does not take the public health 
perspective on access to biomedical research. This may change in the future, as it has been one 
main topic during the 2017 conference for the 20th anniversary of the Oviedo organised by the 
DH-BIO537. 
275. European law has acknowledged several times the need for better representation of 
older adults in clinical drug trials, but without comparable decisions as for paediatric or orphan 
medicines. First of all, the European Commission does provide for regular funding through 
framework programs. However it is difficult to evaluate how much funding has been dedicated 
to geriatric clinical research as it is scattered between funding for diverse diseases which are 
frequent yet not exclusively related to very old age like cardiovascular or neurodegenerative 
diseases and general funding on the topic of ageing, which might favour clinical research on 
geriatric medicines but not directly. The European Commission estimates that more than 115 
million Euros have been attributed to projects related to ageing538.  
276. Second of all, the European Medicines Agency has shown great interest in older 
adults representation in clinical trials since 2006539. Its activities have led to the elaboration, 
instead of a regulation like for paediatrics, to a strategy, the Geriatric Medicines strategy540. The 
goal of the Strategy was to enhance geriatric medicines and increase representation of old, very 
old and frail adults in clinical trials, for instance through the creation of the Geriatric Expert 
Group within the Agency giving free scientific advice and through the perspective of a stricter 
evaluation of research protocols in favour of geriatric patients. Although the means are quite 
similar to orphan or paediatric medicines, the fact that none of it is mandatory was its greatest 
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shortcoming. The Geriatric medicines Strategy was never applied, except for the scientific 
activity of the Geriatric Expert Group for instance with guidelines on frailty541 or various reviews 
and revisions of existing guidelines in Europe (93% would not comply) or of the geriatric data in 
marketed products (75% would be incomplete)542. The Agency has recently published a public 
consultation on a reflection paper about the development of medicines for geriatric use543.  
277. It seems thus that the activity of the European Union will remain focused on 
unbinding scientific guidelines for now. The new Regulation on clinical trials does not include 
elements in favour of older adults’ representation. It does require the research protocol to 
justify age and sex distribution of participants compared to the future or probable patient 
population544. Recitals 15 and 19 of the Regulation do explicitly designate “frail or older people” 
as a “vulnerable group” requiring specific expertise and specific study of medicines’ effects. 
However, these provisions will certainly not constitute a trigger for better representation of 
older adults in clinical trials, given that extensive regimes of incentives and obligations are barely 
working for orphan and paediatric medicines.  
1.2.2 Developing countries 
278. Instead of “low resource settings” we will now only talk about “developing 
countries” because the goal here is to emphasize the ethnic, environmental and cultural 
differences of participants that have an impact on clinical trials. In fact, testing medicines with 
participants from developing countries can cause problems of extrapolation of the results for 
European patients. Still our focus will not be on a potential vulnerability of European patients 
due to the ethnic differences with trials participants. On the contrary, we will focus on the 
vulnerability of local participants of the developing countries (1.2.2.1), who most of the time lack 
health care and deem clinical trial participation as their only opportunity to access medical 
treatment, whereas the trials do not target medical conditions that are relevant for the local 
population. Organised exploitation is made possible by an, although improving, insufficient 
European legal framework (1.2.2.2). 
1.2.2.1 Vulnerability to health exploitation 
279. Participants from developing countries are not only vulnerable regarding their 
inability to protect their interests (social, economic and systemic factors as was mentioned 
before), they are also vulnerable because of their health and the impossibility for them to 
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receive treatment 545 . The global health disparities are increasingly growing 546 , and the 
proportion of trials conducted on poorer participants for richer patients is exploding547. Around 
90% of the global research costs are allocated to only 10% of the health needs548. 
280. Sponsors tend to have more freedom to use placebos in developing countries than 
in most European countries. Any experimental treatment has to be compared either to a 
placebo or to the currently available treatment in order to prove efficacy. Comparing a 
treatment to a placebo can be dangerous if it means depriving the patient/participant of an 
effective treatment, especially in developing countries where the trial might be the only chance 
for a patient to get a medication. In order to legitimate their use of placebo, some sponsors use 
the argument that patients in developing countries would anyway not get any treatment at all, 
either because it would be too expensive, or because the country is not able to store and/or to 
commercialise the medication549. 
281. Another example would be the question of (free) access to the experimental 
medication that turned out to be safe and effective. There seem to be quite an ethical consensus 
on the (moral) obligation for sponsors to provide for the medicine after the end of the trial550. 
However recent and diverse reports have shown that in practice this ethical principle is rarely 
applied551. 
1.2.2.2 Improving but insufficient European legal framework 
282. The European legal framework is increasingly getting involved on these issues, but it 
still seems insufficient. The explanatory report of the Additional Protocol to the Oviedo 
Convention on biomedical research specifies that “importance of the aim of research” required 
at article 7 implies relevance to the health needs of the local community552. The legal framework 
of the European Union is more extensive on the topic. 
283. To begin with, several organs from the European Union are explicitly pleading for 
ethical principles to be respected when conducting clinical trials in developing countries. For 
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example, the sponsor has to guarantee other benefits than those from the trial itself, like basic 
health care for participants even when unrelated to the trial, ethical or scientific capacity 
building, and donation of equipment553, to name a few. But the most important principle here is 
the principle that requires the clinical trial conducted in a developing country to target the 
specific needs of the local population554. As the European Group of Ethics emphasised, the 
condition can be specific to the local community, it can be particularly spread in this community, 
or the trial aims at elaborating a more general treatment but in the sole interest of the 
community (for instance in order to find a less expensive version of a medication) 555. In order for 
European sponsors to grasp the medical priorities of a developing country, they must develop a 
partnership to collaborate with local physicians and experts556. 
284. The latter principle has been materialised thanks to the creation of the first 
partnership between European and developing countries EDCTP in 2003557 that was mentioned 
previously. The ethical principle requiring sponsors to respond to local health needs is not only 
written down in the decision but it is concretely applied. In fact, EDCTP was first focussing on 
HIV/AIDS, malaria and tuberculosis which were deemed to be the three main poverty related 
diseases, for which the European Union doled about 200 million Euros (article 1.2). Among 
others, 100 clinical trials were conducted, 8 of them leading to improvement of treatments558. 
Although the EDCTP enabled professional education and specialisation of hundreds of African 
investigators as part of these collaborative clinical trials, the problem remains persistent and 
research is still insufficient and scattered559. Contributing for up to 22% of all global investments 
related to poverty and neglected infectious diseases560, the European Union renewed the 
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partnership with EDCTP 2561. This time more neglected diseases were included like dengue, 
yellow fever, Ebola and many more562. The funding was tripled to 683 million Euros563. 
285. The European Parliament insisted again in its 2017 Resolution on access to quality 
medicines that local health needs in developing countries still require attention through capacity 
building and public-private partnerships. It invites the Union to further intensify the efforts, 
especially for vulnerable communities564. Recent calls for projects within EDCTP 2 launched in 
2018 for instance concerned a phase I-III trial in Sub-Saharan Africa (30 millions for 3 to 5 
projects)565, or any clinical trial aimed at reducing health inequities of pregnant women, 
neonates or children (38 millions for 5 to 10 projects) 566. 
286. In sum, European law does take into account health related vulnerabilities, but 
offers protection in a scattered manner: the form of protection may vary from an organized and 
complete palliative regime to various indirect and parallel instruments. The reasons for this 
choice of certain vulnerable groups over others are rather unclear. Nevertheless the very 
existence of such measures is promising for the awareness on health vulnerability that it brings. 
In the next paragraph, we will examine how to legally and ethically justify and generalize a 
mandatory promotion of the health needs of vulnerable and marginalized patients through an 
equitable representation in clinical trials. 
2 Towards a mandatory health promotion of vulnerable patients 
through equitable representation in clinical trials 
287. In this paragraph, an argument will be built for an equitable access to medicines 
through equitable representation in clinical trials. The notion of equity can act as a bridge 
between moral, legal and ethical norms, all of which refer to justice567. We begin by justifying 
the legitimacy of an ethical principle of health promotion of vulnerable patients through 
equitable representation in clinical trials (2.1) before examining the different elements from 
European law that could base and support such a claim (2.2). 
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2.1 FOUNDATION OF AN ETHICAL PRINCIPLE OF EQUITABLE REPRESENTATION IN 
CLINICAL TRIALS 
288. Observing the causes and consequences of health vulnerability (2.1.1), we will 
explain how it can be considered as a normative principle (2.1.2). 
2.1.1 Vulnerability as an observation 
289. Exclusion of vulnerable patients from clinical trials can happen for two reasons. The 
first one is related to health issues of the participant. If the patient/participant is vulnerable, it is 
going to be more time consuming, more complex and more expensive to conduct a trial. Patients 
can have a decisional vulnerability as we have seen in Section 1 (legal incapacity, de facto 
incapacity as well as a simple inability to defend one’s own interests), and investigators could be 
reluctant to include them because of all the supplementary protections (and thus complications) 
that it implies. Patients can also have a rather medical or health related vulnerability increasing 
the risks of adverse events during a clinical trial: comorbidities, chronic disease, palliative care568, 
but also as we have seen before physical frailty, pregnancy or ethnic differences. 
290. The second reason for exclusion of vulnerable patients is related to economic 
factors569. As we have seen with orphan or paediatric medicines, market needs do not always 
match health needs of vulnerable patients. To begin with, a clinical trial is limited in time and 
scale to reduce costs to the minimum that is already colossal. Recruiting a homogeneous and 
uncomplicated set of participants (male adult in good health versus frail elderly woman) will 
increase the chances of obtaining positive and homogeneous results570. Moreover, the exclusion 
of vulnerable patients from representation in clinical trials is also due to other economic factors, 
notably the choice of experimental treatment or disease, to develop a drug according to the 
disease prevalence or to the probable reimbursement. The reasonable chances of financial 
profitability do play a big role in pharmaceutical industries choosing their focus of research. 
291. This exclusion leads to frequent off-label use of drugs, i.e. administration of a drug 
outside of the available information from the marketing authorisation571. As we have said before 
regarding orphan and paediatric medicines, the absence of information on medicines can lead to 
risks of overdosing and possible serious adverse effects, as well as risks of under-dosing and thus 
non-treatment. Risks that are not taken by vulnerable participants will inevitably be taken later 
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on by vulnerable patients but without the safety-net provided by the obligatory close 
surveillance and medical care during a clinical trial. 
292. One particularly revealing example is that of pregnant women. There is very little 
information on the effects of drugs on pregnant women and on their foetus/embryo because of 
their almost systematic exclusion from clinical trials572. A British study showed that, among all 
prescriptions to pregnant women in one hospital during three months, only 25% were 
administered according to a pregnancy related marketing authorisation, 19% were based on 
literature studies, 55% were contraindicated, and 10% were deemed very dangerous573. The lack 
of information prevents prescribing physicians to know about the teratogenicity when 
administering a medication, i.e. the potential dangers for the embryo or foetus574. This led to the 
famous Thalidomide scandal when over 10 000 neonates suffered from congenital dysmorphia 
because of a simple medicine against nausea administered during pregnancy575. Moreover, the 
fear from potential unknown teratogenic effects prevents pregnant women from receiving the 
correct care, which can be very dangerous for instance if she is suffering from a chronic disease, 
diabetes or a psychiatric disease. Their exclusion from clinical trials also prevents physicians from 
getting the specific information that would be needed to adapt to the particularities of the 
pregnant body: « A pregnant woman is not just a woman with a bigger belly. The maternal-fetal-
placental system brings its own pharmacokinetics and dynamics »576. 
293. Health vulnerability and consequent undocumented and dangerous off-label use 
does not only concern pregnant women, it is very frequent in vulnerable populations577. Another 
study reported that more than a third of prescriptions in palliative care were off-label578, the 
same in psychiatric hospitals with about 40% of off-label prescriptions 579  as well as in 
oncology580.  
                                                                    
572 Lyerly A. D., Little M. O. & Faden R., "The second wave: Toward responsible inclusion of pregnant women in research", 
International Journal of Feminist Approaches to Bioethics, Vol. 1, n°2, 2008, p. 11. 
573 Herrin C., McManus A., & Weeks A., "Off-label prescribing during pregnancy in the UK: an analysis of 18,000 
prescriptions in Liverpool Women's Hospital", Int J Pharm Pract, Vol. 18, n°4, 2010, pp. 226-229. 
574 Friedman J. M., "The obscenity of postmarketing surveillance for teratogenic effects", Birth Defects Research, Part 1 : 
Clinical and Molecular Teratology, Vol. 94, n°8, 2012, pp. 670-676; Schonfeld T., "The perils of protection: Vulnerability and 
women in clinical research", Theoretical Medicine and Bioethics, Vol. 34, n°3, 2013, pp. 197-198. 
575 Feldschreiber P. & Breckenridge A., "After Thalidomide – do we have the right balance between public health and 
intellectual property", Reviews on Recent Clinical Trials, Vol 10, 2015, p. 15. 
576 Lyerly A. D., Little M. O. & Faden R., "The second wave: Toward responsible inclusion of pregnant women in research", 
op. cit., p. 7; Schonfeld T., "The perils of protection: Vulnerability and women in clinical research", op. cit., p. 197. 
577 Lenk C. & Duttge G., "Ethical and legal framework and regulation for off-label use : European perspective", Therapeutics 
and Clinical Risk Management, n°10, 2014, p. 538. 
578 Kwon J.H., Kim M.J., Bruera S., Park M., Bruera E., Hui D., "Off-Label Medication Use in the Inpatient Palliative Care Unit", 
J Pain Symptom Manage, Vol. 54, n°1, 2017, pp. 46-54 ; Culshaw J., Kendall D., Wilcock A., "Off-label prescribing in palliative 
care: a survey of independent prescribers", Palliat Med, Vol. 27, n°4, 2013, pp. 314-319. 
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2.1.2 Vulnerability as a normative principle 
294. Drawing from the idea of social justice, the notion of vulnerability triggers a 
renewed debate on the repartition and distribution of social goods581. We will first explain why 
we consider the principle of social justice as a basis for an ethical obligation to promote the 
health of vulnerable people (2.1.2.1) and then develop the idea of a social responsibility to 
represent them in clinical trials (2.1.2.2). 
2.1.2.1 Social justice as a basis for an ethical obligation to promote the 
health of vulnerable people 
295. John Rawls’ theory of justice tends to be more prone to protect vulnerable people 
than other social justice theorists582. According to Rawls, distributive justice should permit to 
compensate inequities by providing for a set of primary goods583. Still a repeated critique against 
his theory is that it mainly evaluates inequities with the criteria of income or material goods584, 
because he considers that some inequities cannot be compensated or would be too expensive to 
systematically compensate585. As a consequence, Rawls’ theory of justice does not take into 
account very ill or seriously handicapped people586. Not only vulnerable people are not taken 
into account, but their “non-existence” prevents society from adapting to them as they would do 
for other members of society, which further marginalizes vulnerable people. 
296. Amartya Sen and Martha Nussbaum’s capability theory will bring a new perspective 
on social justice and on inclusion of vulnerable people587. They suggest focusing rather than on 
income, on the actual possibilities of a person to choose and achieve personal goals. « Capability 
concentrates on the opportunity to be able to have combinations of functionings (…), and the 
person is free to make use of this opportunity or not. A capability reflects the alternative 
combinations of functionings from which the person can choose one combination »588. This 
resonates with the lack of effectivity of vulnerable people’s rights589: they have rights but are 
prevented or not given the opportunity to enjoy their rights. Capabilities emphasize, rather than 
                                                                    
581 Roman D., "Leçon 5 : Accès au droit et à la justice", Vulnérabilité et droit, 5 leçons du 13 février au 8 mai 2017, 
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on the passive perspective of not violating someone’s liberty, on the active perspective of 
actively promoting adequate means for the person to exercise his or her liberty590. 
297. This is particularly true concerning the capability of health. Indeed, two philosophers 
– Norman Daniels and Sridhar Venkatapuram – have extended Rawls’ theory of justice to suggest 
health related goods591 or a “entitlement to the capability to be healthy”592. They are both 
basing their suggestion on the fact that health is both a means for other capabilities, a “meta-
capability” 593, a primary good that has to be prior to everything else to guarantee normal 
functioning of a person594 ; and an end in itself given how much impact social, cultural, 
environmental and political factors have on the quality of health protection595. When those 
factors can be controlled, for instance through political choices, it becomes a moral obligation 
for society to react and offer protection, especially concerning vulnerable people596. 
2.1.2.1 Social responsibility to represent vulnerable people in clinical 
trials 
298. The level of health protection in a given society varies according to the context. The 
higher the general level of health, the lower is the tolerance for health problems597. “It makes 
profound sense that, because individuals living in rich countries continually push at the upper 
boundaries of longevity, individuals in such societies should be able to make claims for the social 
basis of the most commonly achieved life plans, or even states of well-being”598. As a 
consequence, in our modern societies where medicine is constantly improving and where 
personalised medicine is developing, it is less and less acceptable for vulnerable people to not 
have adequate treatments and be administered off-label drugs. 
299. Claiming for an obligation to adequately and equitably include vulnerable patients in 
clinical trials can even be supported by ethics principles. The aspect of justice is now obvious 
here 599  as exclusion from clinical trials maintains and even worsens health disparities. 
Beneficence and non-maleficence600 could also very much justify such an obligation in order to 
prevent then dangers of not treating a disease or off-label use: “Though proper protection of 
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vulnerable populations is without question mandatory, it appears that the strong focus on 
preventing harm has been realised mainly by setting high standards for the enrolment of such 
populations in clinical research projects. But the result has been a considerably less than 
satisfactory therapeutic situations for vulnerable populations in comparison with that for the 
non-vulnerable majority”601.  
300. The obligation to equitably include vulnerable people in clinical trials would also be 
supported by ethics of care, emphasising on interdependence and protection602. In fact, ethics of 
care also focuses on resilience and on giving the means to as much autonomy as possible and 
preventing situations from getting worse (rather than only treating the symptoms) 603. As Joan 
Tronto criticises, ethics of care is, because of its emphasis on inter-dependence between 
individuals, too often limited to private relations whereas it should have and it definitely has a 
political aspect604. 
301. Finally, the idea of considering an equitable representation of vulnerable people in 
clinical trials as an ethical obligation is also supported by main research ethics stakeholders. This 
is for instance the case of the World Medical Association who, in the Declaration of Helsinki, 
considers that “groups that are underrepresented in medical research should be provided 
appropriate access to participation in research” (§13), and that research on vulnerable groups 
should focus on “the health needs or priorities of this group” in order for them “to benefit from 
the knowledge, practices or interventions that result from the research” (§§19-20).  
302. This also the case of the CIOMS guidelines, especially in the 2016 revised version 
where several guidelines and provisions are dedicated to a claim of adequate representation of 
vulnerable participants in the perspective of a fair distribution of research benefits. First, 
Guideline 1 mentions the “social value” of research, which cannot create unjust situations and 
has to be evaluated notably with the “significance of the health need”. Second, it is mainly 
Guideline 3 which is helpful for our claim as it urges “Sponsors, researchers, governmental 
authorities, research ethics committees and other stakeholders” to “ensure that the benefits 
and burdens of research are equitably distributed”, and it even explicitly states: “Because 
categorical exclusion from research can result in or exacerbate health disparities, the exclusion 
of groups in need of special protection must be justified. Groups that are unlikely to benefit from 
any knowledge gained from the research should not bear a disproportionate share of the risks 
and burdens of research participation. Groups that are under-represented in medical research 
should be provided appropriate access to participate”. 
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303. Even if Guideline 3 does not use the explicit term “vulnerable”, and even if Guideline 
15 on vulnerable groups does not mention the principle of equitable distribution of benefits of 
research because it is focused on decisional vulnerability, one can deduce the link between 
Guideline 3 and health related vulnerability. In fact, the principle is further developed in the 
comments of Guideline 3 for most vulnerable categories as well as in each respective guideline: 
low resource settings (Guideline 2), incapacitated adults (Guideline 16), children (Guideline 17), 
women (Guideline 18)605 and pregnant women (Guideline 19). 
2.2 ELEMENTS OF EUROPEAN LAW SUPPORTING EQUITABLE REPRESENTATION IN 
CLINICAL TRIALS 
304. In the search for provisions in European law supporting a principle of equitable 
representation of vulnerable people in clinical trials, two main legal areas appear as a potential 
basis: fundamental rights and a potential principle of equitable access to benefits of clinical trials 
(2.2.1), and pharmaceuticals market law and notably the requirement to promote a high level of 
human health protection (2.2.2). 
2.2.1 Fundamental rights and equitable access to benefits of clinical 
trials 
305. In favour of equitable access to benefits of clinical trials, we can find both rights of 
vulnerable patients (2.2.1.1) as well as obligations for pharmaceutical companies (2.2.1.2). 
2.2.1.1 Rights of vulnerable patients 
306. First of all, vulnerable patients should be guaranteed an equal health protection. 
This is the case for the Council of Europe with vulnerability being more and more used in the 
case law of the European Court of Human Rights as a tool to better protect equality606 including 
sometimes in health protection607. Council of Europe’s Committee on Social Rights is also 
increasingly giving importance to health protection, particularly when it comes to vulnerable 
categories and when the health system is well-developed in the given Member State608. This is 
also the case in the law of the European Union, observing two growing issues: vulnerability 
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through the lens of equality and non-discrimination and solidarity rights609 as well as equity of 
health protection regarding vulnerable people610 
307. Second of all, this equal health protection should lead to equal representation in 
clinical trials. The Council of Europe’s Oviedo Convention protects equitable access to health 
care in its article 3, which has to be evaluated depending on the Member State’s resources611. 
Article 5 on informed consent can actually also be used to claim an equal representation in 
clinical trials as “informed” consent is not possible for most vulnerable patients for which no 
data is available on specific safety and efficacy. The law of the European Union also protects 
informed consent to (future) treatments (for instance through article 3 of the Charter of 
fundamental rights), however, other provisions that relate more directly to equal representation 
of vulnerable people in clinical trials are not binding. The textbook published by the European 
Commission on research ethics does explicitly denounce discriminations and injustices in access 
for vulnerable people to benefits of research and safe treatments612. Moreover, the previously 
mentioned 2017 resolution of the European Parliament insists on access to quality medicines to 
be part of the fundamental right to health protection and health care access613. It also 
denounces the dangers of off-label use of medicines and the fact that 5% of hospital admissions 
are due to drugs’ adverse effects and that adverse drug effects is the 5th major cause of death in 
the European Union614. Particular emphasis is put on vulnerable categories like children and 
older adults615. Even if this Resolution cannot have a direct impact on national legislations, it 
may have an impact on future European Union law or jurisprudence as it brings increasing 
awareness. 
2.2.1.2 Obligations of pharmaceutical companies 
308. Those patients’ rights might however go against rights and freedoms of 
pharmaceutical companies. European law protects freedom of research in article 13 of the 
Charter of fundamental rights of the European Union, in article 15 of the Oviedo Convention and 
article 4 of its Additional Protocol on biomedical research. However, those rights are rather 
formulated in favour of researchers and their potential findings for public health, against 
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limitations from public authorities616. The reverse situation of public authorities wanting 
investigators to prioritize one type of research over another to favour vulnerable patients is not 
mentioned. In fact it seems far stretched from the current jurisprudence to impose research 
obligations to private companies, even on an important issue like health. The only possibility 
would be for judges to use limitations to freedom of expression (often related to freedom of 
research like in the case of Hadjanastassiou against Greece617) in order to prevent sponsors from 
hiding the lack of research and the consequent lack of data reliability regarding their marketed 
medications618 and oblige them to write all cases in which it has not been tested and might have 
unpredictable adverse effects. However, the Parliamentary Assembly of the Council of Europe 
adopted a resolution and a following recommendation suggesting ways to guarantee the 
primacy of public health interests over the interests of the pharmaceutical industry619. Even if 
this document does not have a mandatory effect, it is still interesting to note that the Council of 
Europe is recommending measures to Members States for which it does not usually have a role, 
notably on the conditions for market authorisations or on how to guarantee the absence of 
conflic of interests bewteen public health authorities and private stakeholders from the 
pharmaceutical industry.  
309. Because of its links with market considerations, pharmaceuticals related instruments 
are also related to freedoms to work, to conduct a business, as for instance protected in articles 
15 and 16 of the Charter of fundamental rights of the European Union and in article 1 of the 
Social Charter. However, health interest is deemed to have priority over economic interests, 
especially regarding pharmaceuticals620. Moreover, health protection constitutes an exception, 
Member States are allowed to go against European Union market considerations when it aims to 
favour national protection of health (articles 36, 52 et 62 TFEU). European judges have been 
keen on accepting these exceptions even against former case law621. Unfortunately, isolated 
national measures are probably not the key for equitable representation of vulnerable people in 
clinical trials because they would be easy to circumvent by conducting a trial in another Member 
State or outside European Union. 
310. In this same 2017 resolution, the European Parliament introduced in the field of 
access to medicines the notion of “social responsibility”622 of pharmaceutical companies. This 
has been developed in international law especially concerning developing countries and 
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emergency situations623. But the European Parliament is calling for national and European 
measures guaranteeing, in cooperation with the pharmaceutical industry, that research and 
development be oriented towards unmet medical needs624. In the Additional Protocol on 
biomedical research, such a suggestion could consist in strengthening the requirement of quality 
of research and scientific expertise (article 8). Both of which imply that the objectives of 
research must be relevant and feasible and most of all important regarding unmet medical 
needs625 
2.2.2 Pharmaceuticals market and high level of human health 
protection 
311. European Union law is slowly acknowledging the importance of clinical trials for 
access to medicines for vulnerable populations (2.2.2.1), and promoting a legal framework 
fostering complementary trials on vulnerable people with authorized medicines (2.2.2.2). 
2.2.2.1 Clinical trials as a mean for access to medicines of vulnerable 
people 
312. Even when it refers to “medical vulnerability”626, Council of Europe does not actually 
refer to a lack of access to quality medicines or to representation in clinical trials. Rather it only 
considers medical vulnerability as a cause for decisional vulnerability, which does not apply to 
our concern here. 
313. On the contrary, the new clinical trials Regulation from the European Union has 
created a generic sub-category of vulnerable people, which could, although only potentially, 
serve as provision to introduce a protection regime for health vulnerability, pleading for better 
representation. In fact, article 10.4 of Regulation 536/2014 introduces a new vulnerable 
category: “specific groups or subgroups of subjects”, which seems to be a more generic version 
of a parliamentary amendment initially referring to “persons with specific needs including the 
elderly, frail people and people with dementia”627. The latter has been complemented and 
moved to recital 15 referring to “vulnerable groups such as frail or older people, people suffering 
from multiple chronic conditions, and people affected by mental health disorders”, and recital 
19 referring to “other identified specific population groups, such as elderly people or people 
suffering from rare and ultra rare diseases”. 
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314. Article 10.4 does not go further than requiring a specific expertise for these “specific 
groups and subgroups” and thus does not acknowledge the need for representation in trials. This 
need is nonetheless highlighted in recital 14, added according to a parliamentary amendment628: 
“Unless otherwise justified in the protocol, the subjects participating in a clinical trial should 
represent the population groups, for example gender and age groups, that are likely to use the 
medicinal product investigated in the clinical trial”. Moreover, this need is also underlined in 
recital 15: “In order to improve treatments available for vulnerable groups such as frail or older 
people, people suffering from multiple chronic conditions, and people affected by mental health 
disorders, medicinal products which are likely to be of significant clinical value should be fully 
and appropriately studied for their effects in these specific groups, including as regards 
requirements related to their specific characteristics and the protection of the health and well-
being of subjects belonging to these groups”. Finally, recital 13 and article 6 of Regulation 
536/2014 do require future patients to be represented in clinical trials, as an evaluation criteria 
of relevance629. Another criteria of relevance given in article 6 is the compliance with national or 
European regulatory authorities’ recommendations. Interestingly, this could be referring to the 
previously mentioned work of the European Medicines Agency on geriatric medicines or on 
health needs of developing countries. 
315. This generic category is thus promising, especially as the European Parliament 
Resolution has raised the issue of access to quality medicines for vulnerable people and has put 
pressure on the European Commission to guarantee trial subject to better represent future 
patients and to take more into account unmet medical needs630. In particular, the Parliament is 
giving recommendations insisting on paediatric medicines (Recommendations 65-66), orphan 
medicines (73), poverty related diseases (109), various unmet medical needs regarding cancer 
(70), Hepatitis C (69) or antimicrobial agents (64), elderly people (63), pregnant women (63) and 
even female patients as such (68). 
 
2.2.2.2 A legal framework fostering complementary trials on authorized 
medicines 
316. Failure of clinical trials to provide enough information on vulnerable people being 
administered medicines can be compensated with a more proactive pharmacovigilance system. 
Pharmacovigilance is not directly our topic of interest, but it is worthwhile to quickly mention it 
for its complementary role. In fact, European Union law does allow for a few drug categories to 
be marketed although there were not enough trials conducted but with the condition of a 
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proactive pharmacovigilance phase, which would later complete the needed information631. This 
is the case for certain serious or life-threatening conditions, for emergency public health 
situations and for orphan diseases. Furthermore, the European Medicines Agency has provided 
for good clinical practices regarding pharmacovigilance in vulnerable categories like children632 
and pregnant women633, and is currently developing a similar instrument for older adults634. 
317. Nevertheless, pharmacovigilance might not be enough to palliate the 
aforementioned lacks of trials on vulnerable people – especially when there is no proactive 
obligation for sponsors like the one that exists for medical devices635. European Union law does 
offer the possibility to conduct or even to demand the conduct of complementary trials after 
marketing authorisations are granted. In fact, two separate provisions might foster 
complementary trials on vulnerable people. First, the Regulation 536/2014 introduced a new 
category of trials, “low intervention trials”, for which conditions for authorizations will be 
facilitated because they concern already authorised medicinal products and only pose minimal 
risks and burdens to participants (article 2.2.3). This is particularly interesting for vulnerable 
people as the simplified and faster procedures are meant to be more attractive for sponsors (for 
instance regarding deadlines, insurance or consent procedures, see articles 76.3 and 3.3.c.) 
318. Second, the new pharmacovigilance framework strengthened the provisions on 
post-marketing safety studies as a condition for obtaining and keeping a marketing 
authorisation. This new possibility has been described as one of the major input of the 
pharmacovigilance framework reform in 2010 and 2012636. They can be imposed by the 
European Commission when granting the marketing authorisation but also anytime during the 
pharmacovigilance phase, for instance if some adverse events are reported and justify a more 
proactive data collection through phase IV clinical trials637. Those studies can indeed be 
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especially useful to gather data on the long term use, on specific populations groups (like older 
adults or pregnant women for instance) or specific contexts of use (poly-medication for 
example) 638. In its 2017 Resolution, the European Parliament emphasised again the importance 
for the European Commission to make sure this new possibility will be used by the European 
Medicines Agency and the number of post marketing safety studies will be increased639. 
 
*** 
 
319. To conclude, the injustice created towards vulnerable patients is more and more 
acknowledged and is gaining some traction in the legal framework of the European Union 
regarding clinical trials. Specific regimes for paediatric and orphan medicines have now been 
implemented for more than a decade and have generated valuable, although still insufficient, 
results in terms of access to quality medicines. Although not going as far as implementing a 
specific regime for clinical trials for older adults similar to what is done for paediatric patients 
and those with rare disease, the European Union is attempting to promote research on unmet 
medical needs for older adults as well as for poverty related diseases in developing countries. 
320. However, these provisions are quite scattered and, most importantly developed 
over political decisions lacking coherency as there are a lot more vulnerable groups who would 
need the same promotion of their health interests, the most illustrative example being for 
instance pregnant women. As we have demonstrated, this protection should rather stem from a 
more generic approach grounded in the need for equitable access to health care, and promoted 
through different instruments like specific phase III clinical trials, specific pharmacovigilance 
practices, or phase IV clinical trials be it low intervention trials or post marketing safety studies.  
321. An optimistic point of view would consist in noting all the different tools available to 
promote an equitable representation of vulnerable people in clinical trials. However a more 
pessimistic perspective would be to recall that the implementation of those tools will depend on 
a political will with which the European Medicines Agency must come to terms with when giving 
advices and recommendations to the European Commission. 
 
  
                                                                                                                                                                                                                   
European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products, Recital 16 & 
Article 1.4. 
638 EMA, Guideline on good pharmacovigilance practices (GVP). Module VIII – Post-autorisation safety studies (Rev 3), 
EMA/813938/2011 Rev3*, London, 2017, p. 6. 
639 European Parliament Resolution of 2 March 2017, Recommendation 74. 
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Conclusion 
 
 
 
 
 
 
 
 
322. This work analysed what constitutes a vulnerable group within clinical trials and 
critically examined how they are protected in the current European law. This analysis was carried 
out through the lens of type of risk or damage that could result when participating in a clinical 
trial. We found that there are two main types of risks in clinical trials: first of all the risk to 
autonomy and second, the risk to health. 
323. Decisional vulnerability, i.e. the inability to protect one’s own interests, seems to be 
the main criteria for designating a vulnerable group, notably vulnerable participants. Thus, the 
notion of vulnerability is quite reduced and is all the more so that European law is only 
recognizing and protecting legal or de facto incapacity. As demonstrated, a lot of decisional 
vulnerabilities can have unfortunate consequences on informed consent but are not sufficiently 
protected, for instance, in the cases of dependence, social disadvantage, lack of healthcare, 
mental or psychiatric difficulties or even just the fact of being in a low resource setting. 
324. Interestingly, vulnerable people can also exclusively have health related 
vulnerability, such as a physically frail (but mentally competent) older adult. The confusion 
between health and decisional vulnerability stems from the frequent parallel existence of the 
two, for example, in children, or in elderly people who are both physically and cognitively frail. 
However, vulnerability can be solely related to health, as an inherent characteristic and/or as a 
consequence of exclusion from clinical trials and thereby, their benefits. European Union law 
offers protection against discrimination in representation in clinical trials, thanks to two 
palliative regimes for orphan and paediatric medicine, and scattered provisions for geriatric 
medicine and poverty related diseases. However, here again the recognition of vulnerability is 
very restricted as there are, given the abundant literature, many more vulnerable people who 
are under-represented in clinical trials, the best example being pregnant women. 
325. The task of finding and highlighting a principle of protection of vulnerability in 
European law and ethics is tricky. As demonstrated, vulnerability is a complex and polysemous 
notion that is used in European law with great disparities and incoherences. Basing the reflection 
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on the type of risks that are specific to clinical trials, this thesis suggested a concept of 
vulnerability. The latter distinguished between decisional vulnerability and health related 
vulnerability, with the hope to better understand the rationale for protection offered in 
European law, and most of all to highlight the elements to improve in order to give more 
coherency (and better equity) to the European legal framework protecting vulnerable people in 
clinical trials. 
326. The notion of vulnerability has constituted an enlightening lens through which we 
could analyse European law on clinical trials. Maybe science and technology will soon outrun 
these specific ethical reflexions on participation and representation of vulnerable people in 
clinical trials by using the power of statistics and big data and the future Union portal and 
database. Furthermore, in silico trials i.e. computer simulated trials640 are currently emerging 
and penetrating European law641. They might considerably reduce development costs of drugs 
and make up for deficiencies regarding vulnerable people for instance regarding recruitment 
difficulties, as it has already started for orphan paediatric diseases642 and hopefully as it will 
develop further. 
 
                                                                    
640 Viceconti M., Henney A. et Morley-Fletcher E., “In silico clinical trials : how computer simulation will transform the 
biomedical industry”, International Journal of Clinical Trials, Vol. 3, n°2, 2016, pp. 37-46 ;  
641 In Silico trials are already fostered in the United States and will also be in Europe. FDA News Website, “Congress Pushes 
for In Silico Trials Modeling”, 18 July 2017, https://www.fdanews.com/articles/182663-congress-pushes-for-in-silico-trials-
modeling [3 June 2018]; A working group has been created in the European Medicines Agency on modeling and simulation. 
EMA Website,  http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/PDCO/people_listing_000123.jsp&mid=WC 
0b01ac05806f485 [3 June 2018]. 
642 Carlier A., Vasilevich A., Marechal M., de Boer J. et Geris L., “In silico clinical trials for pediatric orphan diseases”, 
Scientific reports, n°8, 2018, pp. 2465-2473. 
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